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Not every individual who experiments with cocaine will acquire compulsive drug 
use. The mechanism underlying this individual difference in susceptibility to drug 
addiction is still poorly understood. Recent studies have identified genes and ad-
verse life events (stress) as risk factors. The objective of this thesis is to investigate 
the contribution of the adrenal stress hormones glucocorticoids and epinephrine 
to the psychostimulant effects of cocaine in the inbred DBA/2 and C57BL/6 mouse 
strains. Behavioural sensitisation, measured as an enhanced locomotor response to 
repeated cocaine exposure, was used as a model for the long-term neural adapta-
tions underlying certain aspects of drug addiction.
The results demonstrate that adrenal hormones play a critical role in cocaine 
sensitivity, which depends on genetic background because surgical removal of the 
adrenals or ‘adrenalectomy’ fully prevented cocaine sensitisation in the DBA/2, 
but not the C57BL/6 strain. The impact of genetic background was further empha-
sised by strain-specific changes in the midbrain dopamine system that mediates 
the rewarding effects of drugs of abuse. The effects of adrenalectomy could only 
be fully reversed by co-administration of glucocorticoids and epinephrine. These 
findings show that, depending on genetic background, adrenal stress hormones are 
important risk factors for vulnerability to cocaine, suggesting that pharmacologi-
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Cocaine, together with amphetamine, is one of the most well-characterised and 
widely abused psychostimulant drugs. In humans, psychostimulants increase alert-
ness and induce a subjective sense of well being. However, with repeated expo-
sure, these drugs produce changes in the brain that, within a vulnerable individual, 
may promote continued drug taking behaviour that becomes compulsive in nature 
and increasingly more difficult to control. Despite the powerful psychostimulant 
properties of cocaine, not every individual who experiments with the drug will 
acquire compulsive drug use. In fact, the risk of becoming cocaine dependent 
after occasional use of cocaine is estimated at 15-20%. Similarly, there is large 
variation in behavioural responsiveness of laboratory animals to psychostimulant 
drugs. Comparable individual differences in vulnerability exist for all known drugs 
of abuse and these depend on complex interactions between genes and life experi-
ences, acting together with contextual factors such as the environment in which 
the drug is taken and drug availability. Especially stress, and the neuroendocrine 
response it evokes, has gained increasing attention as it has been demonstrated to 
enhance vulnerability to drugs of abuse in both humans and laboratory animals.
The research in this thesis focuses on a further analysis of factors that increase vul-
nerability to cocaine, with special emphasis on stress hormones. It is hypothesised 
that stress hormones increase vulnerability to cocaine, but that their actions are 
dependent on the genetic background of the individual and the context in which 
these hormones operate. The focus is on glucocorticoid hormones that are secreted 
from the adrenal glands as final step in the activation of the hypothalamic-pituitary-
adrenal (HPA) axis. Glucocorticoid concentrations are pharmacologically manipu-
lated in two inbred mouse strains in order to study the interplay between genetic 
background and glucocorticoids. In addition, the context required for the glucocor-
ticoid actions will be investigated in one of the two mouse strains that proves to be 
most susceptible to the impact of glucocorticoids on cocaine sensitivity.
In the following chapters, a summary is presented on the actions of cocaine and the 
neurobiology of the brain reward circuit, with emphasis on dopamine. Furthermore 
the neuroendocrinology of the stress response and the HPA-axis are described. 
Finally, individual differences in psychostimulant sensitivity are discussed with 





Cocaine is a psychoactive alkaloid that is obtained from the leaves of the coca plant 
(Erythroxylum coca) indigenous to Peru, Colombia and Bolivia. From archaeologi-
cal findings and studies on the presence of cocaine metabolites in mummies it has 
become evident that coca use dates back to as far as 2500 – 1800 BC 94,208,551. 
Chewing of coca leaves was an integral part of many pre-Hispanic cultures where 
it was first used in religious ceremonies and celebrations by priests and members 
of the upper social classes. Only from the time of the Inca empire (1450-1530), 
the whole of the population could access coca and its psychostimulant properties 
started to outweigh its symbolic meaning 15,208.
When the Spanish colonised South America, physicians recognised the beneficial 
effects of coca on mood and energy status of the indigenous population. However, 
it was not until the 19th century, when cocaine was first isolated by the German sci-
entist Friedrich Gaedcke (1855) that the drug came into focus of western medicine. 
Rapidly after the discovery of this new alkaloid, two important events occurred 
that changed cocaine use: Von Anrep recognised cocaine’s analgesic properties and 
Sigmund Freud described its euphoric and psychomotor effects 377,669,747. By the 
end of the 19th century (between 1880 and 1930) the drug was readily prescribed 
as remedy for all kinds of indications such as asthma, mountain- and sea sickness, 
pregnancy vomiting and cramping pains and it was sold in various forms including 
cigarettes, powder, wine and even in coca cola™ 15,669.
In contrast to Freud’s earlier observation that ‘Absolutely no craving for the further 
use of cocaine appears after the first, or even after repeated taking of the drug...’ 
it became evident by the turn of the 20th century that cocaine does possess addic-
tive properties and several waves of cocaine abuse were reported throughout this 
century, peaking in the 1980’s when, in America alone, 1.6 million new cases of 
cocaine use were reported (SAMHSA, Office of Applied Studies, National Survey 
of Drug Use and Health, 2002 and 2003). The recognition of scientists that drug 
dependence is a chronic relapsing brain disease, characterised by lasting changes 
in brain chemistry and function, rather than a ‘weakness of character’, has paved 
the way for the ongoing scientific research into the neurobiology of addiction that 
has started only around 30 years ago (reviewed in: 441).
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1.2 neurochemistry and actions
Psychostimulant drugs such as cocaine and amphetamine act as indirect agonists of 
the monoaminergic systems, including the dopamine system (described in detail in 
section 2). Cocaine blocks the dopamine-, norepinephrine- and serotonin re-uptake 
transporters (DAT, NET and SERT respectively) thereby prolonging the availability 
of the monoamines in the synaptic cleft 549,550. Amphetamine not only reduces 
monoamine re-uptake (primarily via the vesicular monoamine transporter), but also 
inhibits metabolism and stimulates release of these neurotransmitters (reviewed in: 
642).
As the dopamine system in the brain is considered to play a crucial role in 
reward 735, the predominant hypothesis has been that the addictive properties of 
cocaine are related to its ability to block the DAT 372. This ‘dopamine hypothesis’ 
has been challenged by the observation that mice lacking the DAT still experience 
the reinforcing effects of cocaine 567,632 and display cocaine-induced increases in 
extracellular dopamine in the nucleus accumbens (NAc) 62. The complete DAT 
knockout may however have resulted in compensatory adaptations that alter nor-
mal functioning of the reward pathways. In a very recent report, Chen et al. provide 
compelling evidence for the role of the DAT in cocaine reward. The authors show 
that transgenics expressing a functional DAT that is insensitive to cocaine, do not 
display drug-induced increases in locomotion and NAc dopamine release or drug 
reinforcement 102.
Via its actions on the NET, cocaine also has profound effects on the autonomic 
sympathetic nervous system (described in section 3.1). The sympathomimetic effects 
of cocaine include increases in heart rate, blood pressure, respiration and body 
temperature, vasoconstriction and pupil dilation 142,524. Cocaine use is therefore 
associated with a high risk of death due to cardiovascular collapse, respiratory fail-
ure, stroke and cerebral haemorrhage. Furthermore, cocaine suppresses appetite, 
which can lead to malnourishment.
In addition to its effects on monoaminergic transmission, cocaine is known 
to block sodium channels which, together with its vasoconstrictive properties, is 
considered to mediate the anaesthetic effects of the drug 427. Furthermore, a recent 
study has demonstrated that the local anaesthetic actions of cocaine are related to 
increases in intracellular Ca2+ concentrations that may, in addition to drug-induced 
vasoconstriction, contribute to the neurotoxic effects of cocaine 185.
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2. tHE braIn doPaMInE systEM
2.1 biochemical aspects
Dopamine is a monoaminergic neurotransmitter belonging to the class of cate-
cholamines that also includes norepinephrine and epinephrine. All catecholamines 
are synthesised from phenylalanine via a cascade of enzymatic reactions, the end 
product being determined by the number of steps (figure 1). The rate-limiting step 
in the synthesis of dopamine is conversion of tyrosine to dihydroxyphenylalanine 
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Figure 1: Biosynthesis cascade of the catecholamines dopamine, norepinephrine and 
epinephrine.




vesicles in the presynaptic terminals and are, upon neuronal depolarisation, released 
by exocytosis into the synaptic cleft where they can bind to receptors on post-
synaptic nerve terminals. Within the intra- and extracellular space, catecholamines 
are subject to enzymatic degradation by catechol-O-methyl transferase (COMT) 
and monoamine oxidase (MAO) resulting in formation of the two principal metabo-
lites homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC). In addi-
tion, catecholamine transporters such as the dopamine transporter (DAT) and the 
norepinephrine transporter (NET) reabsorb the catecholamine into the presynaptic 
terminal where it can either be stored in vesicles or degraded.
2.2 dopaminergic pathways
Dopaminergic neurons are widely distributed throughout the brain, the three major 
circuits being the nigrostriatal, mesocorticolimbic and tuberohypophysial pathways 
138.
Dopaminergic neurons of the tuberohypophysial pathway are located in the 
arcuate nucleus of the hypothalamus and suppress prolactin and α-melanocyte-
stimulating hormone (αMSH) secretion in the pituitary 224. These actions are outside 
the scope of this thesis and will not be further discussed.
The nigrostriatal and mesocorticolimbic dopamine systems are both anatomically 
and functionally intertwined 271 (see figures 2 and 4). A central component of both 
dopaminergic circuits is the striatal complex, consisting of the caudate nucleus 
and putamen (together referred to as the caudate putamen: CP, or dorsal striatum) 
and the nucleus accumbens (NAc, together with portions of the olfactory tubercle 
referred to as ventral striatum). The NAc can be further divided into ‘core’ and 
‘shell’ subregions 263,752, the former resembling more closely the CP while the latter 
is considered an integral part of the mesocorticolimbic tract.
The striatal complex receives input from the neocortex and relays information via 
the globus pallidus, subthalamic nucleus and substantia nigra pars reticulata (SNr) 
to the thalamus and ultimately the cerebral cortex, thereby completing the cortico-
striato-thalamo-cortical loop (reviewed in: 7). The cortex, thalamus and limbic 
structures such as the hippocampus and amygdala provide the striatum with cog-
nitive, sensory and emotional input, via predominantly excitatory (glutamatergic) 
afferents. By contrast, the two major striatal output pathways consist of GABA-ergic 
projections to the globus pallidus and the substantia nigra pars reticulata (SNr). 
Furthermore, there are reciprocal GABA-ergic connections between the ventral 
tegmental area (VTA) and the NAc shell 325,680. The striatal complex contains a large 
population of cholinergic interneurons and a high concentration of neuropeptides 
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such as enkephalin, dynorphin, substance P, somatostatin, neuropeptide Y and 
cholecystokinin (reviewed in: 270). The dense dopaminergic innervation of the 
striatal complex originates from three nuclei in the ventral mesencephalon (A8-
10). Based on the origin of this dopaminergic innervation and functional studies, a 
rough distinction has been made between the nigrostriatal and mesocorticolimbic 
dopaminergic pathways. It should be noted that this is an oversimplification since 
there are many reciprocal connections between the two systems.
2.2.1 Mesocorticolimbic dopamine
Cell bodies of the mesocorticolimbic dopamine pathway are localised in the ventral 
tegmental area (VTA, A10 cell group) and project to limbic regions including the 
NAc shell, limbic cortex (prefrontal- cingulate- and entorhinal cortices), amygdala, 
lateral septum, bed nucleus of the stria terminalis, ventral pallidum (VP, ventral 
analogue of the globus pallidus) and the olfactory tubercle (figure 2).
The mesocorticolimbic dopaminergic pathway plays an essential role in regu-
lation of reward, motivation and goal-directed behaviours (reviewed in: 733). The 
dopaminergic projection from the VTA to the NAc forms a neural substrate underly-
ing the reinforcing properties of natural rewards such as food, water and sex 25,89,342, 
psychological rewards 42,356,457 and drugs of abuse (see section 4.1). Furthermore, 












Figure 2: Schematic representation of the mesocorticolimbic and nigrostriatal dopamine 
projections in the mouse brain.
Midsagittal section showing the location of the A9 and A10 cell groups and the projection 
areas of the nigrostriatal and mesocorticolimbic neurons, respectively. SN: substantia nigra, 
VTA: ventral tegmental area.
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the mesocorticolimbic pathway has been implicated as the principal dopaminergic 
pathway involved in the aetiology of psychoses 239,331 and has, together with the 
nigrostriatal system, been associated with the pathology of attention-deficit hyper-
activity disorder 631.
2.2.2 Nigrostriatal dopamine
The nigrostriatal system consists of dopaminergic neurons that originate in the sub-
stantia nigra (SN, A9 cell group) and project to the CP and the NAc core subregion 
(figure 2). The SN can be subdivided in a pars compacta (SNc) and a pars reticulata 
(SNr), the former containing the cell bodies of the nigrostriatal dopaminergic neu-
rons, whereas the latter contains the GABA-ergic neurons that form one of the two 
major output pathways of the striatal complex to the motor thalamus (the other 
being via the globus pallidus).
The nigrostriatal dopaminergic pathway has traditionally been implicated in 
motor control, e.g. regulation of voluntary movement and stereotyped behaviours 
259,452. Loss of nigrostriatal dopaminergic neurons is the main pathological feature 
of Parkinson’s disease and antipsychotic drugs that antagonise dopamine recep-
tors have considerable extrapyramidal side effects (tardive dyskinesia) due to their 
actions within the nigrostriatal pathway 260,546. Conversely, stereotyped behaviours 
produced by increasing doses of psychostimulants such as cocaine and amphet-
amine have been linked to the activating effects of these drugs on striatal dopamine 
345. More recent studies have indicated that the dorsal striatum plays a role in learn-
ing and memory and, more specifically, stimulus-response (habit) learning 489,749.
2.3 dopamine receptors
Already in 1979, it was recognised that dopamine can bind to two types of G-
protein coupled receptors that either inhibit or stimulate adenylate cyclase and can 
be distinguished on the basis of their pharmacological and biochemical properties 
340. Indeed, at the end of the 1980s, the D2 receptor was the first to be cloned 64 
followed within two years by the D1 receptor 159,462,646,757. The discovery of three 
additional receptors (D3, D4 and D5), two splice variants of the D2 receptor (‘short’ 
and ‘long’) and genetic polymorphisms in the D4 receptor has made the pharmacol-
ogy of dopamine increasingly more complex, while at the same time providing new 
opportunities for more specific therapeutics 107,139,238,258,463,630,645,659,689,690,727. Based 
on G-protein coupling, pharmacology, genomic organisation and central nervous 
system (CNS) distribution, the receptors were classified into two families: the D1 
family, consisting of the D1 and D5 receptors, and the D2 family including the D2, 
D3 and D4 receptors (for a review see: 309). Receptors of the D1 family are coupled 
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to Gs proteins and activate adenylate cyclase to produce cAMP, whereas the D2 
receptors inhibit cAMP production via Gi proteins (reviewed in: 311).
While the D1 receptor is the most abundant dopamine receptor in the CNS, D1 and 
D2 receptors are present in all dopaminoceptive brain regions, including the CP, 
NAc, olfactory tubercle and prefrontal cortex (PFC). Both receptors are detected in 
the septum, hippocampus, hypothalamus and thalamus, but expression levels vary 
considerably per receptor and per subregion 222,311,726. Furthermore, the D1 receptor 
is extensively expressed in the amygdala 726. In contrast to the D1 receptor, the D2 
receptor is present on the dopaminergic neurons in the VTA and SNc and, upon ac-
tivation, functions as autoreceptor that inhibits neuronal activity 442,726. Some brain 
regions, including the SNr, have numerous binding sites for the D1 receptor but do 
not express D1 mRNA, suggesting that, in these areas, the D1 receptor is present in 
afferent projections only. Although co-localisation of D1 and D2 receptor mRNAs 
has been demonstrated in a considerable percentage of striatal neurons 385, there is 
also a clear segregation into two neuronal populations: D1 receptors are expressed 
predominantly on neurons that contain substance P and project to the dopaminer-
gic cell bodies in the VTA and SNc, whereas D2 receptors are preferentially found 
on neurons that co-express enkephalin and project to the VP 233,375,407.
The D3, D4 and D5 receptors are much less abundantly expressed than the D1 
and D2 receptors. The D3 receptor has an interesting distribution pattern as it is 
expressed in regions receiving dopaminergic innervation from the VTA such as the 
shell of the NAc, the bed nucleus of the stria terminalis, the olfactory tubercle and 
the islands of Calleja and also in limbic regions including the hippocampus and the 
amygdala. Low densities of the D3 receptor have also been found in the CP. The pres-
ence of D3 in the SNc, and to a lesser extent in the VTA, suggests that this receptor 
can function as dopaminergic autoreceptor 57,177,178. The D4 receptor is also associ-
ated with the limbic regions such as the NAc shell, amygdala, frontal cortex and hy-
pothalamus and low levels are detected in the CP 480,649,689 although it is considerably 
less abundant than the D2 and D3 receptors. By contrast, D5 receptor expression is 
restricted to few brain regions including the hippocampus, mammillary nuclei and 
the parafascicular nucleus of the thalamus 443,659. More recently, the presence and 
functional importance of the D5 receptor in the NAc has been demonstrated 211.
3. tHE strEss rEsPonsE
The term ‘stress’ is frequently used to describe the negative emotional state experi-
enced when a person perceives that the demands (e.g. resulting from work or social 
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engagements) exceed the resources the individual is able to mobilise. Therefore, 
stress has a negative connotation, as it is associated with a reduced feeling of well 
being and, after prolonged periods, with the development of stress-related disease 
(e.g. anxiety and depression). In the present society most, if not all, individuals feel 
that they have experienced stress, however there is not a clear-cut definition for this 
phenomenon.
From the scientific point of view however, the stress response is part of an organisms 
natural defence mechanism to demanding situations. The internal environment of 
all living organisms is regulated in such a way that a dynamic equilibrium, called 
homeostasis, is maintained. Changes in the internal or external environment that 
threaten homeostasis (stressors) turn on a spectrum of physiological and behavioural 
responses aimed at restoring homeostatic balance 146. This process of adaptation is 
also known as ‘allostasis’, meaning ‘achieving stability through change’. However, 
when exposed to stressful situations repeatedly, or when the allostatic mechanisms 
remain activated when no longer needed, the price that has to be paid for maintain-
ing stability (allostatic load) may become too high, resulting in the development 
of stress-related pathology 433. The concept of allostasis is however a matter of 
debate as, in contrast to a physiological adaptive process as proposed by McEwen, 
it has also been suggested to represent a pathological maladaptive process (see 
e.g. Koob and Le Moal 361,433). In 1936, Selye first defined the concept of stress as 
‘the non-specific response of the body to any demand’ 615. Non-specific indicates 
that the stress response is comprised of a fixed set of neuroendocrine adaptations, 
irrespective of the nature of the stressor. These include activation of the autonomic 
sympathetic nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA) 
axis (figure 3), which are described in detail in the following sections. Nowadays, 
it is known that the degree to which the neuroendocrine cascades are activated 
depends on the severity of the stressor but can also show considerable individual 
variation due to genetic background and life history 146.
3.1 the sympathetic nervous system
Activation of the autonomic sympathetic nervous system (ANS), culminating in 
the release of the catecholamines norepinephrine and epinephrine into the gen-
eral circulation, is the first and most rapid aspect of the stress response (figure 3). 
Norepinephrine is released from the post-ganglionic sympathetic nerve terminals 
throughout the body and exerts local control over autonomic effector organs, 
whereas epinephrine is secreted from the medulla of the adrenal glands and acts as 
a humoral messenger that can provide additional autonomic stimulation.
Chapter 1 
22
Together with the parasympathetic nervous system, the sympathetic nervous system 
forms the autonomic nervous system that innervates the skin and all visceral organs. 
Whereas the parasympathetic component is involved in maintaining the vegetative 
(resting) state of the body, the sympathetic component regulates processes related to 
a more active state of the body and increases energy expenditure. Furthermore, the 
sympathetic nervous system is involved in maintaining a constant internal environ-
ment regarding blood pressure, blood glucose and oxygen availability. Activation 












Figure 3: Schematic representation of the hypothalamic-pituitary-adrenal (HPA) axis and 
the autonomic sympathetic nervous system (ANS).
Black arrows indicate the HPA-axis, grey arrows the ANS. Exposure to stress leads to the 
release of corticotrophin-releasing hormone (CRH) from the paraventricular nucleus (PVN) 
of the hypothalamus. This, in turn, induces secretion of adrenocorticotrophic hormone 
(ACTH) from the pituitary, which results in the release of corticosterone from the adrenal 
cortex. Via GRs in the hypothalamus and pituitary, corticosteroids exert a negative feedback 
action, thereby reducing the enhanced HPA-activity. In addition, corticosteroids can 
affect brain function in many regions. Exposure to a stressor also results in rapid release 
of catecholamines (epinephrine and norepinephrine) from the adrenal medulla and 
sympathetic nerve terminals that can, indirectly via the vagal nerve (n. vagus), solitary tract 
nucleus (NTS) and locus coeruleus (LC), lead to release of norepinephrine in the brain.
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concept of ‘fight or flight’, proposed by Cannon in 1911, indicates that arousal in 
response to a perceived threat involves several elements which prepare the body 
physiologically either to take a stand and fight off an attacker, or to flee from the 
danger 86. These ‘elements’ comprise increases in heart rate, blood pressure and 
respiration, more acute hearing and vision and transportation of blood from the 
extremities to the large muscles and the brain.
Epinephrine and norepinephrine exert their effects via two types of receptors be-
longing to the adrenoreceptor family: α and β, which can be further subdivided 
in α1, α2, β1 and β2. Depending on the receptors present and the interaction 
with the cholinergic system, smooth muscles are either contracted or relaxed and 
cellular secretion is stimulated or inhibited. Furthermore, the adrenoreceptors are 
present in the brain, where they mediate central noradrenergic neurotransmission 
261,672-674. Noradrenergic projections in the brain arise from the locus coeruleus (LC, 
A6 cell group) and the lateral tegmental group (consisting of the A1, A2 (nucleus of 
the solitary tract, NTS), A5 and A7 cell groups) and innervate many brain regions 
including the thalamus, hypothalamus, hippocampus, amygdala, cerebral cortex, 
and midbrain 324,482. The CNS adrenergic receptors are however not a direct target 
for the peripheral catecholamines, as these are not likely to pass the blood-brain-
barrier due to their hydrophilic structure 725.
3.2 the HPa-axis
Activation of the endocrine cascade between the hypothalamus, pituitary and 
adrenal glands (HPA-axis) comprises a second aspect of the stress response (figure 
3) 146. Exposure to a stressor rapidly induces the parvocellular neurons in the para-
ventricular nucleus of the hypothalamus (PVN) to secrete corticotrophin releasing 
hormone (CRH) and arginine vasopressin (AVP) into the portal vessel system, the 
vascular link between the hypothalamus and the anterior pituitary. CRH stimulates 
the corticotroph cells of the anterior pituitary to produce adrenocorticotrophic hor-
mone (ACTH) from its precursor pro-opiomelanocortin (POMC) and to release the 
hormone into the general circulation. Whereas CRH is the primary trigger for ACTH 
production and release, AVP is believed to amplify the CRH effect. ACTH travels via 
the general circulation to the adrenals where it stimulates production of glucocor-
ticoid hormones in the cortical layer of the gland. The principal glucocorticoid in 
humans is cortisol, whereas rodents including rats and mice have corticosterone.
In addition to stress-induced activation, the HPA-axis follows circadian rhythmicity 
that is controlled by the suprachiasmatic nucleus 63, resulting in peak concentrations 
of plasma glucocorticoids around the start of the active period. Furthermore, an 
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ultradian rhythm of corticosteroid release, with intervals of less than 24 hours, has 
been demonstrated in a variety of species 217,601,732. The HPA-axis is also powerfully 
activated by psychostimulant drugs such as cocaine and amphetamine in both 
humans and laboratory rodents 31,281,355,448,461,590. Both drugs stimulate secretion 
of hypothalamic CRH, which is mediated by multiple neurotransmitter systems, 
including catecholaminergic (dopaminergic, noradrenergic), glutamatergic, opiate, 
serotonergic and cholinergic systems 52,140,596.
Glucocorticoid hormones enable an organism to respond and adapt to a stressor 
and prepare for a subsequent event. Glucocorticoid actions can be considered indi-
rect: depending on timing, context and endpoint these hormones either facilitate or 
attenuate physiological or behavioural outcomes. In the words of Robert Sapolsky: 
‘glucocorticoids can permit, suppress or stimulate an ongoing stress response and, 
in addition, prepare an organism for subsequent stressors’ 591. In short, gluco-
corticoids permit sympathoadrenal activity and cardiovascular activation, direct 
metabolism towards mobilisation of energy stores, have potent anti-inflammatory 
and immunosuppressive properties, inhibit reproduction and, as they can cross the 
blood-brain-barrier, have profound effects on brain function and behaviour.
The lipophilic glucocorticoid hormones readily pass the cell membrane and can 
bind to two types of intracellular receptors: the mineralocorticoid receptor (MR) and 
the glucocorticoid receptor (GR) 147. As the name indicates, the MR was originally 
identified as the receptor for a mineralocorticoid hormone aldosterone that is also 
produced in the adrenal cortex and primarily regulates salt and water balance in the 
kidney. Whereas in the kidney metabolic inactivation of glucocorticoids by 11β-
hydroxysteroid dehydrogenase prevents these hormones from binding MR 189,223, in 
the brain activity of this enzyme is low and glucocorticoids can readily activate both 
MR and GR 116,374,541. In fact, the MR has a 10-fold higher affinity for glucocorticoids 
than GR 147. Therefore, brain MR is almost fully saturated at low circulating levels 
of glucocorticoids, during the circadian trough, whereas the GR becomes occupied 
only at increasing levels of the adrenal steroids, during stress or at the circadian 
peak 541. Additional factors that determine uptake of glucocorticoids in the brain 
and other target tissues include the efflux transporter p-glycoprotein that is present 
at the blood-brain-barrier 336 and corticosteroid binding globulin, a plasma protein 
that binds circulating endogenous glucocorticoids 276.
Another striking difference between the two receptor types is their localisation in 
the brain. GR has a relatively widespread distribution pattern with highest concen-
trations in brain regions involved in HPA-axis regulation such as the PVN and the 
hippocampus. By contrast, MR expression is more restricted to the limbic regions 
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such as the hippocampus, amygdala, septum and low levels are also detectable in 
the CP 4,98,494,541,636,686.
The differences in receptor affinities and distribution have led to the hypothesis 
that the MR and GR mediate different aspects of glucocorticoid signalling. Whereas 
MR is suggested to regulate maintenance of HPA-axis activity and the threshold of 
the system to stress (‘proactive mode’), GR is proposed to mediate steroid control 
of recovery from stress (‘reactive mode’) 148,149. The most striking example of the 
reactive mode is the negative feedback exerted by glucocorticoids on HPA-axis 
activity itself, by binding to GR in the PVN and the pituitary 148,341. In brain regions 
where both receptor types are co-localised, such as the hippocampus, the outcome 
of glucocorticoid action critically depends on the balance between MR and GR 
activation 317,481,685. Furthermore, MR and GR may, depending on the context, act 
synergistically or antagonistically.
MR and GR belong to the superfamily of nuclear receptors that regulate gene 
transcription. Upon binding of a ligand in the cytosol, the receptor dissociates 
from a protein complex and translocates into the nucleus. The activated receptors 
form dimers and bind to specific glucocorticoid response elements (GREs) in the 
promotor areas of genes, where they recruit transcriptional machinery and activate 
transcription. The fact that the steroid receptors not only form homodimers (GR/GR) 
but also heterodimers (GR/MR) adds another level of functional diversity to cor-
ticosteroid action 668. Furthermore, in addition to transactivation, glucocorticoids 
can also induce transrepression. This mechanism can involve direct protein-protein 
interactions of monomeric receptors with other transcription factors, the most well 
known being NFκB and AP-1 603,723. The existence of negative GREs, mediating 
transrepression rather than transactivation, has also been described for the promo-
tors of the CRH and COMT genes 184,413. Furthermore, there is considerable diversity 
in the stochiometry of the transcriptional co-regulator proteins that are thought to 
determine the magnitude and nature of the steroid response 446. Interestingly, it has 
recently been demonstrated that glucocorticoids exert their actions not only via 
nuclear receptor-mediated transcriptional regulation, but also via a non-genomic 
mechanism involving membrane-bound receptors and requiring a considerably 
shorter time span 55,103,176,338. Indeed, evidence is now accumulating that adrenal 
glucocorticoids regulate a wide range of behaviours via a rapid non-genomic 
mechanism (see e.g. 339,450,451,584,589).
Taken together, the actions of glucocorticoids are highly context-dependent. Fac-
tors such as timing (allowing genomic vs. non-genomic actions), cellular context 
(e.g. target tissue, presence of receptor types, transcription factors and co-regulator 
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proteins), organismal context (e.g. genetics, current neuroendocrine status) and 
endpoint determine whether the glucocorticoids are stimulatory, inhibitory or even 
without effect.
4. nEurobIoloGy oF rEward
4.1 dopamine
The mesocorticolimbic dopamine system plays a critical role in the behavioural and 
reinforcing effects of all classes of abused drugs. In the following paragraphs, the 
focus is on psychostimulants. The evidence presented is based on studies using the 
self-administration paradigm that, to date, is the most representative animal model 
for aspects of human drug abuse. Some methodological considerations regarding 
this model are described in box 1.
Psychostimulants such as cocaine and amphetamine increase extracellular do-
pamine concentrations in the NAc to a greater extent than in the CP 170, an effect 
which is most pronounced in the NAc shell subregion 526. It was demonstrated with 
selective lesions that drug-induced dopamine release in the NAc, but not the dorsal 
striatum, is critical for the locomotor stimulant effect of cocaine and amphetamine 
344,345, which is considered to have predictive value for the reinforcing properties of 
these drugs 733. During cocaine and amphetamine self-administration, extracellular 
dopamine levels in the NAc are tonically elevated 171,503 and fluctuate with pha-
sic increases just after, and phasic decreases just before, infusions 234,537,734. These 
observations have led to the hypothesis that animals self-administer the drugs to 
compensate for the falling concentrations of dopamine.
Cocaine and amphetamine are self-administered directly into the NAc 104,440,506,569, 
primarily in the shell subregion 569, and dopamine-selective lesions in the VTA or 
NAc attenuate maintenance of psychostimulant self-administration 79,409,502,556,557, 
whereas their effects on initiation of this behaviour are more controversial 235,409. By 
contrast, destruction of noradrenergic or serotonergic neurons does not influence 
psychostimulant self-administration 213,556. Paradoxically, whereas lesions attenu-
ate self-administration, dopamine D1 and D2 receptor antagonists administered 
systemically or directly into the VTA, NAc or amygdala, enhance the rate of psy-
chostimulant-maintained self-administration 8,78,299,301,411,439,506,538,750 while reducing 
the motivation to obtain the drug under a progressive ratio schedule 28,299,439,538. 
The increase in drug intake is thought to reflect a decrease in the magnitude of the 
reinforcer, which is in agreement with the reduced motivation to obtain cocaine. 
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Cocaine, but not amphetamine, is also self-administered directly into the medial 
prefrontal cortex (mPFC) and this is critically dependent on the dopaminergic in-
nervation of this brain region 242,247,248. Ablation of dopamine in the mPFC enhances 
acquisition and maintenance of intravenous cocaine self-administration at low 
box 1: The self-administration model.
To date, the most representative animal model for human substance abuse is the self-administration 
model, which has been developed for both laboratory rodents and non-human primates. In brief, 
animals are equipped with intravenous or intracerebral catheters and, upon voluntary performance 
of an instrumental response (e.g. to push a lever, or to poke the nose in a designated hole), earn a 
drug infusion. Different stages of the paradigm and variations therein allow for distinct features of 
drug addiction to be modelled.
 In the acquisition phase, animals obtain a drug infusion by performing a fixed number of re-
sponses, the so-called ‘fixed ratio schedule’. Acquisition of self-administration is therefore a measure 
of the reinforcing- or abuse potential of the drug (the extent to which it facilitates the acquisition 
of an instrumental response required to obtain it). Furthermore, during this phase, individual differ-
ences in sensitivity to the reinforcing effects of drugs can be distinguished.
 Once self-administration is acquired, animals maintain stable responding that may be subject to 
secondary reinforcers: environmental stimuli that are associated with the drug (primary reinforcer). 
Different aspects of drug taking can be studied during the maintenance phase: i) Dose-response 
relationships: shifts in the typical inverted U-shaped dose-response curve provide another measure 
for individual differences in vulnerability to the drug reward 513, ii) The motivation to obtain the 
drug: under a progressive ratio schedule the effort (number of instrumental responses) required to 
obtain a drug infusion is progressively, and most often exponentially, increased. The ‘break-point’ at 
which an animal stops responding is an index of its motivation to work for a drug infusion, and iii) 
Continuance despite negative consequences: persistence of drug seeking, even when drug infusion 
is coupled to an adverse conditioned stimulus such as foot-shock 167,692.
 During extinction, the drug-paired instrumental response is no longer reinforced by drug infusion. 
At this stage, the persistence of responding (thus fruitless drug seeking) provides a measure for the 
motivation to obtain the drug and may represent a certain degree of ‘difficulty in limiting intake’ 167. 
Furthermore, during the extinction phase, there may be physical withdrawal symptoms, the nature of 
which varies across classes of abused drugs. Finally, reinstatement of drug seeking can be induced in 
abstinent animals by a priming injection of the drug itself, presentation of drug-associated cues that 
have acquired incentive motivational properties, or stressful events.
 Thus, depending on the design, the self-administration model allows for several features of human 
drug abuse to be modelled, including i) extreme motivation to obtain the drug, ii) difficulty in limit-
ing intake, iii) continuance despite negative consequences, iv) withdrawal, and v) high propensity for 
relapse. Deroche-Gamonet et al. recently scored outbred rats for multiple ‘addiction-like’ behaviours 
(i, ii and iii) in a cocaine self-administration paradigm and found that only a subset of rats (17%) 
shows a high score for all three characteristics, which is in good agreement with the risk of becoming 
cocaine dependent after single use of the drug in humans (15-20%) 167.
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doses of the drug and also the motivation for cocaine self-administration under a 
progressive ratio schedule 438,605. Other studies have however not found effects of 
dopaminergic lesions in the mPFC on psychostimulant self-administration 379,425, 
which may be due to variations in the extent of the lesions.
Finally, dopamine also plays a prominent role in reinstatement of cocaine seek-
ing, induced by re-exposure to the drug itself, drug-associated cues or stressors 9,11,
12,38,88,115,152,227,351,352,434,435,604,612,613,644,740. Whereas dopamine in the medial and dorsal 
PFC plays a role in cocaine- and stress-induced reinstatement 88,434,435,644, dopamine 
in the basolateral and central nuclei of the amygdala contributes to cue- and drug-
induced reinstatement 8,38,612. Interestingly, in addition to the D1 and D2 receptors, 
there appears to be a prominent role for the D3 receptor in all types of reinstatement 
of cocaine seeking 97,227,523,712,740,741.
In summary, there is convincing evidence for the role of the mesocorticolimbic 
dopamine system in psychostimulant reward. In addition, in accordance with the 
notion that the dorsal striatum plays a role in stimulus-response (habit) learning 
489,749, it has been demonstrated that the nigrostriatal dopaminergic pathway is in-
volved in established, or habitual, cocaine-seeking behaviour in both humans and 
laboratory rodents 307,697,711.
4.2 Glutamate
It has become increasingly evident that in addition to dopamine, glutamate plays 
an essential role in drug reward and reinforcement. Dopaminergic neurons in 
the NAc and VTA receive extensive glutamatergic input from the PFC, amygdala 
and hippocampus 48,112,215,256,264,343,654. Cocaine and amphetamine both stimulate 
glutamate release in the PFC and NAc 540 which is potentiated with repeated 
exposure 539. Glutamate enhances dopaminergic transmission by increasing activ-
ity of the dopaminergic neurons in the VTA, and facilitating dopamine release 
from the presynaptic terminals in the NAc 48,215,335,654. Many of the actions of the 
excitatory transmitter rely on this stimulatory interaction with the dopamine 
system. For example, basal and psychostimulant-induced locomotion, which are 
critically dependent on dopamine, are stimulated and inhibited by glutamatergic 
agonists and antagonists, respectively 534,650. However, as described below, some 
of the actions of the excitatory transmitter in psychostimulant reinforcement are 
independent of dopamine.
Glutamate acts via two classes of receptors: ionotropic (ligand-gated ion chan-
nels) and metabotropic (G-protein coupled) receptors, each consisting of multiple 
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subtypes that may, depending on localisation and function, have distinct roles in 
drug reinforcement. During maintenance of cocaine self-administration, stimula-
tion of ionotropic glutamate receptors in the NAc causes a leftward shift in the 
dose-response curve, whereas antagonism of these receptors is ineffective 128. The 
authors argue that signalling via ionotropic receptors in the NAc enhances cocaine 
reward whereas it is not required for maintenance of cocaine self-administration. 
Conversely, blockade of the metabotropic glutamate receptor 5 (mGluR5) reduces 
cocaine-maintained self-administration and the motivation to obtain the drug under 
a progressive ratio schedule, while elevating reward thresholds for intracranial self-
stimulation 350,380,495,658. Furthermore, mice lacking the mGluR5 do not self-administer 
cocaine and do not show increased locomotion after cocaine administration, de-
spite the fact that dopamine function is comparable to that of wild-type mice 105. 
These studies point to an important role for mGluR5 in cocaine reward, which may 
be independent of dopamine transmission.
Glutamatergic transmission via ionotropic and metabotropic receptors modulates 
drug- and cue-induced reinstatement of cocaine seeking which is in good agree-
ment with the role of the PFC and amygdala in relapse to drug seeking 19,27,128,380. 
In fact, the glutamatergic pathway from the PFC to the NAc, and in particular the 
core subregion, plays a critical role in cocaine-primed reinstatement of drug seek-
ing 129,436,492,501 which may also involve the excitatory innervation of the VTA 643. 
Furthermore, it was demonstrated by Cornish et al., that glutamatergic, but not 
dopaminergic, transmission in the NAc is necessary for cocaine-induced reinstate-
ment of drug seeking 129. Excitatory transmission in the NAc also contributes to 
cue-controlled cocaine-seeking 172 and cocaine-associated cues increase glutamate 
release in the NAc 298. Similarly, accumbal glutamate release is enhanced during 
cocaine- and stress-induced reinstatement 434,436.
Perhaps the most striking evidence for the importance of glutamate in addiction 
processes, comes form the observation that many of the enduring neuroplastic 
changes associated with repeated psychostimulant (self-)administration involve 
glutamatergic transmission 56,90,283,328,329,402,403,657,742,746. Of particular interest is the 
synaptic plasticity that occurs in reward-related brain regions. It was demonstrated 
that a single in vivo cocaine exposure induces neuronal plasticity of AMPA-mediated 
currents at excitatory synapses onto dopamine cells in the VTA 676. Furthermore, the 
structural plasticity in the NAc core and mPFC associated with cocaine-induced 
behavioural sensitisation, is localised to portions of the dendritic tree that might 




When integrating the evidence described in the previous paragraphs, the neurocir-
cuitry that mediates reward and translates biologically relevant stimuli into adaptive 
behavioural responses, also termed the ‘motive circuit’ can be envisaged as consisting 
of a network of several brain regions that communicate via multiple neurotransmit-
ters. Similarly, neuroimaging studies in humans have indicated that cocaine craving is 
associated with the activation of several brain regions, including the PFC, amygdala, 
hippocampus and the striatal complex 106,229,353. A simplified representation of the 
motive circuit is shown in figure 4 (for a review see: 328).
In line with the classical ‘dopamine hypothesis’ of addiction, the mesocorticolimbic 
dopaminergic projection from the VTA to the NAc, PFC and amygdala forms the 














Figure 4: Schematic drawing of the ‘motive circuit’.
Arrows indicate neuronal connections that are either dopaminergic (black), glutamatergic 
(grey) or GABA-ergic (dashed). Rectangles with similar colour indicate a sub-circuitry in 
the motive circuit. PFC v/d: prefrontal cortex ventral/dorsal subdivisions, NAc: nucleus 
accumbens, VTA: ventral tegmental area, SN c/r: substantia nigra pars compacta/reticulata, 
Amy: amygdala, CP: caudate putamen, VP: ventral pallidum.
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regions) and amygdala in turn, send glutamatergic afferent projections to the VTA 
and the NAc. The PFC provides the subcortical dopamine systems with cognitive 
input and is involved in anticipation/predictability of reward 656,671, whereas the 
amygdala is involved in establishing learned associations between motivationally 
relevant events and otherwise neutral stimuli (cues) that become predictors of the 
event 201. Two subcircuits can be distinguished, with the NAc shell being more 
closely connected with the VTA, the ventral PFC, the amygdala and the medial 
VP. By contrast the NAc core is more tightly associated with the dorsal PFC, the 
dorsolateral VP and the SNc 328,754. Dopaminergic signalling within the NAc shell 
subcircuit is critically involved in the reinforcing properties of psychostimulants 
as well as in establishment of self-administration and behavioural sensitisation. 
However, it has been proposed that glutamatergic transmission, and in particular 
the subcircuitry involving the dorsal PFC and the NAc core, mediates expression 
of these behaviours when they have become more compulsive and habitual, such 
as during reinstatement of drug seeking 329. Indeed, the PFC and the NAc mediate 
cocaine-, stress- and cue-induced reinstatement 88,434,435, whereas the basolateral 
and central nuclei of the amygdala play a prominent role in cue- and stress-induced 
relapse to cocaine seeking respectively 330,370,618. In addition, it was recently 
demonstrated that the dorsal striatum is critical for cue-controlled cocaine seeking 
697. Despite the prominent role for glutamate in expression of addictive behaviours, 
the mesocorticolimbic dopaminergic projection remains compulsory, although in 
more advanced stages dopamine release in the PFC and amygdala, rather than in 
the NAc, may be required 88,434,612.
4.4 other neurotransmitters
In addition to dopamine and glutamate, other neurotransmitters including gamma-
aminobutyric acid (GABA) 61,554, norepinephrine 143,183,193,384, serotonin 209,467, ace-
tylcholine 629, endogenous opioids 688 and endocannabinoids 412 are involved in 
reward processes. It is beyond the scope of this thesis to describe their involvement 
in detail. Of particular interest are GABA, because of its role in connectivity and 
output of the nuclei of the motive circuit (see section 2.2 and figure 4), and serotonin 
and norepinephrine because of the actions of cocaine on the SERT and NET respec-
tively. Whereas GABA appears to have an overall inhibitory role in psychostimulant 
reinforcement 59,60,85,173,180,204,278,555,625, the roles of serotonin and norepinephrine are 
more controversial. Serotonin can facilitate or suppress psychostimulant reinforce-
ment, depending on the receptor subtypes and brain regions involved (for reviews 
see: 209,467). However, studies using amphetamine- and cocaine-like analogues 
with varying serotonin releasing potency, have demonstrated that the serotonergic 
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activity of these compounds is inversely related to their reinforcing potential 558,721. In 
agreement with this, enhancement of serotonergic transmission attenuates cocaine 
self-administration 93,500. Controversy exists regarding the role of the noradrenergic 
system. Several studies did not find support for the involvement of norepineph-
rine in psychostimulant reinforcement, whereas others point to a facilitatory role 
143,183,548,556,602,722,739. There is however strong evidence for the involvement of the 
noradrenergic system in stress-induced reinstatement of cocaine, ethanol and mor-
phine seeking 193,376,384,620.
5. IndIVIdual dIFFErEncEs In cocaInE sEnsItIVIty
5.1 Human studies
Despite the fact that cocaine is a highly addictive substance and large numbers of 
people experiment with it for variable periods of time, not every individual who 
tries the drug once will become an addict 478. The same holds true for all other ad-
dictive drugs. Studies on the incidence of cocaine dependence, making use of large 
populations in America, have indicated that the risk of becoming dependent on co-
caine within 1-2 years after the first use of the drug is between 5 and 6% 479,715. The 
risk of cocaine dependence increases with time, being 15-16% after 10 years but 
reaches a plateau of around 20% after 20 years 715. Table 1 shows the prevalences 
(during lifetime or recent: in the month prior to data collection) of the use of several 
addictive drugs in The Netherlands. The ratio between recent and lifetime use will 
give a crude indication of the percentage of problem users, although these data are 
confounded by first-time usage during the year prior to data collection. Despite 
the fact that the drugs differ considerably in prevalences and ratio, they share the 
common feature that only a relatively small percentage of lifetime users progresses 
table 1: Drug use in the Dutch population (>12 years old) in 2001(%).
lifetime recent* recent / lifetime
cocaine  2.9 0.4 13.8
Ecstacy  2.9 0.5 17.2
amphetamine  2.6 0.2  7.7
Heroin  0.4 0.1 25.0
cannabis 17.0 3.0 17.6
* During the month prior to data collection.
Source: National Drug Monitor 2005, Trimbos Institute, Utrecht, The Netherlands.
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to problem users. Collectively, these data point to the existence of pronounced 
individual differences in sensitivity to addictive drugs, which has been confirmed in 
many studies (e.g.: 158,478).
5.2 animal studies
From animal studies, a similar picture has emerged. Within a large population of 
animals, phenotypes can be distinguished based on pre-existing traits, that are 
either vulnerable or resistant to the rewarding effects of psychostimulants such as 
cocaine and amphetamine 167,203,323,354,511,513,684 or display differential motivation to 
obtain the drugs 287. In the work of Piazza et al. it was shown that ‘novelty seek-
ers’ (rats that display higher locomotor responses and corticosterone secretion in 
response to a novel environment), also called ‘high-responders’ (HRs), were more 
prone to acquire amphetamine self-administration than rats with a low exploratory 
response 511. Homberg et al. used a different criterion to pre-select animals and 
showed that rats being more vulnerable to stress-induced anxiety (as indexed by 
self-grooming) display higher motivation to self-administer cocaine 287. These two 
animal models may represent two different motivational aspects of psychostimulant 
use: to engender a positive mood state (‘high’) or to alleviate negative affect 24 
with the drug acting either as positive or as negative reinforcer respectively. Most 
interestingly, comparable pre-existing personality traits have been reported among 
human cocaine users 268,731: Gunnarsdottir et al. showed that a distinction could be 
made between so-called ‘self-medicators’ and ‘sensation seekers’. The former dis-
played higher anxiety scores whereas the latter were characterised by high novelty 
seeking scores 268.
It is of great importance to unravel the mechanisms behind individual differences 
in psychostimulant sensitivity. This will not only increase the understanding of the 
neurobiology of addiction but also open new perspectives for individualised pre-
vention and treatment programs. As proposed by Ellenbroek et al., addiction, like 
most other psychiatric diseases, can best be described by the so-called ‘three hit 
model of psychopathology’. This model is based on the assumption that psychiatric 
diseases result from the interplay between three factors, being i) genetic factors, ii) 
early life events, and iii) later life stressors 190. In addition, drug-induced neuroadap-
tations, contextual factors (such as drug availability, environment in which the drug 
is taken, social aspects) and pharmacokinetic properties of the drug itself (see e.g.: 
588) may contribute to individual differences. Evidence for the role of genetics, early 





There is considerable evidence that genetic susceptibility plays a role in the pro-
gression from substance use to dependence and ultimately addiction. Like for most 
diseases, the genetic contribution to addiction is highly complex, as heredity reflects 
both the variance attributable to genetic factors themselves and the variance result-
ing from interactions between genes and environment 132. Thus, genetic factors not 
only determine individual differences in drug pharmacokinetics and vulnerability to 
the reinforcing properties of drugs, but also susceptibility to the effects of life events 
thereupon 710.
Twin studies have indicated that addictions are among the most heritable of psy-
chiatric disorders 254. Although most research has focused on alcohol and tobacco 
abuse, which have much higher prevalences that illicit drug use, several studies 
have indicated that there is a substantial genetic component in vulnerability to 
the reinforcing properties of cocaine 348,670, which is more pronounced for cocaine 
abuse than use 348. Interestingly, it has been proposed that the genetic component in 
drug addiction is not substance-specific but rather extends to all classes of abused 
drugs 349. In addition, there may be genes that are specific to a certain type of drug 
and its neurobiological and pharmacological profile.
Studies in humans have identified several genes that are associated with cocaine 
dependence, of which the D2 receptor gene has gained most attention. There is 
a strong association between cocaine dependence and certain alleles of the D2 
receptor gene (A1 and B1) 475 and the A1 allele has also been associated with the 
occurrence of severe alcoholism 121, nicotine and opioid dependence, polysub-
stance abuse and obesity (for a review see: 473,476). Conflicting data have, however, 
also been reported 231. Carriers of the A1 allele have lower numbers of D2 receptors 
in the striatal complex and several additional metabolic and neurophysiological 
differences within dopamine rich brain regions (reviewed in: 474). Interestingly, this 
allele has also been associated with the occurrence of post-traumatic stress disorder 
(PTSD) 123, which is intriguing in view of the high co-morbidity between PTSD and 
drug abuse (see section 5.5). This finding suggests that the D2 receptor gene might 
engage in gene-environment interactions, which has been supported by studies 
showing that cigarette craving 198 and cognitive function 41 were differentially af-
fected by stress in carriers vs. non-carriers of the A1 allele.
Other genes that have been associated with either cocaine dependence or 
cocaine-induced paranoia in humans include the DAT 230,267, the D3 receptor 120, 
the serotonin transporter 312,426, dopamine-β-hydroxylase 133, the cannabinoid 1 
receptor 122, prodynorphin 99, the mu-opioid receptor 761, myelin-related genes 6 
and homer 1 137. However, the difficulty with association studies is that it cannot be 
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distinguished whether genes play a role in establishment of addiction, underlie as-
pects of withdrawal, or rather represent a compensatory homeostatic mechanism.
In laboratory studies, outbred strains can be used to identify subgroups of animals 
that are either vulnerable or resistant to psychostimulants, environmental manipu-
lations and the interaction between these factors (see also section 5.2). Selective 
breeding of these subgroups can result in stable lines of susceptible and resistant 
animals that can be subsequently used for the identification of ‘susceptibility genes’. 
The ‘APO/SUS’ and ‘APO/UNSUS’ rats are an example of this approach being suc-
cessfully applied. These lines were generated by selective breeding of outbred rats 
that had been initially selected on the basis of SUSceptibility to APOmorphine-
induced gnawing (gnawing score: APO/SUS: >500/45 min, -UNSUS: <10/45 min, 
in response to 1.5 mg/kg apomorphine). Whereas APO/UNSUS rats self-administer 
more cocaine under habituated conditions, the APO/SUS rats take more of the 
drug under stressful circumstances 684. Furthermore these animals display several 
behavioural, neuroanatomical, neurochemical and endocrine differences related 
to the brain dopamine system, the HPA-axis and prolactin (for a review see: 191). 
Gene-expression analysis revealed one gene that is differentially expressed in the 
hippocampus of APO/SUS vs. -UNSUS rats: the Aph-1b component of the gamma-
secretase gene, which plays a role during (neuronal) development. Whereas APO/
UNSUS rats have three copies of the gene, the APO/SUS rats possess only one 
or two 125. The gene-dosage imbalance correlates with a number of behavioural 
phenotypes and it will be an interesting challenge to elucidate the mechanisms that 
underlie the contribution of this genetic variation alone, and in interaction with 
environmental factors.
Inbred mouse strains provide another valuable tool to study the impact of genes on 
behaviour. Differences between strains are attributable to genetic traits, whereas 
individual differences within a strain reflect the contribution of environmental 
factors. However, in both cases, gene-environment interactions are likely to play 
a significant role. An array of recombinant inbred mouse strains, generated from 
two parental inbred strains, can be used to identify quantitative trait loci (QTL): 
chromosomal markers that are associated with a certain phenotypic characteristic. 
In addition, broad-scale gene-expression profiling, and expression analysis of genes 
known to be involved in a certain type of behaviour, can be used to identify genes 
that underlie the phenotypic differences between inbred (and outbred) strains. Many 
inbred mouse strains have been tested for sensitivity to drugs of abuse and underly-
ing genetic predisposition and it is outside the scope of this thesis to describe them 
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all. However, the C57BL/6 and DBA/2 strains will be discussed in detail in section 
6, as these strains are used in the experiments presented in this thesis.
Studies in laboratory rodents have led to the identification of a considerable num-
ber of candidate genes that are associated with psychostimulant vulnerability and 
self-administration. Knockouts and transgenics can subsequently be used to further 
elucidate the putative role of these genes in addiction. Some examples of very 
promising genes include ∆FosB 101,117,294,346,432, cyclic AMP response element bind-
ing protein (CREB) 357,614,717 and their downstream targets, extracellularly regulated 
kinase (ERK) 39,679, cocaine- and amphetamine-regulated transcript (CART) 181,371, 
homer proteins 653 and glutamate receptors 221,403,662.
5.4 Early life events
Epidemiological studies have indicated that traumatic experiences in early life, 
such as physical or sexual abuse and neglect, are correlated with a higher risk of 
substance abuse in adolescence and adulthood (e.g.: 207,280,586). Even more convinc-
ing evidence for the role of early environmental factors has come from twin studies. 
For instance, in twins discordant for childhood sexual abuse, the exposed twin is at 
higher risk for substance abuse disorders than the non-exposed twin 347.
Several groups have investigated the effects of early life manipulations on sensi-
tivity to psychostimulants in laboratory rodents. Most frequently, these studies apply 
maternal separation as stressor. In this paradigm, pups are repeatedly separated 
from the mother, either alone or with the litter, during early postnatal days for time 
periods that can vary between several minutes to multiple hours. A wealth of data 
indicates that these manipulations have profound effects on emotional, stress and 
HPA-axis reactivity of animals in adulthood (see e.g. 80,81,219,525,528). Maternal separa-
tion has consistently been reported to alter both acquisition and maintenance of co-
caine self-administration, although controversy exists as to whether these processes 
are facilitated or inhibited by the neonatal manipulation 363,365,366,429,756. Similarly, 
conflicting data have been reported regarding the effects of maternal separation on 
the exploratory response in a novel environment, psychostimulant-induced loco-
motion and drug- or stress-induced behavioural sensitisation to psychostimulants 
58,83,393,428,728.
The discrepancies may in part be attributable to experimental differences in the 
neonatal manipulations, including individual or litter separation, frequency and du-
ration of the separation, the nature of the control group, the circadian cycle and the 
temperature during maternal absence. Especially the duration of the manipulation 
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may be of great importance, as Moffett et al. have shown that daily 3 hours separa-
tions enhanced acquisition of cocaine self-administration when compared to non 
handled controls, whereas these behaviours were blunted in animals separated for 
15 minutes per day 458. In support of this, it has been proposed that short periods 
of maternal separation (also termed ‘handling’) result in reduced emotionality and 
HPA-axis responsiveness to stress in adulthood, whereas prolonged separations 
(also termed ‘maternal deprivation’) have reverse effects (reviewed in 386,445). Con-
flicting results have also been obtained for the influence of isolation rearing during 
adolescence, a paradigm in which animals are housed separately from weaning for 
prolonged periods of time (multiple weeks), on cocaine self-administration. This 
procedure has been reported to either enhance or retard acquisition of intravenous 
cocaine self-administration 505,606,743 and to retard acquisition of intra NAc self-
administration of amphetamine 504.
Despite considerable differences in experimental design and outcome, it is evident 
that early life stressors, such as maternal separation, have profound effects on psy-
chostimulant sensitivity in adulthood. In line with this, early life manipulations have 
been shown to alter neuroanatomical and neurochemical parameters in multiple 
neurotransmitter systems in the brain, including the dopamine system (for a review 
see: 286,444).
5.5 later life stressors
Stressful life experiences are associated with a greater susceptibility to drug abuse 
and craving in humans 334,364,542,627. Furthermore, there is high prevalence of PTSD 
pathology among drug addicts when compared to the general population 205,468,487 
and the severity of PTSD symptoms has been positively correlated with the extent of 
cocaine use and craving 18,585. In addition, stress-induced cocaine craving is associ-
ated with alterations in neuronal activity in reward-related regions in the brain 628.
In laboratory rodents, stress increases dopamine release in the NAc, CP and mPFC 
1,303,305,532 and potentiates psychostimulant-induced dopamine release 635. In line with 
the neurochemical effect, stress increases the locomotor response to psychostimu-
lants, administered either systemically or into the NAc 164,272,284,383,389,635. Acquisition 
of cocaine and amphetamine self-administration is enhanced by stress 244,277,510,536,660 
the extent of which may depend on the nature of the stressor 536. The few studies 
that have examined the effects of stress on cocaine maintained self-administration 
report enhanced rates of responding and higher cocaine intake after stress 131,417. 
Furthermore, exposure to a stressor can reinstate extinguished cocaine seeking 194. 
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It is interesting to note that there are considerable individual differences in sus-
ceptibility to the impact of stress on psychostimulant-induced dopamine release, 
-locomotion and -self-administration 20,323,580.
5.5.1 The HPA-axis
Many studies have focused on the contribution of the HPA-axis in mediating the 
effects of stress on drug sensitivity. It has been demonstrated that acute cortisol 
administration triggers craving in individuals with cocaine dependence 192 and that 
cortisol levels are positively correlated with amphetamine-induced dopamine re-
lease in the ventral striatum and dorsal CP, and the positive subjective effects of the 
drug 486. In addition, it was recently shown that the extent of stress-induced craving 
is positively correlated with the time to cocaine relapse, whereas stress-induced 
CRH and cortisol responses were predictive of the amount of cocaine taken per 
occasion 627. By contrast, ketoconazole, a cortisol synthesis inhibitor, has been 
reported to increase cocaine and opioid use 367 while having no influence on the 
subjective effects of smoked cocaine 719. Similarly, acute hydrocortisone was found 
not to affect subjective responses to d-amphetamine 714.
In animal models, corticosterone in the range of stress-induced levels increases 
basal and psychostimulant-induced dopamine release in the NAc and potentiates 
locomotor responses to the drugs 77,164,518,577. Conversely, surgical removal of the 
adrenals (adrenalectomy: ADX) decreases basal and cocaine-induced dopamine 
release 508,580 in the shell subregion of the NAc 30 and reduces psychostimulant-
induced locomotion 77,166,420,423. The ADX effects can be restored by replacement 
of corticosterone in the range of circadian physiological concentrations 30,77,423,508. 
Furthermore, ADX inhibits the effects of stress on dopamine release and the be-
havioural responsiveness to psychostimulants 166,420,577,580. It has however also been 
argued that HPA-axis activation is not required for stress-induced dopamine release 
304. A series of experiments by the group of Piazza might provide an explanation for 
this discrepancy, as it was demonstrated that effects of glucocorticoids on dopamine 
release may be state-dependent, e.g. only occurring in the dark-period, during eat-
ing and in HR rats (see section 5.2) 518,580.
Acquisition of cocaine and amphetamine self-administration is facilitated by ad-
ministration of corticosterone 418,516 and blocked by ADX 245. Corticosterone dose-
dependently reverses the effects of ADX and fully restores self-administration when 
hormone concentrations are within the range of those induced by stress 163. Further-
more, the effects of stress on acquisition and maintenance of self-administration are 
Chapter 1 
39
abolished when corticosterone secretion is prevented surgically or pharmacologi-
cally 84,577.
During the maintenance phase, metyrapone and ketoconazole, both corticoster-
oid synthesis inhibitors, decrease cocaine self-administration 245,246, although this 
effect was only observed for low doses of cocaine. By contrast, exogenous corti-
costerone did not affect maintenance of cocaine self-administration 243. The authors 
argue that during ongoing self-administration, corticosterone concentrations are 
elevated to such extent that additional increases are without effect. By contrast, in 
the case of low dose cocaine self-administration, corticosteroid synthesis inhibitors 
might reduce corticosterone concentrations below the threshold critical for reward 
241.
Spontaneous relapse to cocaine self-administration is dose-dependently facili-
tated by corticosterone and reduced by metyrapone 163,517. However, ketoconazole 
has been demonstrated only to decrease stress-primed, but not cocaine-primed 
reinstatement of cocaine self-administration 415,416. In these studies, metyrapone and 
ketoconazole were effective in a dose-range that reduced or blocked stress-induced, 
but not basal, corticosterone concentrations. By contrast, it has also been argued 
that stress-induced relapse to cocaine seeking does not require concentrations of 
corticosterone in the range of those induced by stress 195,621 but rather basal levels 
of the hormone 195.
Further evidence for the role of the HPA-axis in psychostimulant reinforcement has 
come from studies showing that the magnitude of the corticosterone response to 
stress can be predictive of the propensity of animals to self-administer psychostimu-
lants 244,516. In addition, administration of corticosterone either 10 minutes prior to a 
self-administration session or in the amphetamine solution, facilitates amphetamine 
self-administration in animals that do not spontaneously acquire this behaviour 
(low responder (LR) rats) while decreasing amphetamine intake in HR rats (see sec-
tion 5.2) 516. Interestingly, corticosterone in the range of stress-induced levels is 
self-administered by laboratory rodents, indicating that the adrenal glucocorticoid 
itself possesses reinforcing potential 512. In support of this, it has been shown that 
glucocorticoids can trigger synaptic adaptations in dopaminergic neurons similar to 
those induced by psychostimulants 582. There is substantial evidence that the effects 
of glucocorticoids on dopamine transmission and sensitivity to the behavioural and 
reinforcing effects of psychostimulants are mediated via the GR 153,168,308, that is 
expressed by the majority of midbrain dopamine neurons 279.
Taken together, the HPA-axis and adrenal glucocorticoids play an important role 
in the neurochemical-, behavioural- and reinforcing effects of psychostimulants. 
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Whereas basal and drug-induced dopamine release and the locomotor response to 
psychostimulants require corticosterone in the range of basal circadian concentra-
tions, corticosterone in the range of stress-induced levels is required for cocaine 
self-administration. In addition, stress can further facilitate all these processes. 
Importantly, there are pronounced individual differences in psychostimulant sensi-
tivity and the influence of stress thereupon, and this may be in part attributable to 
differences in susceptibility to adrenal glucocorticoids.
5.5.2 CRH
In addition to adrenal glucocorticoids, CRH has gained increasing attention for its 
role in drug addiction. CRH belongs to a family of neuropeptides that also includes 
urocortin 2 and 3 and can bind to two classes of receptors: CRH1 and CRH2, the 
latter consisting of multiple subtypes. Hypothalamic CRH is the critical regulator of 
HPA-axis activity via CRH1 receptors in the pituitary. However, during the last de-
cades, evidence has accumulated that CRH, its family members and receptors have 
a broad extrahypothalamic distribution in the CNS and act as neurotransmitters and 
neuromodulators that regulate the response to stress at multiple levels 150. Therefore, 
the CRH system has been implicated in stress-related neuropsychiatric disorders 
including depression, anxiety disorders 547, PTSD 282, and Alzheimer’s disease 16. It 
is thus not surprising that CRH plays a role in drug addiction. For a comprehensive 
overview on the effects of CRH and related peptides in drug addiction, the reader is 
advised to consult these excellent reviews 358,592,599. The following paragraph focuses 
on the role of CRH in responsiveness to psychostimulants.
Administration of cocaine releases CRH not only from the hypothalamus 599, but also 
from extrahypothalamic sites 545,594. CRH mediates HPA-axis activation in response 
to cocaine 595 and contributes to psychostimulant-induced locomotor hyperactiv-
ity and stereotypy 118,404,530,597, cocaine-induced dopamine release in the NAc and 
VTA 404, conditioned place-preference for cocaine 404, behavioural sensitisation 
produced by repeated exposure to psychostimulants and stress 76,119,196,359,530 and 
may contribute to maintenance of cocaine self-administration (250, but also see a 
contradictory report 530). These actions of CRH appear to be mainly attributable to 
the CRH1 receptor 530 and are parallel to the effects of stress and adrenal glucocor-
ticoids on psychostimulant sensitivity. It is therefore likely that hypothalamic CRH, 
via activation of the HPA-axis, contributes to the abovementioned behavioural and 
reinforcing effects of psychostimulants 599.
However, the CRH system has also been demonstrated to play a prominent role 
in drug withdrawal and reinstatement of extinguished drug seeking. CRH con-
tributes to the anxiogenic behaviour which is manifested during early withdrawal 
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from cocaine 593 and the amygdala has been proposed to mediate this effect 544,758. 
Furthermore, a series of studies by Erb, Shaham and colleagues have indicated that 
the CRH system mediates footshock stress-induced relapse to cocaine and heroin 
seeking, while only minimally influencing drug-induced reinstatement 195,617. More 
recently, the CRH1 receptor has also been proposed to play a role in cue-induced 
cocaine craving 269. The bed nucleus of the stria terminalis (BNST), but not the 
amygdala, mediates the effects of the CRH system on stress-induced reinstatement 
of drug seeking 197 under conditions where stress-induced corticosterone secretion 
is not required 195,619.
These findings indicate that, whereas extra-hypothalamic CRH peptides contribute 
to the anxiogenic effects associated with drug withdrawal and stress-induced rein-
statement of drug seeking, the majority of the effects of CRH on the neurochemical, 
behavioural and reinforcing properties of psychostimulant drugs depend on its role 
in HPA-axis activation and corticosterone secretion.
6. sElEctEd InbrEd MousE straIns
The C57BL/6 and DBA/2 inbred mouse strains have been used extensively to inves-
tigate the contribution of genetics and life events to the psychopharmacology of do-
pamine. These strains display profound differences in the functional and anatomical 
characteristics of the brain dopamine systems and in behavioural responsiveness to 
dopaminergic agonists and addictive drugs. In addition, the C57BL/6 and DBA/2 
strains differ considerably in susceptibility to the impact of life events on psycho-
stimulant sensitivity (reviewed in: 531).
Characteristics of the midbrain dopamine system of the two strains are depicted 
in table 2. Remarkable is the strain difference in D2 receptor density in the termi-
nal fields (higher in C57BL/6) and the cell body regions (higher in DBA/2) of the 
mesocorticolimbic and nigrostriatal dopamine system 69,199,470. D2 receptors in the 
VTA and SNc can function as autoreceptors, which suggests that DBA/2 mice have 
greater autoinhibitory control over dopaminergic signalling. In support of this, the 
DBA/2 strain is more sensitive to apomorphine-induced inhibition of behaviour 
and dopamine metabolism when the dopaminergic agonist is administered in a 
dose-range that is likely to selectively activate the high-affinity D2 autoreceptors 
(for review see: 531). Furthermore, DBA/2 mice are characterised by low basal levels 
of HVA in the nucleus accumbens 72,760. However, there are no strain differences in 
basal dopamine release in the NAc 760.
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Table 3 summarises behavioural and neurochemical responses of the two strains to 
psychostimulant drugs. C57BL/6 mice are more active in a novel environment, which 
may have predictive value for the susceptibility to amphetamine self-administration 
484,511. Indeed, C57BL/6 mice are more sensitive to amphetamine-induced locomo-
tion and -reward, whereas controversy exists regarding susceptibility to the rewarding 
effects of cocaine. With respect to behavioural sensitisation to repeated psychostimu-
lant exposure, robust strain differences have been reported, although the nature and 
direction thereof varies considerably across laboratories.
Some of the discrepancies obtained with the behavioural paradigms may have 
resulted from the strain differences in susceptibility to environmental stimuli, such 
as contextual information and stress. Whereas C57BL/6 mice have greater contex-
tual- and spatial memory and are more susceptible to context-dependent sensitisa-
tion, the DBA/2 strain is more responsive to the impact of stress or environmental 
manipulations on psychostimulant sensitivity 10,20,65,499,559,575,581,677. Indeed, a period 
table 2: Characteristics of the midbrain dopamine system of DBA/2 relative to C57BL/6 
mice.
dba/2 vs. c57bl/6 reference
d2 nac ↓ 69
cP ↔ ↓ 69,199,470
Vta ↑ 69
sn ↑ 69
d1 nac ↔ 69
cP ↔ / ↓ 69,199,470
Vta ↔ 69
sn ↔ 69
dat cP ↔ / ↑ 199,314,737
da nac ↔ 760,320,704
da cP ↔ 320
da PFc ↔ ↑ 320,704
HVa nac ↓ 704,760
Arrows indicate a significant difference compared to the C57BL/6 strain. Dopamine 
receptor (D1 and D2) and dopamine transporter (DAT) densities were measured by 
radioligand binding. Dopamine (DA) and homovanillic acid (HVA) concentrations were 
determined by microdialysis or high-performance liquid chromatography (HPLC) on tissue 
samples. NAc: nucleus accumbens, CP: caudate putamen, VTA: ventral tegmental area, SN: 
substantia nigra, PFC: prefrontal cortex.
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of food shortage abolishes the strain differences in amphetamine-induced place 
preference and locomotion by altering responsiveness selectively in the DBA/2 
strain 71. Furthermore, chronic stress induces sensitisation to the locomotor stimu-
lant effects of amphetamine and promotes stereotypy in drug-free mice only in the 
DBA/2 strain 20,67. Interestingly, it has recently been shown in DBA/2 mice that food 
restriction can increase action potential-dependent dopamine release in the nucleus 
accumbens, the component of dopamine release that is controlled by the prefrontal 
cortex and most likely mediates behavioural sensitisation 705. Furthermore, repeated 
stress induces strain-dependent alterations in dopamine receptor densities, which 
are summarised in table 4. Of particular interest are the adaptations in D2 receptor 
density that appear to counteract the initial strain differences.
In view of the strain differences in susceptibility to environmental manipulations, 
it is interesting to note that the C57BL/6 and DBA/2 strains also display differences 
in HPA-axis function. Whereas C57BL/6 mice show a greater increase in corticoster-
one secretion in response to mild stressors such as exposure to a novel environment 
table 3: Neurochemical and behavioural responses to psychostimulant drugs of DBA/2 
relative to C57BL/6 mice.
dba/2 vs. c57bl/6 reference
amphetamine
da nac ↓ 700,760
da PFc ↑ 700
locomotion ↓ 65,700,760
cPP ↓ 71
acquisition sa ↓ 447
sensitisation ↓ / ↑ 20,65,484,559
cocaine
da nac NI -
da PFc NI -
locomotion ↑ 483,568,665
cPP ↓ 483
acquisition sa ↑ /↓ 91,257,568
Maintenance sa ↓ 257,568
sensitisation only DBA/2 / neither strain 483,666
Arrows indicate a significant difference compared to the C57BL/6 strain. Dopamine 
(DA) concentrations were determined by microdialysis. DA: dopamine, NAc: nucleus 
accumbens, PFC: prefrontal cortex, CPP: conditioned place preference paradigm, SA: self-
administration paradigm, Sensitisation: of drug-induced locomotion, NI: not investigated.
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(S. Dalm, personal communication, 66), more severe stressors (e.g. electrical shock, 
restraint) induce greater HPA-axis activation in the DBA/2 strain 68,321,622.
Because of the profound differences in the function and anatomy of the brain do-
pamine systems and the differential susceptibility to environmental challenges, the 
C57BL/6 and DBA/2 inbred strains provide an interesting animal model to investi-
gate the contribution of genotype and life events to psychostimulant sensitivity.
7. IncEntIVE sEnsItIsatIon: FroM tHEory to anIMal ModEl
The current view that drug addiction is a chronic relapsing brain disease implies 
that it must be associated with persistent neuroadaptations in the brain. This concept 
forms the core of the ‘incentive-sensitisation’ theory first proposed by Robinson and 
Berridge in 1993 560,561. According to this theory, repeated exposure to drugs of 
abuse induces long-lasting neuronal adaptations in the brain systems that regulate 
table 4: Stress-induced changes in the dopamine system of DBA/2 and C57BL/6 mice.
dba/2 c57bl/6 reference
d21 nac ↑ ↔ 69
cP ↔ ↔ 69
Vta ↓ ↑ 69
sn ↓ ↔ 69
d11 nac ↑ ↔ 69
cP ↔ ↓ 69
Vta ↔ ↔ 69
sn ↔ ↔ 69
da2 nac ↓ (trend) ↑ (trend) 704
da2 PFc ↑ (trend) ↓ 704
Arrows indicate a significant difference compared to control mice of the same strain. 
Dopamine receptor (D1 and D2) densities were measured by radioligand binding. 
Dopamine (DA) concentrations were determined by high-performance liquid 
chromatography (HPLC) on tissue samples. 1 Mice were exposed to restraint stress on 
9 consecutive days and sacrificed 24 hours after the last stress experience under basal 
conditions. 2 Measured 2.5 minutes after onset of a single session of restraint stress. NAc: 
nucleus accumbens, CP: caudate putamen, VTA: ventral tegmental area, SN: substantia 
nigra, PFC: prefrontal cortex.
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the motivational effects of these drugs, rendering them hypersensitive to drugs and 
drug-associated stimuli. A prominent role is proposed for the mesocorticolimbic 
dopamine system, which is involved in the perception of the ‘incentive value’, or 
the attractiveness, of stimuli. Hypersensitivity of this system would thus make drugs 
increasingly more attractive or ‘wanted’, thereby enhancing motivation to obtain 
the drugs. This excessive wanting may represent (some aspects of) drug craving and 
the persistent nature of the sensitised state has been proposed to be a determinant 
of the high vulnerability of addicts to relapse, which remains even after prolonged 
periods of drug abstinence 152,154,561.
In laboratory rodents, sensitisation to repeated drug exposure has been studied 
in different paradigms and typically manifests itself as an increased behavioural 
or neurochemical response upon re-exposure to a drug. For instance, pre-
exposure to psychostimulants or a history of drug self-administration increase 
drug-induced do pamine overflow in the NAc 399,709, the predisposition to acquire 
drug self-administration 509,522,678, the incentive motivational properties of drugs 
162,399,449,464,647,709, drug-induced place preference 624 and the locomotor stimulant ef-
fects of drugs 130,520. As reviewed by Vezina, the increases in psychostimulant-induced 
dopamine release and -locomotion and in the pursuit and self-administration of 
drugs all reflect adaptations in a common neural substrate, most notably the meso-
cortico limbic dopamine system 708. Furthermore, psychostimulant sensitisation 
results from complex interactions between the neuropharmacological effects of the 
drugs and environmental factors associated with drug exposure 22,562. Interestingly, 
also pre-exposure to stress, which is known to increase dopamine release in the 
NAc, can induce cross-sensitisation to the neurochemical-, behavioural- and rein-
forcing properties of psychostimulants 20. Finally, there are considerable individual 
differences in the propensity to develop behavioural sensitisation, which depend on 
the interplay between genetic- and environmental factors 20,65.
Psychomotor sensitisation, the gradual augmentation of the motor stimulant effects 
of drugs that occurs with repeated intermittent exposure, is a model that has been 
widely exploited to investigate the neuronal mechanisms underlying behavioural 
sensitisation. In line with the ‘incentive sensitisation’ theory, psychomotor sensitisa-
tion in rodents is a long-lasting phenomenon 392,497 that is characterised by time-
dependent neuroadaptations in the motive circuit involving multiple neurotrans-
mitters, most notably dopamine and glutamate 520,693. Two different time domains 
can be distinguished in behavioural sensitisation: the initiation- and the expression 
phase. During initiation, animals are exposed to the psychostimulant, most often 
repeatedly, and the neuronal adaptations that underlie the augmented behavioural 
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responsiveness are initiated. Expression of sensitisation, reflecting the existence of 
enduring neuroadaptations, is tested by re-exposing animals to the drug following a 
withdrawal interval in which no drug is administered and that may vary in duration. 
Furthermore, expression of sensitisation is not a unitary phenomenon, as the be-
havioural hypersensitivity intensifies with prolonged withdrawal and the associated 
neuroadaptations change over time 497,520.
As reviewed by Vanderschuren and Kalivas 693, initiation and expression of psy-
chomotor sensitisation involve distinct neuronal mechanisms which are not fully 
identical for cocaine and amphetamine. It applies to both psychostimulants that 
initiation of psychomotor sensitisation is dependent on the VTA and involves gluta-
matergic transmission 75,130,187,289,391, whereas the NAc plays an indispensable role in 
expression of previously established sensitisation which is associated with facilitated 
dopaminergic transmission 327,694. Discrepancies between the two psychostimulants 
include a role for the NAc in initiation of cocaine-, but not amphetamine sensitisation 
151,288,707, and for the PFC in both stages of cocaine sensitisation 391,521, whereas this 
has been less well established for amphetamine 394. In addition, dopamine appears 
to be necessary only for initiation of amphetamine sensitisation 430,706, whereas 
a role for glutamate in expression of sensitisation has been more convincingly 
demonstrated for cocaine than amphetamine 310,332,333. Taken together, psychomo-
tor sensitisation involves dopamine-glutamate cross talk between different nuclei 
of the motive circuit, with a more distinct role for the corticofugal glutamatergic 
projection in cocaine than in amphetamine sensitisation. In addition, as described 
in section 4.4, other neurotransmitter systems modulate the motive circuit and thus 
psychomotor sensitisation.
Behavioural sensitisation to psychostimulants is associated with many cellular and 
structural neuroadaptations within the motive circuit, a comprehensive summary 
of which is outside the scope of this thesis. As reviewed by Pierce and Kalivas 520, 
these neuroadaptations can be collectively viewed upon as ‘increasing the gain 
of the motive circuit’. In the case of cocaine sensitisation, the following neuro-
adaptations have been described. Within the NAc, dopaminergic and glutamatergic 
neurotransmission (drug-induced transmitter release and receptor transduction) are 
enhanced 5,327,496,539, both of which appear critical for expression of sensitisation. 
In the VTA, glutamatergic transmission is facilitated whereas GABA-ergic transduc-
tion is reduced, both via a D1 receptor-dependent mechanism 50,326. These changes 
would permit enhanced activity of the mesocorticolimbic dopaminergic neurons. 
Furthermore, drug-induced dopamine release is reduced in the PFC 634, thereby 
disinhibiting corticofugal glutamatergic projections to the subcortical dopamine 
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system. Finally, GABA-ergic transmission in the VP is augmented in cocaine-
sensitised rats 520.
In addition to neurochemical changes, psychostimulant sensitisation is associ-
ated with persistent morphological alterations within the mesocorticolimbic and 
nigrostriatal dopamine systems. These include increases in the number of dendritic 
branches and the density of dendritic spines on the medium spiny neurons of the 
NAc shell, core and striatum, and on the pyramidal cells in the PFC 392,564,565. Most 
interestingly, induction of psychomotor sensitisation to cocaine has been associated 
with structural changes in the NAc core, but not shell, subregion 390. Furthermore, 
these changes in connectivity may occur preferentially at the site of dopamine-
glutamate synapses 392. Finally, comparable structural changes have been demon-
strated in animals with a history of cocaine self-administration 563. These structural 
changes represent by far the most convincing evidence for the enduring nature of 
psychostimulant sensitisation and provide additional justification for the sensitisa-
tion phenomenon being interpreted as underlying certain aspects of addiction.
It must be noted, that the ‘incentive sensitisation’ theory is only one of the theoretical 
constructs for a mechanism underlying compulsive drug seeking. Several more ‘ex-
posure theories’, implying that addiction results from changes induced by the drug 
itself, have emerged (for a review see: 698). For instance, compulsive drug use has 
been postulated i) to result from a gradual progression from goal-directed behaviour 
to an automated process or habit, that is driven by drug-associated stimuli rather 
than drug reward 661, ii) to be in part attributable to drug-induced dysfunction of the 
PFC, resulting in reduced frontostriatal control over impulsive behaviour, especially 
related to the drug and associated stimuli 316, and iii) to result from a functional 
downregulation of the brain reward systems, resulting in an allostatic state in which 
the hedonic set point is shifted 360. Evidence has accumulated in favour of all these 
theories and they are therefore likely to represent mechanisms that contribute to dif-
ferent, or partially overlapping, stages of the development of compulsive drug use 
698. Most likely, ‘incentive sensitisation’ represents initial changes in the addiction 
process as it can be induced by a single administration of a psychostimulant 694 and 
transition from controlled to compulsive drug use has been associated with a loss 
of behavioural and neural sensitisation 36. However, as discussed in the previous 
paragraphs, the enduring nature of the structural and neurochemical changes as 
well as the association between sensitisation and relapse 152,154, suggest that ‘incen-
tive sensitisation’ might also apply to more advanced stages of addiction.
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8. scoPE and outlInE oF tHE tHEsIs
objective
As outlined in the previous paragraphs, there are considerable individual differ-
ences in susceptibility to the behavioural and reinforcing effects of psychostimulant 
drugs. To explain these individual differences, it is evident that both genes and 
life experiences influence psychostimulant sensitivity, although the mechanisms via 
which they act and interact are still poorly understood. This thesis focuses on a fur-
ther analysis of the contribution of the HPA-axis to individual differences in cocaine 
sensitivity in a mouse model. The objective is to assess the role of adrenal gluco-
corticoid hormones in the susceptibility to the psychostimulant effects of cocaine, 
as well as to examine the dependence of their action on the genetic background of 
the individual and the context in which these hormones operate.
The specific aims pursued in the thesis are:
i) To test the hypothesis that the contribution of adrenal glucocorticoids to cocaine 
sensitivity depends on the genetic background of the individual.
ii) To determine whether the interaction between glucocorticoids and genetic 
background is accompanied by basal and/or cocaine-induced adaptations in 
the midbrain dopamine system.
iii) To investigate the time-window for the actions of glucocorticoids in relation to 
cocaine exposure.
iv) To explore the possibility that the sympathetic nervous system is implicated in 
the action of corticosterone.
Experimental approach
The interaction between glucocorticoid hormones and genetic background is stud-
ied in two inbred mouse strains: C57BL/6 and DBA/2. As outlined in section 6, 
these strains can be considered a model for genetic differences in i) the midbrain 
dopamine system, ii) susceptibility to the behavioural and reinforcing properties of 
psychostimulants, and iii) the effects of environmental manipulations thereupon. The 
strain that proves most susceptible to the impact of adrenal hormones on cocaine 
sensitivity will thereafter be used to investigate the context in which glucocorticoids 
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operate, with emphasis on the timing of the corticosteroid action and the role of 
the sympathetic nervous system. Behavioural sensitisation, the progressive aug-
mentation of the locomotor response with repeated cocaine exposure, is used as a 
read-out parameter as this is a well-characterised model thought to underlie certain 
aspects of drug addiction. Adrenal hormones are surgically and pharmacologically 
manipulated by adrenalectomy (surgical removal of the adrenals, ‘ADX’) and hor-
mone replacement respectively. Endocrine parameters (corticosterone and ACTH 
plasma concentrations) will be measured to determine potential strain differences 
in HPA-axis responsiveness to cocaine.
outline
In chapter 2 the hypotheses are tested that i) adrenal stress hormones contribute to 
cocaine sensitivity and ii) this may depend on the genetic make-up of the individual. 
For this purpose mice of the C57BL/6 and DBA/2 strains are ADX or SHAM oper-
ated and subjected to a cocaine sensitisation regimen. Locomotor and endocrine 
(corticosterone) responses are measured at different stages of the sensitisation para-
digm. The strain that is most susceptible to the impact of ADX on cocaine-induced 
behavioural sensitisation (DBA/2) is selected for further research (chapters 4-5).
In chapter 3 it is investigated whether the strain differences in behavioural respon-
siveness to cocaine and the effects of ADX thereupon, as described in chapter 2, are 
associated with changes in the midbrain dopamine system. Tyrosine hydroxylase 
(TH) and dopamine transporter (DAT) mRNA expression and D1- and D2-like re-
ceptor binding are measured under basal conditions in the somatic and dendritic 
regions of the mesocorticolimbic and nigrostriatal dopamine systems. Comparisons 
are made between C57BL/6 and DBA/2 mice that are i) unoperated, ii) ADX or 
SHAM operated, or iii) ADX or SHAM operated and subjected to the sensitisation 
regimen.
chapter 4 describes studies designed to investigate the critical time-window for the 
glucocorticoid effects with respect to i) the stage of behavioural sensitisation, and 
ii) the time of drug exposure, in the DBA/2 strain. To investigate the role of corti-
costerone in expression of behavioural sensitisation, the GR antagonist mifepristone 
is administered to sensitised mice prior to a cocaine challenge. ADX mice are given 
corticosterone replacement from the start of the sensitisation paradigm to investigate 
the role of the glucocorticoid in initiation of sensitisation. Different replacement 
schedules (intermittent administration 2 hrs. or 5 mins. prior to each drug exposure, 
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or continuous substitution via release from a s.c. pellet) are compared to investigate 
the time-dependency of the glucocorticoid effects.
In chapter 5 it is investigated whether the sympathetic nervous system plays an ad-
ditional role in behavioural sensitisation of DBA/2 mice to cocaine. For this purpose, 
ADX mice are given replacement of epinephrine, corticosterone (the most effective 
replacement regimen as determined in chapter 4) or both, and are subjected to the 
cocaine sensitisation regimen. In addition, c-fos mRNA expression in response to 
a cocaine challenge is measured in a number of brain regions of sensitised mice to 
identify a neuronal substrate for the actions of the adrenal hormones.
A general discussion of the data is presented in chapter 6 and the major findings of 
this thesis are summarised in chapter 7.
2
adrenalectomy prevents behavioural 
sensitisation of mice to cocaine in a 
genotype-dependent manner
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The objective of the present study was to investigate the contribution of adrenal 
stress hormones to strain differences in cocaine sensitivity.
 For this purpose, we have studied sensitisation to the locomotor stimulant effect 
of cocaine and, in parallel, cocaine-induced corticosterone secretion in two inbred 
mouse strains: C57BL/6 and DBA/2. Adrenalectomy (‘ADX’: surgical removal of the 
adrenal glands) was performed in a subset of animals to investigate the contribution 
of the adrenals. ADX and SHAM operated mice were subjected to repeated 
injections of cocaine (15.0 mg/kg) or saline for 9 consecutive days, followed by 
a 5 day withdrawal interval and a saline challenge on day 14. All animals were 
challenged with 7.5 mg/kg cocaine on day 15.
We report that repeated cocaine exposure induced locomotor sensitisation 
in both strains, while endocrine sensitisation was only observed in the DBA/2 
strain. By contrast, cocaine attenuated corticosterone responses in C57BL/6 mice 
throughout the sensitisation paradigm. We have therefore identified one strain, the 
DBA/2 strain, that displays parallel sensitisation of cocaine-induced locomotion 
and -corticosterone secretion. Most interestingly, ADX prevented locomotor 
sensitisation only in DBA/2 mice, suggesting that behavioural sensitisation depends 
on the integrity of adrenal function and on secretion of adrenal glucocorticoids in 
this strain.
The present results demonstrate that adrenal stress hormones facilitate 
behavioural sensitisation to cocaine in a genotype-dependent manner and suggest 




Behavioural responses to psychostimulant drugs are characterised by a large 
degree of individual variability, both in humans and laboratory animals 191,479,509. 
Psychostimulants activate the mesocorticolimbic dopamine system and individual 
vulnerability to their effects may reflect a given predisposition to dopaminergic 
psychosis, such as observed in drug addiction, schizophrenia and psychotic de-
pression. Knowledge of factors that enhance vulnerability to psychostimulants 
will therefore greatly increase our insight in the neurobiology of dopaminergic 
psychopathologies.
The existence of marked strain differences in responsiveness to drugs such as am-
phetamine and cocaine has demonstrated that genetic traits contribute to variations 
in psychostimulant vulnerability. Two inbred mouse strains that have been used fre-
quently to study the psychopharmacology of dopamine are the C57BL/6 and DBA/2 
strains. These strains display profound differences in the anatomy and functioning 
of the mesocorticolimbic dopamine system and in behavioural responsiveness to 
dopaminergic agonists and addictive drugs (reviewed in: 531). Compared to DBA/2 
mice, C57BL/6 mice are more sensitive to amphetamine-induced locomotion and 
reward and display higher drug-induced dopamine release in the nucleus accum-
bens 65,71,700,701,760. Paradoxically, while C57BL/6 mice are also more vulnerable to 
the rewarding effects of cocaine, they appear less sensitive to cocaine-induced 
locomotion 483,665. Robust differences between the two strains have also been re-
ported for behavioural sensitisation to repeatedly administered psychostimulants, 
although the magnitude and direction thereof appears to be highly dependent on 
the design of the sensitisation paradigm 20,65,483,559.
Interestingly, the strain differences in dopaminergic transmission and sensitivity to 
the rewarding properties of psychostimulants are not stable, but can change under 
the influence of environmental challenges, pointing towards a role for the neuroen-
docrine stress system in psychostimulant vulnerability 70,71,533,704. Indeed, a wealth 
of data suggests that stress modulates behavioural and neurochemical responses to 
psychostimulants and other addictive drugs 241,358,514,515,618.
Stressful stimuli, either physical or mental, induce concomitant activation of the 
hypothalamic-pituitary-adrenal axis (HPA-axis) and the sympathetic nervous system 
resulting in release of glucocorticoid hormones and epinephrine from the adrenal 
glands 146. Glucocorticoids in particular, have been shown to modulate transmis-
sion in the mesocorticolimbic dopamine system and to facilitate behavioural re-
sponses to psychostimulants such as locomotor activity, behavioural sensitisation, 
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self-administration and relapse (reviewed in: 421). Furthermore, corticosterone in the 
range of stress-induced levels has reinforcing potential and stress can, like drugs of 
abuse, increase strength of excitatory synapses on midbrain dopaminergic neurons 
512,582. Strong evidence indicates that the glucocorticoid-dopamine interactions are 
dependent on activation of the glucocorticoid receptor, that is widely distributed 
throughout the brain and is expressed by the majority of the midbrain dopaminergic 
neurons 144,153,168,279,308,579,582.
Taken together, these data suggest that variations in HPA-axis responsiveness to 
stress may contribute to individual differences in psychostimulant vulnerability, as 
was elegantly addressed by Piazza et al. 516. In this respect, laboratory mouse or 
rat strains with differential stress responsivity provide a valuable tool to study the 
interaction between the neuroendocrine stress system and the mesocorticolimbic 
dopamine circuit. With respect to the C57BL/6 and DBA/2 inbred strains, few studies 
have addressed differences in HPA-axis activation and findings are contradictory. In 
one study, C57BL/6 mice displayed higher peak corticosterone levels in response to 
novelty which is in line with our findings (S. Dalm, personal communication), but 
contradictory to two reports using other stressors and experimental designs 66,321,622. 
In addition, there may be differences between these strains in psychostimulant-
induced HPA-axis activation, but this has to our knowledge not been reported yet. 
Differences in basal, stress- or psychostimulant-induced glucocorticoid release may 
however play a prominent role in the observed strain differences in psychostimulant 
sensitivity.
The present study was designed to test the hypothesis that adrenal stress hormones 
contribute to strain differences in cocaine sensitivity. The C57BL/6 and DBA/2 mouse 
strains were used as model for genetic differences in dopamine and HPA-axis func-
tion. We have measured behavioural sensitisation to the locomotor stimulant effect 
of cocaine and, in parallel, corticosterone responses to single and repeated cocaine 
exposure. In order to show involvement of the adrenal, we have tested whether 
strain differences persist when the adrenal is surgically removed (adrenalectomy: 
‘ADX’) prior to the onset of drug treatment.
MEtHods
animals
Male C57BL/6 Rj (C57BL/6) and DBA/2 Rj (DBA/2) mice were obtained from Janvier 
(Le Genest Saint Isle, France) and received in the animal facility at the age of 8 
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weeks. Mice were housed in groups of four of the same strain in perspex cages 
(35x19x14cm) with food and water available ad libitum at a 12 hour light-dark cycle 
(lights on: 7 am) in a temperature (21±1ºC) and humidity (55±5%) controlled room. 
Surgery was performed 2 weeks after arrival in the animal facility. Animals were 
briefly handled in the week before surgery and otherwise left undisturbed. Animal 
experiments were approved by the local Committee for Animal Health, Ethics and 
Research of Leiden University. Animal care was conducted in accordance with the 
EC Council Directive of November 1986 (86/609/EEC).
Experimental design
The study consisted of 8 experimental groups. Per mouse strain (C57BL/6 and 
DBA/2) animals were either SHAM operated (SHAM) or adrenalectomised (ADX). 
Each surgical group was subdivided into a cocaine (COC) and a saline (SAL) group, 
indicating the treatment given during the treatment period of the sensitisation para-
digm. Each experimental group consisted of 9-12 animals.
surgery
Animals were individually housed 1 day prior to surgery. The cages were transported 
to the operating room on the morning of the surgery where mice were allowed to re-
cover from transportation for 2 hours. Inhalation anaesthesia consisted of a mixture 
of isoflurane (3 l/min), N2O (0.8 l/min) and O2 (0.4 l/min). During surgery mice were 
placed on a heat pad (37ºC). The skin on the back was shaved and disinfected and 
an incision of approximately 1 cm was made above and parallel to the spinal cord. 
Through a small opening in the muscle layer left and right of the spinal cord the 
adrenals were removed from the surrounding fat tissue. The skin was closed using a 
simple running suture. SHAM animals were treated similarly with the exception of 
the actual removal of the adrenals. Mice were kept individually housed for 24 hours 
following surgery after which they were housed two animals per cage of similar 
surgery and strain. After surgery all animals were given free access to 0.9% NaCl in 
addition to normal drinking water. The sensitisation paradigm was started following 
a recovery period of 1 week.
drugs
Cocaine hydrochloride (BUFA Pharmaceuticals B.V., Uitgeest, The Netherlands) 
was dissolved in sterile saline, stored in aliquots at -20˚C and defrosted on the day 
of administration. Cocaine (room temperature) was administered intraperitoneally 
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(i.p.) in a volume of 200µl/25 grams bodyweight and a dosage of 7.5 or 15.0 mg/
kg. Control groups received an equal volume of saline. From the start of the sen-
sitisation paradigm, animals were weighed once every two days and the injection 
volumes were adjusted accordingly.
sensitisation paradigm
One day prior to the first drug administration and thus the first behavioural test, 
animals were individually housed and kept single housed for the remainder of the 
experiment.
The sensitisation paradigm consisted of a treatment phase (days 1-9), a with-
drawal interval (days 10-14), a saline challenge (day 14) and a cocaine challenge 
(day 15). The treatment phase consisted of i.p. injections of 15.0 mg/kg cocaine 
(COC) or saline (SAL) on 9 consecutive days and locomotion was measured on days 
1 (first administration) and 9 (last administration). On days 2-8 animals received the 
injections in the home cage. The treatment period was followed by a withdrawal 
interval of 5 days (no treatment). On the last day of the withdrawal period (day 14), 
all animals received a saline challenge and on day 15, all animals received a chal-
lenge of 7.5 mg/kg cocaine. All injections were given 2 to 5 hours after lights on.
Measurement of locomotor activity
Behavioural tests were performed on days 1, 9, 14 and 15 in the room where animals 
were housed. Mice were placed in a test cage (same type and size (35x19x14cm) 
as the home cage) containing a standardised amount of sawdust. The cage was 
covered with a perspex lid. Following a 2 hour habituation period, animals were 
injected and activity was monitored on video for 30 minutes. At the end of this 
period, a blood sample was taken from the tail vein for endocrine measurements 
and the animals were returned to their home cage.
analysis of locomotor activity
Video images were digitised and analysed using Ethovision Videotracking, Motion 
Analysis & Behavior Recognition System version 1.96 (‘VTMAS’, Noldus Informa-
tion Technology B.V., Wageningen, The Netherlands). The position of the animal 
was sampled 5 times per second. Of each recording (30 minutes) 27 minutes were 
analysed since the animals were subjected to blood sampling at 30 minutes after 
injection. Data are represented in total distance moved over the entire 27 minute 
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treatment period and per 3 minute time blocks (cm). Locomotion was defined as 
movement with a minimal distance of 2 cm.
corticosterone and adrenocorticotrophic hormone (actH)
Blood samples were taken from the tail vein by a small incision with a razorblade 
30 minutes after injection at the test days 1, 9, 14 and 15. Blood was collected in 
small EDTA coated tubes (Microvette DB 200 K3E, Sarstedt, Nümbrecht, Germany). 
Mice were euthanised in the morning of day 16, 24 hours after the cocaine chal-
lenge, and trunk blood was collected following decapitation in large EDTA coated 
tubes (Tube 10 ml, 95x16.8 mm, K3E, Sarstedt, Nümbrecht, Germany). Plasma was 
obtained by centrifugation at 13000 rpm for 20 minutes at 4ºC and subsequently 
stored at -20ºC. Corticosterone and ACTH concentrations were determined by 
in-duplo measurement using radio-immuno-assay (RIA) kits from MP Biomedicals 
according to the protocol provided by the manufacturer (Corticosterone double 
antibody 125I RIA kit and ACTH double antibody 125I RIA kit, MP Biomedicals, Asse-
Relegem, Belgium). All samples were analysed in one assay to exclude inter-assay 
variability. ADX effectively clamped plasma corticosterone to basal concentrations 
in both strains, and only animals with successful ADX were included in the study.
statistics
Statistical analysis was performed using SPSS for Windows software (release 
7.5, SPSS Benelux B.V., Gorinchem, The Netherlands). Locomotor activity, corti-
costerone and bodyweight data were subjected to repeated measures ANOVA with 
two between subject factors (surgery and treatment) and one within subject factor 
(test day). Subsequent analyses were performed per test day: two factor ANOVA 
for surgery and treatment. Locomotion represented per 3 minute time blocks was 
subjected to repeated measures ANOVA with two between subject factors (surgery 
and treatment) and one within subject factor (time block). ACTH data were analysed 
by two factor ANOVA for surgery and treatment. Correlations between locomotor 
activity data and corresponding corticosterone concentrations were analysed using 
Pearson’s test (two-tailed). When statistical significance was revealed, post hoc tests 
were performed (Tukey HSD, or for within-subject comparison paired t-test). Differ-





The effects of ADX on locomotion of C57BL/6 and DBA/2 mice were studied during 
the different phases of the sensitisation paradigm. Figures 1A (C57BL/6) and 1B 
(DBA/2) depict total distance moved in the four behavioural tests (days 1, 9, 14 and 
15) for the treatment groups SHAM/SAL, SHAM/COC, ADX/SAL and ADX/COC.
C57BL/6
The effects of ADX on cocaine-induced locomotion and sensitisation of C57BL/6 
mice are shown in figure 1A. Surgery did not influence the response of C57BL/6 
mice in any treatment group or at any time point (F[surgery]1,35=0.374, p=0.545). 
Locomotion was significantly affected by treatment (F1,35=58.745, p<0.001), 
day (F3,105=20.466, p<0.001) and the interaction between both (F3,105=17.921, 
p<0.001).
On days 1 and 9 of the treatment period, locomotion was increased three-
fold by cocaine (15.0 mg/kg) in comparison with saline, irrespective of surgery 
(day 1: F[treatment]1,39=40.438, p<0.001, F[surgery]1,39=0.508, p=0.418, day 
9: F[treatment]1,40=101.574, p<0.001, F[surgery]1,40=0.569, p=0.455, post hoc: 
p≤0.001 compared to saline-treated for both surgical groups on both days). 
Remarkably, cocaine responses were not enhanced on the last compared to the 
first day of the treatment period. Similarly, saline responses on days 1 and 9 were 
comparable.
On day 14, all animals received a saline challenge in the test environment. 
Responses were higher in the cocaine-treated groups irrespective of surgery 
(F[treatment]1,39=9.290, p<0.01, F[surgery]1,39=0.001, p=0.974), although statistical 
significance was not reached when comparing individual groups. The treatment 
effect was however confirmed when locomotion was plotted per 3 minute time 
blocks (F[treatment]1,36=9.312, p<0.01, F[surgery]1,36=0.001, p=0.975, data not 
shown). These data indicate that cocaine treatment induced a distinct, yet small, 
conditioned hyperresponsiveness to the experimental conditions in both surgical 
groups.
On day 15, all animals received a challenge dose of 7.5 mg/kg cocaine. Re-
sponses are depicted in figure 1A (total distance moved) and figure 2A (distance 
moved per 3 minute time blocks). Subsequent statistics refer to total distance moved 
in figure 1A. Cocaine-treated mice displayed augmented locomotion in response 
to the cocaine challenge when compared to saline-treated mice, irrespective of 
surgery (F[treatment]1,39=18.773, p<0.001, F[surgery]1,39=0.256, p=0.616, post hoc: 
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p<0.05 for both SHAM and ADX). In addition, the cocaine-treated groups displayed 
twofold higher locomotion in response to the cocaine challenge when compared 

























































Locomotion dunnere lijn.pzf:C57BL/6 & DBA/2 - Mon Aug 27 20:28:22 2007
Figure 1: Initiation and expression of sensitisation.
Locomotion of C57BL/6 (A) and DBA/2 (B) mice in response to treatment on days 1, 9, 
14 and 15 of the sensitisation paradigm. Adrenalectomised (ADX) or SHAM operated 
animals received daily administrations of 15.0 mg/kg cocaine (COC) or saline (SAL) (days 
1-9), followed by a 5 day withdrawal interval, a saline challenge (day 14) and a 7.5 mg/
kg cocaine challenge (day 15). Data are represented as mean total distance moved over 
the entire 27 minute treatment period (cm) ± SEM, n= 9-12 animals/group. *1 p<0.001, 
*2 p<0.05 vs. SAL (Tukey HSD), # p<0.01 vs. SHAM (Tukey HSD), ¥ p<0.01 vs. SHAM/
COC (Tukey HSD), † p<0.01 vs. day 1 (paired t-test), $1 p<0.001, $2 p<0.01, $3 p<0.05 
vs. saline challenge on day 14 (paired t-test).
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have accounted for the full magnitude of the sensitised response (p<0.001, paired 
t-test for both surgical groups). The dose of 7.5 mg/kg was sufficient to enhance 
locomotion of drug-naïve SHAM mice above their saline response on day 14 and a 
similar effect was observed for ADX mice, although this just failed to reach statisti-
cal significance (SHAM/SAL: p<0.01, ADX/SAL: p=0.06, paired t-test).
Figure 3A depicts individual cocaine responses of SHAM operated C57BL/6 mice 
on days 1, 9 and 15. While responses to the first drug exposure were characterised 
by a considerable degree of inter-individual variability, variation became much less 





























Time after injection (min)
Challenge dunnere lijn en met arcering.pzf:C57BL/6 & DBA/2 - Sun Aug 19 10:39:19 2007
Figure 2: Expression of sensitisation.
Locomotion of C57BL/6 (A) and DBA/2 (B) mice in response to the 7.5 mg/kg cocaine 
challenge on day 15. Previously, adrenalectomised (ADX) or SHAM operated animals 
received daily administrations of 15.0 mg/kg cocaine (COC) or saline (SAL) (days 1-9), 
followed by a 5 day withdrawal interval and a saline challenge (day 14). Data are 
represented as mean distance moved per 3 minute time blocks (cm) ± SEM, n= 9-12 
animals/group. C57BL/6 (A): F[surgery]1,36=0.258, p=0.615, F[treatment]1,36=18.757, 
p<0.001, F[time block]8,288=54.845, p<0.001, F[time block x treatment]8,288=30.951, 
p<0.001. DBA/2 (B): F[surgery]1,38=15.054, p<0.001, F[treatment]1,38=5.449, p<0.05, F[time 




during the course of the sensitisation paradigm and standard errors were very small 
(days 9 and 15). The behavioural responses or the degree of sensitisation thereof were 
not correlated with corticosterone concentrations on any day (Pearson’s correlation 
coefficients: day 1: r=-0.059, p=0.864, day 9: r=0.023, p=0.942, day 15: r=0.496, 
p=0.101, day 9/day 1: r=-0.003, p=0.994, day 15/day 1: r=-0.241, p=0.476).
In summary, these results indicate that while C57BL/6 mice responded strongly 
to the first administration of cocaine (15.0 mg/kg), this locomotor response was not 
further enhanced by 8 drug administrations in this test setting. Despite the lack of 
increased responsiveness during the treatment phase, sensitisation was revealed 
when animals were challenged with 7.5 mg/kg cocaine following a 5 day with-



































Individual responses dunnere lijn.pzf:C57BL/6 & DBA/2 - Sun Aug 12 15:19:32 2007
Figure 3: Cocaine responses of individual animals.
Locomotion of SHAM operated C57BL/6 (A) and DBA/2 (B) mice in response to cocaine 
on days 1, 9 (15.0 mg/kg) and 15 (7.5 mg/kg) of the sensitisation paradigm. Data are 
represented as mean total distance moved over the entire 27 minute treatment period (cm) 
± SEM, n= 11-12. The black dots represent the data points for the individual animals.
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cocaine-treated C57BL/6 mice when challenged with saline. Remarkably, ADX did 
not affect any of the behavioural responses of the C57BL/6 mice measured in this 
study.
DBA/2
The effects of ADX on cocaine-induced locomotion and sensitisation of DBA/2 
mice are shown in figure 1B. In this mouse strain, not only treatment (F1,38=16.562, 
p<0.001) and test day (F3,114=9.369, p<0.001) but also surgery (F1,38=9.979, p<0.01) 
significantly affected locomotion. In addition, a surgery x treatment x day interac-
tion was found (F3,114=7.051, p<0.001).
Cocaine (15.0 mg/kg) increased locomotion of DBA/2 mice when compared to 
saline on both days 1 and 9 of the treatment period (day 1: F[treatment]1,44=5.178, 
p<0.05, day 9: F[treatment]1,41=22.684, p<0.001). On day 1, drug responses were 
very small, there were no surgery effects and post hoc analysis did not reveal signifi-
cant differences between the treatment groups (F[surgery]1,44=0.012, p=0.915). On 
day 9 however, SHAM animals were strongly activated by cocaine and locomotor 
responses were 8-fold higher compared to those of saline controls (p<0.001) and 
threefold enhanced compared to drug responses on day 1 (p<0.01, paired t-test). In 
ADX mice, on the contrary, cocaine did not increase activity above saline responses 
on day 9 (p=0.494) and cocaine responsiveness was not augmented when compared 
to day 1 (p=0.701, paired t-test). Furthermore, cocaine-induced locomotion on day 
9 was significantly lower in ADX compared to SHAM mice (F[surgery]1,41=7.910, 
p<0.01, F[surgery x treatment]1,41=7.072, p<0.05, post hoc: p<0.01).
On day 14, all animals received a saline challenge in the test environment. 
Behavioural responses were significantly affected by treatment and surgery 
(F[treatment]1,41=4.988, p<0.05, F[surgery]1,41=11.092, p<0.01), but both effects 
were mainly attributable to the less relevant group comparison between the SHAM/
COC and ADX/SAL groups (p<0.01). No other significant differences were found 
between the treatment groups by means of post hoc analysis.
On day 15, following a 5 day withdrawal period, all animals were challenged 
with 7.5 mg/kg cocaine. Responses are depicted in figure 1B (total distance moved) 
and figure 2B (distance moved per 3 minute time blocks). Subsequent statistics refer 
to total distance moved in figure 2. In SHAM (p<0.05), but not in ADX animals 
(p=0.981), cocaine treatment resulted in augmented locomotor responsiveness to 
the cocaine challenge when compared to saline treatment (F[treatment]1,41=5.459, 
p<0.05, F[surgery]1,41=15.040, p<0.001, F[surgery x treatment]1,41=3.144, p=0.084). 
In addition, the locomotor responses of cocaine-treated ADX mice were significantly 
lower compared to those of cocaine-treated SHAM mice (p<0.01). Interestingly, the 
cocaine responses of the drug-naïve SHAM mice exceeded their saline responses 
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on day 14 (p<0.05, paired t-test) while this was not the case for the drug-naïve ADX 
mice (p=0.385, paired t-test). These data suggest that ADX may also reduce sensi-
tivity of drug-naïve mice to the activating effects of low doses of cocaine, although 
statistical significance was not reached when comparing cocaine responses of the 
SHAM/SAL and ADX/SAL groups by post hoc analysis.
The DBA/2 strain was characterised by a relatively high degree of individual 
variability in cocaine responses after repeated drug exposure (days 9 and 15), re-
flecting the existence of considerable inter-individual differences in behavioural 
sensitisation (figure 3B). The variability within the DBA/2 strain was confirmed in 
subsequent experiments (data not shown). The behavioural responses or the de-
gree of sensitisation thereof in the SHAM/COC group were not correlated with 
corticosterone concentrations on any day (Pearson’s correlation coefficients: day 
1: r=0.024, p=0.939, day 9: r=-0.121, p=0.695, day 15: r=0.230, p=0.450, day 9/
day 1: r=-0.097, p=0.764, day 15/day 1: r=0.318, p=0.314).
In summary, these results indicate that while DBA/2 mice appeared relatively 
insensitive to the first administration of cocaine (15.0 mg/kg), sensitisation to the 
locomotor stimulant effects did develop in SHAM mice during the course of 9 drug 
treatments. Furthermore, sensitisation was expressed in SHAM animals in response 
to a challenge of 7.5 mg/kg cocaine after a 5 day withdrawal period. However, 
ADX abolished the ability of DBA/2 mice to develop and express sensitisation to the 
locomotor stimulant effects of cocaine.
corticosterone
Plasma corticosterone concentrations were measured 30 minutes after treatment 
in the four behavioural tests on days 1, 9, 14 and 15 (figures 4A: C57BL/6 and 4B: 
DBA/2) and following decapitation in the morning of day 16 (figures 5A: C57BL/6 
and 5B: DBA/2, left panels).
C57BL/6
The effects of ADX and drug treatment on plasma corticosterone concentrations 
of C57BL/6 mice are shown in figure 4A. In this strain, main effects were found 
for surgery (F1,34=224.014, p<0.001), day (F4,136=63.347, p<0.001) and the interac-
tion between surgery, treatment and day (F4,136=2.438, p=0.05). On all test days, 
corticosterone concentrations were significantly lower in the ADX groups (day 1: 
F[surgery]1,40=121.402, p<0.001, day 9: F[surgery]1,40=126.309, p<0.001, day 14: 
F[surgery]1,38=220.125, p<0.001, day 15: F[surgery]1,39=115.274, p<0.001, post 
hoc: p<0.001 compared to SHAM groups on all days). Endocrine responses of the 
SHAM animals are described in the following paragraphs.
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On day 1, cocaine attenuated corticosterone secretion observed in response to 






















































Corticosterone dunnere lijn.pzf:C57BL/6 & DBA/2 - Mon Aug 27 21:13:32 2007
Figure 4: Corticosterone concentrations.
Plasma corticosterone concentrations of C57BL/6 (A) and DBA/2 (B) mice 30 minutes 
after treatment on days 1, 9, 14 and 15 of the sensitisation paradigm. Adrenalectomised 
(ADX) or SHAM operated animals received daily administrations of 15.0 mg/kg cocaine 
(COC) or saline (SAL) (days 1-9), followed by a 5 day withdrawal period, a saline challenge 
(day 14) and a 7.5 mg/kg cocaine challenge (day 15). Data are represented as mean 
plasma corticosterone concentration (ng/ml) ± SEM, n= 9-12 animals/group. *1 p<0.001, 
*2 p<0.05 vs. SAL (Tukey HSD), #1 p<0.001, #2 p<0.01, #3 p<0.05 vs. SHAM (Tukey 
HSD), †1 p<0.001, †2 p<0.05 vs. day 1 (paired t-test), †3 p<0.001 vs. days 1 and 9 (paired 
t-test), $1 p<0.001, $2 p<0.05 vs. saline challenge on day 14 (paired t-test), $3 p<0.05 vs. 
saline challenge on day 14, SHAM groups pooled (paired t-test).
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was still observed on day 9 (F[treatment]1,40=2.417, p=0.129, post hoc: p=0.136). 
Within the SAL and COC treatment groups, corticosterone responses were com-
parable on days 1 and 9, suggesting that neither sensitisation nor desensitisation 
occurred in response to either treatment.
When all animals were administered saline on day 14, the difference between 
the two SHAM groups disappeared due to a relative increase in the corticosterone 
response of the cocaine-treated mice. In this group, corticosterone concentrations 
were significantly enhanced compared to days 1 and 9 when animals were treated 
with cocaine (p<0.001, paired t-test for both days) and no longer different from the 
saline-treated group (F[treatment]1,38=0.151, p=0.700). In addition, corticosterone 
responses of both SHAM groups were similar to those of saline-treated mice on days 


































































ACTH & basal CORT dunnere lijn.pzf:C57BL/6 & DBA/2 II - Sun Aug 12 19:25:57 2007
Figure 5: Morning corticosterone and ACTH after sensitisation.
Morning plasma corticosterone and ACTH concentrations of C57BL/6 (A) and DBA/2 (B) 
mice following decapitation on day 16. Previously, adrenalectomised (ADX) or SHAM 
operated animals received daily administrations of 15.0 mg/kg cocaine (COC) or saline 
(SAL) (days 1-9), followed by a 5 day withdrawal period, a saline challenge (day 14) and a 
7.5 mg/kg cocaine challenge (day 15). Data are represented as mean plasma corticosterone 
(ng/ml) and ACTH (pg/ml) concentration ± SEM, n= 9-12 animals/group. #1 p<0.001, 
#2 p<0.01 vs. SHAM (Tukey HSD), *1 p<0.01, *2 p<0.05 vs. SAL (Tukey HSD).
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The cocaine (7.5 mg/kg) challenge on day 15 again attenuated the corticosterone 
response in the two SHAM groups when compared to the saline challenge on day 
14 (p<0.05, paired t-test). The effect of 7.5 mg/kg was less pronounced than that 
of 15.0 mg/kg, indicating that cocaine may dose-dependently attenuate HPA-axis 
activation in this strain.
Morning plasma corticosterone at the time of decapitation on day 16 when 
animals were taken directly from the home cage (figure 5A, left panel), was 
not affected by surgery or previous treatment (F[surgery]1,38=2.654, p=0.112, 
F[treatment]1,38=1.362, p=0.251).
In summary, ADX was effective in clamping plasma corticosterone concentra-
tions to stable low levels. Compared to saline administration, cocaine treatment 
(15.0 mg/kg and to a lesser extent 7.5 mg/kg) attenuated corticosterone responses 
in SHAM operated animals, an effect that was observed throughout the sensitisation 
paradigm. No sensitisation or desensitisation was detected in response to either 
saline or cocaine treatment in the C57BL/6 strain.
DBA/2
The effects of surgery and drug treatment on corticosterone responses of DBA/2 
mice are shown in figure 4B. Main effects were found for surgery (F1,34=224.104, 
p<0.001), treatment (F1,34=51.631, p<0.001), day (F4,136=78.390, p<0.001) and the 
interaction between these factors (F4,136=25.179, p<0.001). Also in the DBA/2 strain, 
corticosterone was significantly attenuated in the ADX groups on each test day (day 
1: F[surgery]1,43=100.558, p<0.001, day 9: F[surgery]1,40=315.116, p<0.001, day 14: 
F[surgery]1,39=76.399, p<0.001 and day 15: F[surgery]1,40=75.619, p<0.001, post 
hoc comparison with SHAM groups: at least p<0.05 on all test days). The endocrine 
responses of the SHAM animals are described in the following paragraphs.
In contrast to C57BL/6 mice, DBA/2 mice responded to cocaine treatment (15.0 
mg/kg) with an elevation of corticosterone when compared to saline treatment on 
both days 1 and 9 of the treatment period (day 1: F[treatment]1,43=27.059, p<0.001, 
F[surgery x treatment]1,43=29.911, p<0.001, day 9: F[treatment]1,40=85.531, p<0.001, 
F[surgery x treatment]1,40=97.050, p<0.001, post hoc: p<0.001 compared to saline 
on both days). In addition, cocaine-induced corticosterone secretion was mark-
edly enhanced on day 9 compared to day 1 (p<0.001, paired t-test), an effect that 
was also observed for the response to saline treatment, although less pronounced 
(p<0.05, paired t-test).
When all animals received saline on day 14, cocaine-treated SHAM mice re-
sponded with a greater elevation in corticosterone compared to saline-treated mice 




On day 15, when all animals were challenged with 7.5 mg/kg cocaine, the 
corticosterone response of the cocaine-treated SHAM group was augmented com-
pared to that of the saline-treated group (F[treatment]1,40=9.026, p<0.01, F[surgery 
x treatment]1,40=13.452, p<0.01, post hoc: p<0.001). Furthermore, the response 
to 7.5 mg/kg cocaine was not different from that on day 1 when animals were 
treated with 15.0 mg/kg. In both SHAM groups, the cocaine challenge enhanced 
corticosterone concentrations above those in response to the saline challenge on 
day 14 (at least p<0.05, paired t-test).
Interestingly, at the time of decapitation on day 16 when animals were taken 
directly from the home cage (figure 5B, left panel), morning corticosterone con-
centrations of the cocaine-treated SHAM mice were higher compared to those of 
saline-treated mice (F[treatment]1,41=7.452, p<0.05, F[surgery]1,41=2.359, p=0.133, 
post hoc: p<0.05).
In summary, ADX was effective in clamping plasma corticosterone concentrations 
to stable low levels. Cocaine increased corticosterone secretion in SHAM oper-
ated DBA/2 mice and repeated drug treatment resulted in sensitisation of HPA-axis 
activation that persisted until the cocaine challenge. Furthermore, cocaine-treated 
SHAM mice displayed higher corticosterone secretion in response to the saline 
challenge and elevated basal morning corticosterone on day 16.
actH
Basal plasma ACTH concentrations, measured following decapitation in the morning 
of day 16, are depicted in the right panels of figure 5A (C57BL/6) and 5B (DBA/2). 
In both strains, ACTH levels were significantly elevated in ADX mice (C57BL/6: 
F[surgery]1,37=40.779, p<0.001, DBA/2: F[surgery]1,39=58.105, p<0.001, post hoc: 
at least p<0.01 compared to SHAM for both strains). In the DBA/2 strain, the ACTH 
elevation was dependent on treatment, being higher in cocaine-treated ADX mice 
(F[treatment]1,39=8.150, p<0.01, F[surgery x treatment]1,39=6.645, p<0.05, post hoc: 
p<0.01 compared to ADX/SAL), whereas this was not the case in the C57BL/6 strain 
(F[treatment]1,37=0.165, p=0.688). In both strains, ACTH levels of SHAM operated 
mice were around 100 pg/ml, irrespective of treatment.
body weight
Table 1 depicts bodyweights on the day prior to surgery and test days 1, 9 and 
15 (7, 15 and 21 days after surgery respectively). Average pre-surgical bodyweight 
of each strain was set at 100%. In the C57BL/6 strain, bodyweight gradually 
increased and exceeded pre-surgical weight on all test days with no effects of 
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surgery or treatment (F[day]3,108=125.281, p<0.001, F[surgery]1,36=0.150, p=0.701, 
F[treatment]1,36=0.137, p=0.713, post hoc: at least p<0.05 compared to pre-surgical 
on all test days, paired t-test). In the DBA/2 strain, bodyweight was reduced on day 
1 compared to pre-surgical weight and recovery occurred faster in the saline-treated 
groups (F[day]3,114=12.099, p<0.001, F[day x treatment]3,114=3.252, p<0.05). In 
contrast to the C57BL/6 strain, final bodyweight did not exceed pre-surgical weight. 
Also in this strain, there was no main effect of surgery or treatment on any day 
(F[surgery]1,38=0.648, p=0.426, F[treatment]1,38=3.098, p=0.086).
dIscussIon
The present data show similarities, but also profound differences, between the 
C57BL/6 and DBA/2 strains in behavioural and endocrine sensitisation to cocaine. 
We have identified one strain, the DBA/2 strain, in which repeated cocaine expo-
sure induces sensitisation of both drug-induced locomotion and -corticosterone 
secretion. Furthermore, only in this strain, behavioural sensitisation was prevented 
table 1: Bodyweight relative to pre-surgical weight (%).
Pre-surgical day 1 day 9 day 15
c57bl/6 sHaM sal 100.5 ± 0.7 104.3 ± 1.0 *1 107.6 ± 1.1 *1 #2 109.4 ± 1.2 *1 #2 †2
coc 100.2 ± 1.2 104.6 ± 1.1 *1 107.0 ± 1.1 *1 #2 108.6 ± 1.3 *1 #1
adX sal 100.5 ± 1.7 103.8 ± 1.6 *3 108.9 ± 2.0 *1 #2 107.2 ± 1.8 *1 #3
coc  98.6 ± 0.6 104.3 ± 1.3 *1 108.8 ± 1.5 *1 #2 106.5 ± 1.6 *2 #3 †2
dba/2 sHaM sal 101.9 ± 1.5  98.7 ± 1.5 *2 102.2 ± 2.3 #2 102.6 ± 2.3 #3
coc  99.2 ± 1.7  97.5 ± 1.9  98.8 ± 1.5 101.2 ± 1.7 #2 †1
adX sal 100.5 ± 1.4  97.2 ± 1.1 103.5 ± 2.0 #2 101.7 ± 2.0 #3
coc  98.5 ± 1.5  95.5 ± 1.6 *3  96.2 ± 2.0  98.5 ± 2.3 †2
Relative bodyweights of C57BL/6 and DBA/2 mice, prior to surgery and on test days 1, 9 
and 15 (7, 15 and 21 days after surgery respectively). For both strains, average pre-surgical 
bodyweight was set at 100%. Animals were adrenalectomised (ADX) or SHAM operated 
and received daily administrations of 15.0 mg/kg cocaine (COC) or saline (SAL) (days 
1-9), followed by a 5 day withdrawal period, a saline challenge (day 14) and a 7.5 mg/
kg cocaine challenge (day 15). Data are represented as percentage of mean pre-surgical 
bodyweight (%) ± SEM, n= 9-12 animals/group. *1 p<0.001, *2 p<0.01, *3 p<0.05 vs. 
pre-surgical (paired t-test), #1 p<0.001, #2 p<0.01, #3 p<0.05 vs. day 1 (paired t-test), 
†1 p<0.01, †2 p<0.05 vs. day 9 (paired t-test).
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by ADX, suggesting that adrenal hormones facilitate sensitisation to the locomotor 
stimulant effects of cocaine and do so in a genotype-dependent manner.
In both strains, cocaine-treated mice expressed behavioural sensitisation in response 
to a challenge dose of cocaine (7.5 mg/kg) after a 5 day withdrawal period. Occur-
rence of sensitisation in both strains was considered an important requirement, 
as the sensitisation paradigm was subsequently employed to investigate the con-
tribution of adrenal stress hormones. Experimental parameters that may influence 
susceptibility of the two strains to psychostimulant sensitisation include i) repeated 
drug administration within or beyond the test context 65, ii) the duration of the 
withdrawal interval 20,559, and iii) habituation to the test setting 20.
It has been argued that C57BL/6 mice are more susceptible to context-dependent 
sensitisation, while DBA/2 mice are more likely to develop context-independent 
sensitisation 20,65,559. The observed hyperactivity of cocaine-treated C57BL/6 mice 
following saline administration in the test setting supports the notion that the 
C57BL/6 strain is susceptible to the influence of contextual information. Therefore, 
a ‘mixed’ design was used in which animals received cocaine both in the test cage 
(days 1, 9 and 15) and in the home cage (days 2-8) on several occasions. This might 
allow the development of either type of sensitisation resulting in augmented co-
caine responsiveness in both strains. In addition, a withdrawal interval was chosen 
comparable to that employed in studies demonstrating expression of amphetamine 
sensitisation in both strains 65,559. Furthermore, animals were habituated to the test 
setting 2 hours prior to drug administration, in order to minimise the contribution of 
strain differences in the behavioural and endocrine response to novelty 66. Finally, 
mice were single housed to avoid variable social influences that could play a role 
during drug exposure in the home cage.
Pronounced strain differences were observed for cocaine responsiveness in 
the treatment phase. In contrast to DBA/2 mice, C57BL/6 mice did not display 
increased drug-responsiveness on the last (day 9) compared to the first day. In view 
of the augmented response of cocaine-treated C57BL/6 mice to the cocaine chal-
lenge, this observation is not likely to reflect a complete lack of sensitisation. As 
discussed in the previous paragraph, a longer time interval may need to elapse 
before sensitisation becomes expressed in the C57BL/6 strain. It is generally ac-
cepted that expression of behavioural sensitisation intensifies with prolonged with-
drawal and that associated neuroadaptations change over time 497,520. In addition, 
it is conceivable that C57BL/6 mice reached a ceiling response already at the first 
drug administration, while behavioural sensitisation could only be unmasked by 
the lower challenge dose of 7.5 mg/kg cocaine. Indeed, an acute administration of 
cocaine (15.0 mg/kg) resulted in pronounced hyperactivity in the C57BL/6 strain 
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while being virtually ineffective in the DBA/2 strain. This finding is coherent with 
data obtained on amphetamine 65,700,760, but discrepant to two reports on cocaine 
483,665. The discrepancy may result from aforementioned differences in experimental 
methods.
Striking strain differences were also observed for HPA-axis responsiveness of SHAM 
operated animals throughout the sensitisation paradigm. In the DBA/2 strain, 
repeated cocaine treatment resulted in a persistent sensitisation of drug-induced 
corticosterone secretion, that was still evident in response to a cocaine challenge 
after a withdrawal period. By contrast, in the C57BL/6 strain, cocaine attenuated 
rather than enhanced corticosterone secretion in the context of a stress-induced 
response (e.g. induced by i.p. injection in the test setting) and there was no differ-
ence between the first and last drug exposure of the treatment phase.
The observed HPA-axis sensitisation in DBA/2 mice is in line with previous reports 
showing that repeated amphetamine treatment can induce hypersecretion of corti-
costerone to a subsequent drug challenge, even after as little as one exposure 29,694. 
Furthermore, cocaine-treated DBA/2 mice displayed an augmented corti costerone 
response to a saline challenge, that may either reflect conditioned activation of 
the HPA-axis in response to drug-associated stimuli specifically 169, or enhanced 
sensitivity to challenging situations in general. In support of the latter, it has been 
shown repeatedly that the effects of psychostimulants and stress on behavioural 
and endocrine sensitisation are interchangeable (e.g. 13,29,493). Furthermore, a small 
degree of sensitisation was also observed during saline treatment, indicating that 
the HPA-axis of DBA/2 mice can sensitise to repeated treatment procedures. It is 
conceivable that cocaine induced more pronounced and persistent endocrine sen-
sitisation due to its higher potency in activating the HPA-axis. Interestingly, morning 
corticosterone concentrations of cocaine-treated mice were elevated one day after 
the drug challenge. This finding supports the notion of a deregulation of HPA-axis 
activity, although the contribution of either drug anticipation or withdrawal symp-
toms to this phenomenon cannot be excluded. Further studies are necessary to 
clarify whether and to what extent the observed HPA-axis sensitisation of DBA/2 
mice is specific for cocaine or cocaine-associated stimuli.
In agreement with previous studies, our findings indicate that sensitisation takes 
place at the level of the pituitary or its regulatory areas, since elevated basal ACTH 
levels were revealed in cocaine- compared to saline-treated DBA/2 mice in which 
the negative glucocorticoid feedback was relieved by ADX 29,610. In addition, the 
elevated morning corticosterone concentrations observed in SHAM operated DBA/2 
mice on day 16 did not correspond with elevated ACTH levels. We interpret this 
observation as hypersensitivity of the adrenal to ACTH. From these data it cannot 
Chapter 2
71
be concluded at what time point during the sensitisation paradigm the apparent 
adrenal hypperresponsiveness develops and how it contributes to the enhanced 
corticosterone responsiveness.
The observation that, in C57BL/6 mice, cocaine attenuated rather than enhanced 
corticosterone responses in comparison with saline, contradicts many reports 
showing enhanced HPA-axis activation in response to psychostimulants, including 
the present results for the DBA/2 strain. In an additional study (data not shown), we 
have confirmed that, in C57BL/6 mice, cocaine attenuates corticosterone secretion 
in the context of a stress-induced response over the entire time span of the endo-
crine response. Strain differences in functioning or wiring of the HPA-axis itself and 
of the neurotransmitter systems that regulate the cocaine-induced corticotrophin 
releasing hormone and corticosterone release may underlie the opposite effects of 
cocaine on stress-induced corticosterone secretion in the two strains 52,66,285,321,622. 
Alternatively, the difference in corticosterone responsiveness may reflect different 
strategies for coping with drug-induced arousal 454. In addition, cocaine may alter 
either the perception of stressful events (e.g. test- and treatment procedures), or the 
kinetics of HPA-axis activation in response to such events, in a strain-dependent 
manner.
We have made the remarkable observation that ADX prevents behavioural sensiti-
sation to cocaine in a genotype-dependent manner. ADX prevented development 
and expression of sensitisation to the locomotor stimulant effects of cocaine in the 
DBA/2 strain, while being ineffective in the C57BL/6 strain. Strain differences have 
also been reported for these two inbred strains regarding the impact of stress on 
dopaminergic transmission, dopamine receptor expression, amphetamine-induced 
conditioned place preference, -locomotion, and -sensitisation, and stereotyped 
behaviour 20,67,69-71,533,704. With respect to psychostimulant-induced behaviour, the 
DBA/2 strain is consistently found to be stress-responsive, while C57BL/6 mice 
appear resistant to environmental manipulations 20,67,71. In the present report, we 
show a similar strain-dependency for the effects of ADX. ADX did not influence 
behavioural responsiveness to cocaine in the C57BL/6 strain, in which cocaine at-
tenuated corticosterone responses, while fully preventing behavioural sensitisation 
in the DBA/2 strain, that displayed cocaine-induced corticosterone secretion and 
sensitisation thereof.
These data suggest that adrenal glucocorticoids, and possibly sensitisation of 
their release, contribute to behavioural sensitisation of DBA/2 mice to cocaine. 
Many studies have shown that glucocorticoid hormones have a facilitatory role in 
behavioural responses to psychostimulant drugs, such as locomotor activity, self-
administration and relapse (reviewed in: 421). Furthermore, strong evidence exists 
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that activation of the glucocorticoid receptor is critically involved in the gluco-
corticoid effects on drug responses 168,308. In mice, basal levels of corticosterone 
that are considered sufficient for occupation of the high-affinity mineralocorticoid 
receptor remain after ADX (the present study, 300), also pointing towards a role for 
the relatively low-affinity glucocorticoid receptor in behavioural sensitisation of the 
DBA/2 strain to cocaine. There were however no strain differences in residual cor-
ticosterone following ADX, excluding this as explanation for the strain-dependent 
effects of ADX on behaviour.
The finding that locomotor sensitisation to cocaine depends on the integrity 
of adrenal function only in the DBA/2 strain, suggests that DBA/2 mice are more 
sensitive to the impact of adrenal stress hormones on cocaine sensitivity than 
C57BL/6 mice. In this respect, it is interesting to note that the DBA/2 strain was also 
characterised by a higher degree of individual variability in behavioural responses 
to repeatedly administered cocaine than the C57BL/6 strain, a phenomenon that 
has been reported previously 483. As inbred strains are considered to be genetically 
homogenous, individual differences are assumed to arise from epigenetic changes 
induced by variations in life-experiences, either in the past or in the present, further 
strengthening the notion that the neuroendocrine stress system may play a regulatory 
role in drug sensitivity of DBA/2 mice. However, the behavioural cocaine responses 
or the degree of sensitisation thereof among the SHAM operated DBA/2 mice did 
not correlate with corticosterone levels at any day. Moreover, there was very little 
variation in corticosterone responsiveness and sensitisation. Therefore, behavioural 
sensitisation of DBA/2 mice to cocaine may depend on glucocorticoids, and pos-
sibly on sensitisation of their release, but these hormones do not account for the full 
extent of individual variability. Further research is therefore required to verify the 
involvement of corticosterone and to investigate whether other adrenal factors such 
as epinephrine also contribute to cocaine sensitivity of DBA/2 mice.
It is of great interest to unravel the mechanisms via which adrenal stress hormones 
facilitate cocaine responsiveness in a genotype-dependent manner. Compared to 
C57BL/6 mice, DBA/2 mice display lower amphetamine-induced dopamine release 
in the nucleus accumbens as a consequence of higher drug-induced dopamine 
release in the prefrontal cortex 700,701. It would be interesting to investigate whether a 
similar mechanism controls the strain differences in cocaine sensitivity and whether 
adrenal hormones modulate the balance between drug-induced dopamine release 
in the prefrontal cortex and the nucleus accumbens. Interestingly, it has recently 
been shown in DBA/2 mice that food restriction can increase action potential-
dependent dopamine release in the nucleus accumbens, the component of do-
pamine release that is controlled by the prefrontal cortex and most likely mediates 
Chapter 2
73
behavioural sensitisation 705. Alternatively, the strain difference in dopamine D2 
autoreceptor-postsynaptic receptor ratio between the cell body and terminal re-
gions of the mesocorticolimbic dopamine system, being higher in DBA/2 mice, 
may have contributed to the differences in cocaine sensitivity. Moreover, it has been 
demonstrated that dopamine D1 and D2 receptor expression can be regulated by 
stressful experiences in a genotype-dependent manner 69.
The present finding, that adrenal stress hormones play an essential role in behav-
ioural sensitisation to cocaine only in certain strains of animals, may provide an 
explanation for some of the discrepancies in literature regarding the contribution 
of adrenal hormones to psychostimulant sensitisation. Strong evidence for the role 
of adrenal glucocorticoids in behavioural sensitisation has been presented most 
notably by Piazza and co-workers (e.g. 168,510), although conflicting data have also 
been reported 21,609. In the light of the current data, these different outcomes can 
be accounted for by different genetic, and perhaps environmental, backgrounds. 
In addition, some of the conflicting data obtained with the C57BL/6 and DBA/2 
strains might be explained by environmental and experimental factors that influ-
ence adrenal stress hormones.
In summary, the present results demonstrate that the C57BL/6 and DBA/2 inbred 
mouse strains not only differ profoundly in behavioural, but also in endocrine 
responsiveness to cocaine. In both strains, intermittent cocaine administration 
resulted in locomotor hyperresponsiveness to the cocaine challenge, while only 
the DBA/2 strain displayed endocrine sensitisation. Remarkably, ADX prevented 
behavioural sensitisation only in the DBA/2 strain, suggesting that in this strain, 
glucocorticoids facilitate behavioural sensitisation to cocaine. All together, these 
results suggest that adrenal stress hormones modulate behavioural sensitisation to 
cocaine in a genotype-dependent manner and that genotypic differences in cocaine 
sensitivity may arise not only from differences in reward related signalling but also 
from differential HPA-axis responsiveness.
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strain differences in the effects of 
adrenalectomy on the midbrain 
dopamine system: implication for 
behavioural sensitisation to cocaine




Adrenalectomy (ADX) abolishes behavioural sensitisation to cocaine in DBA/2, but 
not C57BL/6 inbred mice. The present study therefore tests the hypothesis that this 
ADX effect on behavioural sensitisation in the susceptible DBA/2 strain involves 
changes in midbrain dopamine systems that do not occur in the resistant C57BL/6 
strain.
For that purpose, we have measured tyrosine hydroxylase (TH) and dopamine 
transporter (DAT) mRNA and D1- and D2-like receptor binding in C57BL/6 and 
DBA/2 mice that were i) unoperated, ii) ADX or SHAM operated, or iii) ADX or 
SHAM operated and subjected to a cocaine sensitisation regimen (15.0 mg/kg 
cocaine on 9 consecutive days, followed by a 7.5 mg/kg challenge after a 5 day 
withdrawal). ADX prevented behavioural sensitisation to cocaine in the DBA/2, but 
not the C57BL/6 strain. Mice were sacrificed under basal conditions, in the latter 
case 24 hours after the cocaine challenge.
ADX did not affect markers of the dopamine system in drug naïve mice. By 
contrast, strain-dependent neuroadaptations were found in the midbrain dopa-
mine system of mice subjected to the sensitisation regimen. In the DBA/2 strain, 
the sensitisation-resistant ADX mice were characterised by reduced D2 binding in 
the nucleus accumbens core and rostral caudate putamen (CP). Furthermore, ADX 
prevented the increase in TH and DAT mRNA expression in the substantia nigra 
(SN), and the decrease in D2 binding in the dorsomedial subdivision of the caudal 
CP associated with sensitisation in SHAM mice. In the C57BL/6 strain ADX only 
marginally affected dopaminergic adaptations.
These data suggest that adrenal hormones modulate behavioural sensitisation 
to cocaine in a genotype-dependent fashion possibly through adaptations in pre- 
and post-synaptic components of the midbrain dopamine system. During cocaine 
sensitisation, the DBA/2, but not the C57BL/6 strain, was susceptible to ADX in the 





There are marked individual differences in behavioural responsiveness to psycho-
stimulant drugs that depend on the interplay between heritable traits and environ-
mental factors 191. The midbrain dopamine system, which plays a critical role in the 
behavioural and reinforcing properties of psychostimulant drugs 202, provides an 
important substrate for gene x environment interactions underlying dopaminergic 
psychopathologies. Studies using inbred mouse strains have indicated that there is 
prominent genetic control over anatomy and function of the midbrain dopamine 
system and related behavioural output. Furthermore, environmental factors and 
most notably stress, facilitate the neurochemical, behavioural and reinforcing effects 
of psychostimulant drugs 241,510,635 and there is ample evidence that this depends on 
the interaction between the midbrain dopamine system and adrenal glucocorticoid 
hormones, that are secreted upon activation of the hypothalamic-pituitary-adrenal 
(HPA) axis (for reviews see: 421,515).
Inbred mouse strains provide a valuable tool to study gene x environment interac-
tions in the workings of the midbrain dopamine system. The C57BL/6 and DBA/2 
mouse strains have been widely exploited as a model for genetic differences in 
dopaminergic transmission and associated behavioural output (reviewed in: 531). 
In addition, the two strains exhibit differences in the behavioural and endocrine 
adaptation to stress 66,67,321,622. With respect to behavioural responsiveness to psy-
chostimulants, the DBA/2 strain is susceptible to environmental manipulations, 
whereas C57BL/6 mice appear resistant to stress 20,67,71. The difference in suscep-
tibility to environmental influences may in part be explained by strain-dependent 
adaptations of the midbrain dopamine system to stress, involving genotype-specific 
changes in dopamine D1 and D2 receptor density and -function, and in dopamine 
release and -metabolism in distinct brain regions 69,70,704.
In a previous study, we have investigated in more detail the contribution of adrenal 
stress hormones to cocaine sensitivity of the C57BL/6 and DBA/2 strains 145. C57BL/6 
mice were found to be more responsive to the locomotor stimulant effects of an 
initial cocaine exposure, whereas surgical removal of the adrenals (adrenalectomy: 
‘ADX’) did not influence the acute drug response in either strain. By contrast, both 
strains exhibited psychomotor sensitisation after repeated drug exposure, while this 
was prevented by ADX in the DBA/2, but not the C57BL/6 strain. These findings 
indicate that adrenal stress hormones play an essential role in behavioural sensitisa-
tion to cocaine, but only in the DBA/2 strain.
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The present study was designed to investigate whether a neural correlate for the 
strain differences in behavioural responsiveness to cocaine and the contribution 
of adrenal stress hormones can be found in the midbrain dopamine system. The 
hypothesis is tested that DBA/2 and C57BL/6 strains are susceptible and resistant, 
respectively, to the effects of ADX on midbrain dopamine transmission. For this 
purpose, we have measured dopaminergic markers in the mesocorticolimbic and 
nigrostriatal dopamine systems of C57BL/6 and DBA/2 mice that were i) unoper-
ated, ii) ADX or SHAM operated, or iii) ADX or SHAM operated and subjected to 
a cocaine sensitisation regimen. We have determined tyrosine hydroxylase (TH) 
and dopamine transporter (DAT) mRNA expression and D1- and D2-like receptor 
binding using the radiolabelled ligands SCH23390 and iodosulpride respectively. 
Although these ligands cannot dissociate between the D1 (D1 and D5) and D2 





Male C57BL/6 Rj (C57BL/6) and DBA/2 Rj (DBA/2) mice were obtained from Janvier 
(Le Genest Saint Isle, France) and received in the animal facility at the age of 8 
weeks. Mice were housed in groups of four of the same strain in perspex cages 
(35x19x14cm) with food and water available ad libitum at a 12 hour light-dark 
cycle (lights on: 7 am) in a temperature (21±1ºC) and humidity (55±5%) controlled 
room. Experiments started two weeks after arrival in the animal facility. Prior to this, 
animals were briefly handled and otherwise left undisturbed. Animal experiments 
were approved by the local Committee for Animal Health, Ethics and Research of 
Leiden University. Animal care was conducted in accordance with the EC Council 
Directive of November 1986 (86/609/EEC).
Surgery
In experiments 2 and 3, animals were adrenalectomised (ADX) or SHAM operated. 
Mice were individually housed 1 day prior to surgery. The cages were transported 
to the operating room on the morning of the surgery where animals were allowed 
to recover from transportation for 2 hours. Inhalation anaesthesia consisted of a 
mixture of isoflurane (3 l/min), N2O (0.8 l/min) and O2 (0.4 l/min). Adrenalectomy 
was performed via the dorsal route as described previously 145. SHAM animals were 
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treated similarly with the exception of the actual removal of the adrenals. ADX 
effectively clamped plasma corticosterone to basal concentrations and only animals 
with successful ADX were included in the study.
Tissue preparation
In all experiments, animals were sacrificed in the morning (3-5 hours after lights 
on) under basal conditions. Trunk blood was collected for endocrine measurements 
and brains were rapidly dissected, snap frozen in isopentane (cooled in ethanol 
placed on pulverised dry ice) and stored at -80 ºC until further use.
Sections of 16 μm were cut on a cryostat (Leica CM3050). Based on the brain 
atlas of Franklin and Paxinos 220 (figure 1), sections were taken at the level of the 
nucleus accumbens (NAc: core and shell subregions, bregma +1.44), rostral cau-
date putamen (rCP, bregma +1.44), caudal CP (cCP: lateral (Lat), dorsomedial (DM) 









































Figure 1: Coronal sections of the mouse brain, indicating the areas sampled for optical 
density measurement.
Autoradiographs at the level of A) the nucleus accumbens (NAc) and rostral caudate 
putamen (rCP), and B) caudal caudate putamen after binding of 125I-iodosulpride, and 
C) the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc) after 
hybridisation with the TH mRNA specific oligonucleotide probe. The line-shapes indicate 




bregma -3.52) and substantia nigra pars compacta (SNc, bregma -3.52). Sections 
were thaw-mounted on 0.001% poly-L-lysine (Sigma-Aldrich) coated slides and 
stored at -80 ºC until further use.
In situ hybridisation
Tyrosine hydroxylase (TH) and dopamine transporter (DAT)
In situ hybridisation was performed to investigate the mRNA expression of TH 
and DAT in the cell body regions of the midbrain dopamine systems. The oligo nu-
cleotides (table 1) were 3’ end-labelled with α [33P]deoxyadenosine triphosphate 
(Perkin Elmer, Groningen, The Netherlands, 3000 Ci/mmol, 10 mCi/ml) using termi-
nal deoxynucleotidyl transferase (GE Healthcare Europe Gmbh, Diegem, Belgium) 
according to the manufacturer’s protocol.





Sequences of the 45 and 43-mer oligonucleotide probes complementary to respectively 
tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA. To control for specificity, 
oligonucleotides were used that were identical, except for 6 mismatches (transversions, 
underlined) evenly spaced by 5-7 nucleotides.
For prehybridisation purposes, sections were fixed for 30 min. in 4% para-formal-
dehyde in PBS (pH 7.4), washed twice in PBS, acetylated in 0.1 M triethanolamine 
(pH 8.0) with 0.25% acetic anhydride for 10 min., rinsed for 10 min. in 2 x SSC (150 
mM sodium chloride, 15 mM sodium citrate), dehydrated in an ethanol series, de-
lipidated in chloroform for 1 min., air dried and stored at room temperature. To each 
slide, hybridisation mix (100 µl, containing 1 x 106 dpm. of labelled oligonu cleotide) 
was applied. The hybridisation mix consisted of 50% formamide, 10% dextran sul-
fate, 4 x SSC, 25 mM sodium phosphate (pH 7.0), 1 mM Na pyrophosphate, 20 mM 
DTT, 5 x Denhardt’s, 100 µg/ml poly-A and 100 µg/ml sheared herring sperm DNA. 
Sections were coverslipped and hybridised overnight in a moist chamber at 42 °C. 
The next morning, after removal of the coverslips, sections were rinsed in 1 x SSC 
at room temperature, washed twice for 30 min. in 1 x SSC at 50 °C, washed for 5 
min. in 1 x SSC at room temperature, dehydrated in an ethanol series, air dried and 
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apposed to Kodak Biomax MR film (Kodak, Rochester, NY). After development of 
the films, sections were counter-stained with 0.5% cresyl violet.
Radioligand binding
D1 receptors
D1 receptor binding sites were analysed by in vitro autoradiography using the 3H-
labelled D1-like receptor antagonist SCH23390. Sections were pre-incubated in a 
50 mM Tris buffer (containing 0.1% ascorbic acid, 120 mM NaCl, 5 mM KCl, 1 mM 
CaCl2 and 1 mM MgCl2, pH 7.5) for 60 min. at room temperature. Subsequently, 
sections were incubated with 1 ml of the Tris buffer containing 2 nM 3H-SCH23390 
(GE Healthcare Europe Gmbh, Diegem, Belgium, 66 Ci/mmol, 1 mCi/ml) for 60 
min. at room temperature. As SCH23390 has been reported to bind to serotonergic 
sites, 1 µM mianserin hydrochloride (Sigma-Aldrich Chemie B.V., Zwijndrecht, The 
Netherlands) was added to the incubation buffer. Non-specific binding was deter-
mined in the presence of 40 µM R(+)-SCH23390 hydrochloride (Sigma-Aldrich). 
After incubation, sections were drained, dipped in distilled water (4 ºC), washed 
two times in the Tris buffer (4 ºC) for 10 min., dipped in distilled water (4 ºC) and 
air-dried. Sections were apposed to a Kodak Biomax MS film (Kodak, Rochester, 
NY).
D2 receptors
Binding sites of the D2 receptor family were analysed by in vitro autoradiography 
using the 125I-labelled D2-like antagonist iodosulpride. Sections were pre-incubated 
in a 50 mM Tris buffer (containing 5.7 mM ascorbic acid, 120 mM NaCl, 5 mM 
KCl, 1 mM CaCl2 and 1 mM MgCl2, pH 7.0) for 60 min. at room temperature. 
Subsequently, sections were incubated with 0.4 ml of the Tris buffer containing 
0.1 nM 125I-iodosulpride (GE Healthcare Europe Gmbh, Diegem, Belgium, 2000 
Ci/mmol, 100 µCi/ml) for 30 min. at room temperature. Non-specific binding was 
determined in the presence of 2 µM haloperidol (Sigma-Aldrich). After incubation, 
sections were drained, dipped in distilled water (4 ºC), washed two times in the Tris 
buffer (4 ºC) for 3 min., dipped in distilled water (4 ºC) and air-dried. Sections were 
apposed to a Kodak Biomax MS film (Kodak, Rochester, NY).
Analysis of mRNA expression and radioligand binding
Autoradiographs were digitised and relative expression levels or binding densities 
(grey values on film) were determined by computer-assisted optical densitometry 
using Analysis (analySIS 3.1, Soft Imaging System GmbH) and Scion Image software 
(a PC-version of the Macintosh program NIH Image: http://rsb.info.nih.gov/nih-
image), available from Scion Corporation: http://www.scioncorp.com/). Standard 
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curves of 14C (in situ hybridisation and D2 binding) and 3H (D1 binding) were 
included to ensure that grey values were within the linear range between 0 and 
255. Average optical density per region (in arbitrary units) was corrected for optical 
density in an adjacent region where no mRNA expression / receptor binding was 
observed (deep mesencephalic nucleus for VTA and SNc, corpus callosum for NAc, 
rCP and cCP).
Experimental design
Experiment 1: The basal dopamine system
Drug naïve C57BL/6 and DBA/2 mice were sacrificed under basal conditions two 
weeks after arrival in the animal facilities.
Experiment 2: The effects of ADX on the dopamine system of drug naïve mice
Mice of both strains were adrenalectomised (ADX) or SHAM operated and sacri-
ficed after a post-surgery interval of 3 weeks, which is an identical protocol as used 
in experiment 3.
Experiment 3: The effects of ADX and cocaine sensitisation on the dopamine system
C57BL/6 and DBA/2 mice were ADX or SHAM operated and, after a recovery period 
of one week, subjected to a cocaine sensitisation regimen as described previously 
145. In brief, animals received i.p. injections of 15.0 mg/kg cocaine (COC, BUFA 
Pharmaceuticals B.V., Uitgeest, The Netherlands) or saline (SAL) on 9 consecutive 
days, followed by a withdrawal interval of 5 days, a saline challenge on day 14 
and a 7.5 mg/kg cocaine challenge on day 15. On days 1, 9, 14 and 15, locomotor 
responses were recorded on video and analysed using Ethovision Videotracking, 
Motion Analysis & Behavior Recognition System version 1.96 (‘VTMAS’, Noldus 
Information Technology B.V., Wageningen, The Netherlands). Previously we discov-
ered that ADX prevented initiation and expression of behavioural sensitisation to 
cocaine in the DBA/2, but not the C57BL/6 strain 145. Mice were sacrificed in the 
morning of day 16, 24 hours after the cocaine challenge and 3 weeks after surgery.
statistics
Statistical analysis was performed using SPSS for Windows software (release 7.5, 
SPSS Benelux B.V., Gorinchem, The Netherlands). In experiments 1 and 2, expres-
sion and binding data were subjected to ANOVA with strain (experiment 1) or 
strain and surgery (experiment 2) as factor(s). In experiment 3, analyses were per-
formed per strain (two-factor ANOVA for surgery and treatment). When statistical 
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significance was revealed, post hoc tests were performed (Fisher’s LSD). Differences 
were considered statistically significant when p<0.05.
rEsults
the basal dopamine system
In drug naïve mice, either unoperated (experiment 1) or subjected to SHAM surgery 
(experiment 2), replicable strain differences were found for the dopaminergic mark-
ers, which are summarised in the following paragraphs.
SNc and VTA
Tables 2A and 3A depict the dopaminergic markers in somatic regions of unoperated 
or SHAM operated mice respectively. D1 receptor binding was undetectable and is 
therefore not shown. TH mRNA expression was higher in DBA/2 than in C57BL/6 
mice, both in the SNc and the VTA. Similarly, DBA/2 mice displayed higher DAT 
mRNA expression in the SNc and a comparable, but non-significant, tendency was 
observed in the VTA. In agreement with previous reports, D2 receptor binding was 
higher in DBA/2 compared to C57BL/6 mice in the two dopaminergic cell groups.
Both TH and DAT mRNA are present within the dopaminergic neurons. Similarly, 
D2-like receptors in the cell body regions can function as autoreceptors and are 
localised on the dopaminergic neurons themselves. As all three markers were found 
to be higher in DBA/2 compared to C57BL/6 mice, we hypothesised that DBA/2 
mice possess greater numbers of dopaminergic neurons. To test this, in experiment 
1, the number of TH-positive cells was quantified in in situ hybridisation slides 
that were dipped in photographic emulsion and counterstained with Hoechst to 
visualise cell nuclei. Indeed, the number of TH-positive cells was higher in DBA/2 
compared to C57BL/6 mice in the SNc (21%) and the VTA (32%) (table 2A).
NAc and CP
Strain differences were also observed in D1 and D2 receptor binding in the projec-
tion areas of the midbrain dopamine system (tables 2B and 3B), with a specific pat-
tern for each receptor. DBA/2 mice displayed higher D1 binding in the NAc when 
compared to C57BL/6 mice, which was more pronounced in the shell compared 
to the core subdivision and a similar trend was observed in the rostral CP, which 
reached significance in experiment 2. Because this finding contradicts a previ-
ous report 69 we have in addition measured D1 receptor mRNA expression with 
a specific riboprobe and found this to correspond with receptor binding (DBA/2 
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table 2: The basal dopamine system.
a
c57bl/6 dba/2 F
tH snc  47.8 ± 1.5  53.7 ± 1.5 * F1,19=8.149, p<0.05
Vta  60.2 ± 3.1  72.3 ± 2.3 ** F1,19=9.849, p<0.01
dat snc  52.7 ± 1.4  58.7 ± 1.8 * F1,19=6.714, p<0.05
Vta  50.5 ± 2.0  56.4 ± 2.3 F1,18=3.811, p=0.068
d2 snc  43.9 ± 0.7  48.2 ± 0.6 *** F1,18=19.672, p<0.001
Vta  42.6 ± 0.3  48.0 ± 0.9 *** F1,19=30.891, p<0.001
tH+ snc  66.2 ± 2.6  80.1 ± 5.8 * F1,19=4.755, p<0.05
Vta 113.6 ± 8.6 149.9 ± 9.8 * F1,19=7.770, p<0.05
b
c57bl/6 dba/2 F
d1 nac core 15.9 ± 0.7 18.2 ± 0.8 * F1,19=4.783, p<0.05
nac shell 13.3 ± 0.8 17.8 ± 0.6 *** F1,17=22.031, p<0.001
rcP 22.4 ± 1.1 23.8 ± 0.9 F1,19=0.945, p=0.344
ccP lat 20.5 ± 1.3 18.1 ± 1.0 F1,19=2.086, p=0.166
ccP dM 21.2 ± 1.3 20.8 ± 1.2 F1,19=0.068, p=0.797
ccP VM 17.7 ± 1.2 18.1 ± 1.0 F1,19=0.081, p=0.780
d2 nac core 30.7 ± 1.3 * 25.3 ± 2.0 F1,18=5.020, p<0.05
nac shell 29.7 ± 1.5 27.7 ± 1.3 F1,17=1.016, p=0.329
rcP 42.8 ± 0.9 ** 36.9 ± 1.1 F1,15=16.969, p<0.01
ccP lat 49.3 ± 1.4 56.8 ± 1.8 ** F1,17=10.524, p<0.01
ccP dM 40.3 ± 0.9 * 35.9 ± 1.5 F1,18=6.871, p<0.05
ccP VM 34.8 ± 1.2 34.8 ± 1.2 F1,18=0.001, p=0.976
Tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA expression, TH+ 
cell numbers and D1 and D2 receptor binding in the somatic (A) and dendritic (B) 
dopaminergic subfields of unoperated, drug naïve C57BL/6 and DBA/2 mice. Data 
represent optical density on film (arbitrary units) ± SEM. n=8-10 animals/group. 
*** p<0.001, ** p<0.01, * p<0.05 vs. the other strain (Fisher’s LSD). SNc: substantia 
nigra pars compacta, VTA: ventral tegmental area, NAc: nucleus accumbens, (r/c) CP 




table 3: The effects of ADX on the basal dopamine system.
a
c57bl/6 dba/2
adX sHaM sHaM adX
tH snc 55.4 ± 2.6 49.7 ± 2.0 57.9 ± 2.1 * 56.5 ± 2.1
Vta 49.5 ± 2.5 47.1 ± 1.6 52.8 ± 1.4 * 57.2 ± 2.3 *
dat snc 31.8 ± 1.2 33.9 ± 0.8 40.0 ± 1.1 ** 36.8 ± 1.9 *
Vta 32.2 ± 1.5 31.1 ± 1.1 32.7 ± 1.9 30.3 ± 0.7
d2 snc 35.2 ± 0.6 # 37.1 ± 0.5 42.3 ± 0.2 *** 42.9 ± 0.6 ***
Vta 33.2 ± 0.4 34.2 ± 0.4 36.1 ± 0.5 ** 35.5 ± 0.3 **
b
c57bl/6 dba/2
adX sHaM sHaM adX
d1 nac core 28.4 ± 1.3 27.4 ± 1.1 31.5 ± 1.2 * 28.8 ± 1.2
nac shell 23.3 ± 1.5 20.1 ± 1.0 25.8 ± 1.5 * 24.9 ± 2.4
rcP 33.9 ± 1.1 34.4 ± 1.0 37.9 ± 1.5 * 35.4 ± 1.2
ccP lat 34.3 ± 0.9 34.8 ± 0.9 33.6 ± 1.5 31.4 ± 1.2
ccP dM 32.3 ± 0.8 32.9 ± 0.8 35.4 ± 2.1 33.5 ± 1.5
ccP VM 30.7 ± 1.2 31.7 ± 0.9 33.3 ± 1.9 30.9 ± 1.3
d2 nac core 23.6 ± 1.7 ** 22.5 ± 0.8 * 16.6 ± 2.2 16.6 ± 1.3
nac shell 19.3 ± 2.5 17.6 ± 1.8 13.5 ± 1.1 14.9 ± 1.3
rcP 33.3 ± 1.4 * 34.4 ± 0.7 * 30.7 ± 1.1 28.6 ± 1.6
ccP lat 41.7 ± 1.6 40.8 ± 1.5 47.0 ± 2.6 * 46.8 ± 2.7
ccP dM 32.2 ± 2.2 32.4 ± 1.6 34.1 ± 2.4 31.8 ± 1.7
ccP VM 29.6 ± 1.2 28.5 ± 1.9 31.0 ± 1.6 29.1 ± 1.9
Tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA expression and D1 
and D2 receptor binding in the somatic (A) and dendritic (B) dopaminergic subfields 
of drug naïve C57BL/6 and DBA/2 mice 3 weeks after adrenalectomy (ADX) or SHAM 
surgery. Data represent optical density on film (arbitrary units) ± SEM. n=5-12 animals/
group. *** p<0.001, ** p<0.01, * p<0.05 vs. mice of the other strain subjected to similar 
surgery. # p<0.05 vs. SHAM operated mice of the same strain (Fisher’s LSD). SNc: 
substantia nigra pars compacta, VTA: ventral tegmental area, NAc: nucleus accumbens, 




vs. C57BL/6: NAc core 38.3 vs. 28.0, p<0.05, NAc shell 38.8 vs. 29.0, p<0.01, 
rCp: 39.5 vs. 34.8, ns.). There were no strain differences in D1 binding or mRNA 
expression in the three caudal subdivisions of the CP. By contrast, C57BL/6 mice 
exhibited greater D2 receptor binding in NAc core and the rCP. In experiment 1, a 
similar effect was observed in the DM subdivision of the cCP, but this could not be 
replicated in experiment 2. In the NAc shell, there was no significant strain differ-
ence in D2 binding, although there was a tendency towards higher densities in the 
C57BL/6 strain. In the Lat cCP by contrast, D2 binding was consistently found to be 
higher in DBA/2 when compared to C57BL/6 mice.
the effects of adX on the dopamine system of drug naïve mice
Table 3 depicts the dopaminergic markers measured in drug naïve SHAM and ADX 
mice of both strains. D2 receptor binding was slightly reduced by ADX only in 
the SNc of the C57BL/6 strain (F[strain]1,30=134.245, p<0.001, F[surgery]1,30=1.222, 
p=0.279, F[strain x surgery]1,30=5.080, p<0.05, post hoc: p<0.05). The strain differ-
ences in D1 binding in the NAc and rCP were attenuated by ADX, but a significant 
surgery effect was not revealed in any of the subregions. No other effects of ADX on 
the dopaminergic markers were detected in either strain.
the effects of adX and cocaine sensitisation on the dopamine system
In mice subjected to the sensitisation regimen, there were strain- and surgery-
specific adaptations in D2 receptor binding (figures 2 and 3) and TH and DAT 
mRNA expression (table 4) in subfields of the nigrostriatal system. In the DBA/2 
strain, D2 receptor binding was reduced in the NAc core and rCP of ADX mice 
resistant to behavioural sensitisation when compared to sensitised SHAMs, and a 
similar trend was observed in the NAc shell (core: F[surgery x treatment]1,37=4.220, 
p<0.05, shell: F[treatment]1,37=4.358, p<0.05, rCP: F[treatment]1,36=5.048, p<0.05, 
F[surgery x treatment]1,36=4.138, p<0.05, post hoc: core and rCP: p<0.05, shell: 
p=0.155 vs. SHAM/COC). Furthermore, in the DBA/2 strain, cocaine treatment was 
associated with an increase in TH and DAT mRNA expression in the SNc (TH: 
F[treatment]1,36=5.539, p<0.05, DAT: F[treatment]1,36=4.873, p<0.05, post hoc: 
p<0.05 vs. SHAM/SAL) and a reduction in D2 binding in the DM subdivision of the 
cCP (F[treatment]1,38=4.965, p<0.05, post hoc: p<0.05 vs. SHAM/SAL), which were 
prevented by ADX. The effects of treatment and ADX on D2 binding in the DM cCP 
were also observed in the C57BL/6 strain (F[treatment]1,30=7.008, p<0.05, post hoc: 
p<0.05 vs. SHAM/SAL). There were no other effects of treatment or surgery in either 




This study shows strain differences in the effects of ADX on neuroadaptations in the 
midbrain dopamine system in mice that were subjected to a 9 day cocaine sensiti-
sation regimen. The DBA/2 strain was susceptible to adrenal hormones on measures 
for dopamine in the nigrostriatal system and the NAc core under these conditions 
of behavioural sensitisation, whereas ADX only marginally affected the dopamine 
system in the C57BL/6 strain. This confirms our hypothesis that the DBA/2 strain 
displays parallel susceptibility to the impact of adrenal hormones on behavioural 




































Figure 2 eindversie.pzf:Eindversie DBA 2 - Sun Aug 12 15:58:04 2007
Figure 2: D2 binding in DBA/2 mice subjected to the sensitisation regimen.
D2 receptor binding in adrenalectomised (ADX) or SHAM operated DBA/2 mice subjected 
to the cocaine sensitisation regimen. Previously, animals received 15.0 mg/kg cocaine 
(COC) or saline (SAL) for 9 consecutive days, followed by a 5 day withdrawal interval and 
a 7.5 mg/kg cocaine challenge. Animals were sacrificed 24 hours after the drug challenge. 
Data are presented as percentage of SHAM/SAL (%) ± SEM. n=6-13 animals/group. 
* p<0.05 vs. SAL-treated mice subjected to similar surgery, # p<0.05 vs. SHAM/COC, and 
Ω p<0.05 vs. SHAM/SAL (Fisher’s LSD). NAc: nucleus accumbens, (r/c) CP (DM): (rostral/
caudal) caudate putamen (dorsomedial region).
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that adrenal stress hormones influence psychostimulant sensitivity in a genotype-
dependent manner through adaptations in the midbrain dopamine system.
Compared to the C57BL/6 strain, the DBA/2 strain is less sensitive to the neuro-
chemical-, rewarding- and behavioural effects of amphetamine 65,71,124,447,611,700,701,760, 
and the locomotor-stimulant effect of cocaine 145. This may result from strain dif-
ferences in both pre- and/or post-synaptic transmission in the midbrain dopamine 
system, aspects of which were investigated using the dopaminergic markers.
The greater number of TH-positive neurons in the DBA/2 strain would imply 
greater dopaminergic input in the NAc and CP from the A9/A10 cell groups. By 
contrast, DBA/2 mice exhibit lower amphetamine-induced dopamine release in the 
NAc 701,760 whereas there are no strain differences in basal dopamine release in this 
brain region 760. The apparent discrepancy between the midbrain dopaminergic cell 
numbers and the dopamine release indicates that there must be strain differences in 
presynaptic dopaminergic function. Indeed, the number of dopaminergic neurons 
can 212, but does not necessarily 753, correlate with mesencephalic TH activity. In the 
present study, TH mRNA expression was increased to a lesser extent (12-20%) than 
the number of dopaminergic cells (20-32%) in the DBA/2 compared to C57BL/6 
strain, which is suggestive of a relatively lower TH function in the former strain. 
However, from mRNA expression it is not possible to draw a definitive conclusion 
regarding TH protein content and activity 373.
table 4: TH and DAT mRNA expression in the SNc of mice subjected to the sensitisation 
regimen.
sHaM adX
sal coc sal coc
tH snc c57bl/6 100.0 ± 2.6 100.6 ± 2.4  94.6 ± 3.8  96.3 ± 1.7
dba/2 100.0 ± 2.3 106.1 ± 1.6 *  98.8 ± 1.8 101.6 ± 1.8
dat snc c57bl/6 100.0 ± 4.3 104.4 ± 3.2 103.0 ± 3.9  95.1 ± 3.4
dba/2 100.0 ± 2.0 111.9 ± 3.2 *  99.0 ± 4.6 103.2 ± 3.5
Tyrosine hydroxylase (TH) and dopamine transporter (DAT) mRNA expression in the 
substantia nigra pars compacta (SNc) of adrenalectomised (ADX) or SHAM operated C57BL/6 
and DBA/2 mice subjected to the cocaine sensitisation regimen. Previously, animals received 
15.0 mg/kg cocaine (COC) or saline (SAL) for 9 consecutive days, followed by a 5 day 
withdrawal interval and a 7.5 mg/kg cocaine challenge. Animals were sacrificed 24 hours 
after the drug challenge. Data are presented as percentage of SHAM/SAL (%) ± SEM. n=7-11 
animals/group. * p<0.05 vs. SAL-treated mice subjected to similar surgery.
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Factors that control dopaminergic transmission, possibly in a genotype-dependent 
manner, include regulation by afferent projections and by autoreceptors of the D2 
receptor family. Indeed, when compared to the C57BL/6 strain, the DBA/2 strain dis-
plays lower drug-induced dopamine release in the NAc as a consequence of higher 
dopamine release in the prefrontal cortex 700,701. Furthermore, DBA/2 mice have 
been proposed to exhibit greater autoreceptor-mediated inhibition of dopaminergic 
transmission, due to the higher D2 receptor availability in the VTA and SN 69,470. 
However, the observed difference in cell numbers suggests that the higher D2 
receptor binding in the somatic regions of the DBA/2 strain reflects a greater num-
ber of neurons, rather than a higher density of receptors per cell. Further studies 
































Figure 3 eindversie.pzf:Eindversie C57 2 - Mon Aug 13 08:57:46 2007
Figure 3: D2 binding in C57BL/6 mice subjected to the sensitisation regimen.
D2 receptor binding in adrenalectomised (ADX) or SHAM operated C57BL/6 mice 
subjected to the cocaine sensitisation regimen. Previously, animals received 15.0 mg/
kg cocaine (COC) or saline (SAL) for 9 consecutive days, followed by a 5 day withdrawal 
interval and a 7.5 mg/kg cocaine challenge. Animals were sacrificed 24 hours after the 
drug challenge. Data are presented as percentage of SHAM/SAL (%) ± SEM. n=6-8 animals/
group. * p<0.05 vs. SAL-treated mice subjected to similar surgery (Fisher’s LSD). NAc: 
nucleus accumbens, (r/c) CP (DM): (rostral/caudal) caudate putamen (dorsomedial region).
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necessary to evaluate the capacity for autoinhibition of dopaminergic transmission 
in the two strains. Collectively, these findings suggest that presynaptic regulation of 
dopaminergic neurotransmission may be a crucial factor in restraining the higher 
dopaminergic output that would be expected to arise from the greater numbers of 
TH positive neurons in the DBA/2 strain.
Pronounced strain differences were also found for dopamine receptor binding 
in the terminal fields, which are in agreement with most previous findings 69,199,470. 
Most remarkable is the opposite strain difference in D1 and D2 binding in the NAc 
and rCP. How the regionally differentiated dopamine receptor binding contributes 
to the strain differences in behavioural responsiveness to psychostimulants remains 
to be investigated. One avenue of further research could involve the implication 
of the various dopamine receptor subtypes of the D1 and D2 families, that have 
partially overlapping but also distinct functional characteristics.
We have demonstrated previously, that ADX does not alter the locomotor response 
of C57BL/6 and DBA/2 mice to a single administration of cocaine 145. In parallel, 
no major changes were observed in the basal dopamine system following ADX. By 
contrast, studies in several strains of rats have indicated that depletion of adrenal 
glucocorticoids attenuates basal and cocaine-induced dopamine release and psy-
chostimulant-induced locomotion 77,166,420,423,508,580 and substantially reduces D1 and 
D2 receptor binding in subdivisions of the dopamine system 47,136. The discrepancy 
between the present findings in mice and the observations in rats may be related 
to the residual corticosterone after ADX that circulates in mice, but not in rats 300. 
Indeed, it has been demonstrated in rats that corticosterone in the range of diurnal 
concentrations is sufficient to restore the effects of ADX on basal dopamine release 
and on neurochemical and behavioural responsiveness to an acute psychostimulant 
exposure 30,77,423,508.
ADX prevented behavioural sensitisation in the DBA/2, but not the C57BL/6 strain 
145. Strain- and surgery-specific adaptations were also observed in the midbrain do-
pamine system of mice subjected to the sensitisation regimen. Given that a single 
psychostimulant exposure can induce long-term behavioural, neuroendocrine, and 
neurochemical sensitisation 694, it should be noted that none of the groups were drug 
naïve (all animals were exposed to the cocaine challenge one day prior to sacrifice).
In the DBA/2 strain, TH and DAT mRNA expression were increased in the SNc of 
sensitised SHAM mice, suggesting an enhanced tone of the DA system, which is in 
agreement with previous studies employing comparable withdrawal durations (<1 
week) 33,406,623,633,713. The enhanced expression of the presynaptic markers, which we 
interpret as increased capacity of nigrostriatal dopaminergic neurons under basal 
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conditions, was fully prevented by ADX in the DBA/2 strain, thus correlating with 
behavioural responsiveness to the drug challenge. Although it cannot be concluded 
whether the increases in TH and DAT mRNA are critical for expression of sensitisa-
tion, it does reflect the plasticity of the presynaptic component of the dopamine 
system in the DBA/2 strain. In the C57BL/6 strain, by contrast, sensitisation did not 
correlate with enhanced expression of presynaptic markers, which might indicate 
that this neural adaptation is not required for behavioural sensitisation in the C57BL/6 
background. Alternatively, given the marked time-dependency in neuroadaptations 
associated with psychostimulant sensitisation, the presynaptic adaptations could 
occur after a different withdrawal duration in the C57BL/6 strain 497,520.
The finding that D2 family receptors are subject to regulation by adrenal hor-
mones in a genotype-dependent manner, is in line with previous observations that 
D2 receptors engage in gene x environment interactions, both in humans and in 
laboratory rodents 41,69,198. The sensitisation-resistant ADX mice of the DBA/2 strain 
exhibited reduced D2 receptor binding in the NAc core and rCP, with a similar trend 
in the NAc shell. As discussed previously, D2-like receptors within the terminal re-
gions may represent both pre- and postsynaptic receptors, the former functioning as 
inhibitory autoreceptors. Given the lack of behavioural sensitisation in ADX mice of 
the DBA/2 strain, it is tempting to speculate that the decrease in D2 binding reflects 
a deficit in postsynaptic signalling. Previous studies have demonstrated that super-
sensitivity of postsynaptic D2 receptors may play a role in long-term expression of 
behavioural sensitisation to amphetamine 306,675,695. Furthermore, concurrent activa-
tion of D1 and D2 receptors is required for expression of neural- and behavioural 
phenotypes of cocaine sensitisation 87. Therefore, the reduction in D2 binding in the 
NAc and CP might precipitate the sensitisation deficit of DBA/2 mice in which the 
adrenals were surgically removed.
By contrast, in sensitised SHAM mice of both strains, D2 binding was reduced 
in the DM subdivision of the cCP. Previous studies have demonstrated subsensi-
tivity of axonal and somatodendritic D2 dopamine autoreceptors during the first 
few days of withdrawal from repeated psychostimulant administration 3,736,744,748. 
The decrease in D2 binding associated with a history of cocaine treatment may 
therefore represent such an autoreceptor subsensitivity. The observation that ADX 
prevented the reduction in D2 binding in the DM cCP of both strains, suggests that 
the adaptation in this brain region is not critical for the impact of adrenal hormones 
on behavioural sensitisation. Clearly, the role of the regional changes in D2 recep-
tor binding in behavioural sensitisation requires further investigations. Furthermore, 
it will be necessary to distinguish between the D2 and D3 receptors, given that 
activation of D3 receptors is thought to suppress, rather than enhance, locomotion 
and behavioural sensitisation 543 (but see also 23).
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Collectively, these findings indicate that in the DBA/2 strain, adrenal hormones 
modulate dopaminergic transmission, presumably at the level of both pre- and 
post-synaptic neurotransmission. Further studies are required to investigate the 
importance of the individual neural adaptations in psychostimulant sensitisation, 
e.g. by regional overexpression of TH and DAT or by downregulation of D2 recep-
tors in the NAc and CP. Interestingly, the neural adaptations were most evident 
in the nigrostriatal dopamine system and NAc core. This contradicts the notion 
that the mesocorticolimbic pathway, and particularly the NAc shell, plays a critical 
role in initiation and expression of psychostimulant sensitisation 210,519. However, 
it has become increasingly evident that the mesocorticolimbic and nigrostriatal 
projections are both anatomically and functionally intertwined, and evidence is 
emerging for a role of the latter in behavioural sensitisation. Indeed, expression of 
psychostimulant sensitisation has been associated with structural changes in the 
NAc core, but not the shell, subregion 390 and one study reported sensitisation of 
dopamine transmission specifically in the NAc core 74. Furthermore, alterations in 
cellular activity associated with expression of amphetamine sensitisation have been 
reported to occur in the CP, but not the NAc 696. Finally, the dorsal PFC-NAc core 
connection (via glutamatergic efferents) plays an increasingly more prominent role 
in expression of drug-induced adaptations, under more habitual circumstances 329.
In conclusion, the present data suggest that adrenal hormones modulate behavioural 
sensitisation to cocaine through adaptations in the nigrostriatal dopamine system and 
the NAc core, in a genotype-dependent manner. The DBA/2, but not the C57BL/6 
strain, appeared vulnerable to the impact of adrenal stress hormones on cocaine 
sensitivity at the level of both dopaminergic neurotransmission and, as previously 
described, behavioural responsiveness 145. The ‘susceptible’ DBA/2 phenotype there-
fore provides a good model for further research into the interaction between stress, 
the brain dopamine system and vulnerability to psychostimulant drugs.
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critical time-window for the actions of 
adrenal glucocorticoids in behavioural 
sensitisation to cocaine




Glucocorticoids, secreted by the adrenals in response to stress, have profound ef-
fects on behavioural responsiveness to psychostimulant drugs. We have studied the 
critical time-window for the influence of corticosterone on behavioural sensitisation 
to cocaine in relation to i) the stage of behavioural sensitisation, and ii) the time of 
drug exposure.
Previously, we have identified a mouse strain (DBA/2) in which surgical removal 
of the adrenals (adrenalectomy: ‘ADX’) fully prevented locomotor sensitisation 
to cocaine. To investigate the role of corticosterone in expression of behavioural 
sensitisation, the glucocorticoid receptor (GR) antagonist mifepristone (RU38486) 
was administered to previously sensitised mice prior to a cocaine challenge. Fur-
thermore, ADX mice were given corticosterone replacement at different intervals 
prior to each drug administration, to investigate the role of the glucocorticoid in 
initiation of behavioural sensitisation, and in relation to the time of drug exposure.
Administration of mifepristone to previously sensitised animals failed to block 
expression of cocaine-induced behavioural sensitisation. In ADX mice, intermittent 
replacement of corticosterone (1 mg/kg i.p., either 2 hours or 5 minutes prior to 
each cocaine administration), did not reverse the sensitisation deficit. By contrast, 
chronic corticosterone replacement (20% pellet) partially restored initiation of 
behavioural sensitisation. These data indicate that the presence of corticosterone 
facilitates the initiation rather than the expression of behavioural sensitisation to 
cocaine. However, because high corticosterone concentrations only partially 
reversed the sensitisation deficit of ADX mice, the adrenal glucocorticoid seems 





Adverse life experiences, and the neuroendocrine response they evoke, have 
a profound impact on vulnerability to the behavioural and reinforcing effects of 
psychostimulant drugs (reviewed in: 405,514). The contribution of the hypothalamic-
pituitary-adrenal (HPA) axis and adrenal glucocorticoids (cortisol in humans, cor-
ticosterone in rodents) to psychostimulant sensitivity has been extensively studied 
241,421. In laboratory rodents, glucocorticoids facilitate acquisition, maintenance and 
relapse of psychostimulant self-administration as well as drug-induced locomotion 
and behavioural sensitisation (reviewed in: 144,240,421,515). Furthermore, it has been 
shown that the propensity of animals to acquire psychostimulant self-administration 
positively correlates with their plasma corticosterone concentrations 244,516. The 
observation that glucocorticoids in the range of stress-induced levels are readily 
self-administered by laboratory rodents, suggests that these hormones themselves 
also possess reinforcing potential 512. In support of this, it has been shown that 
glucocorticoids can trigger synaptic adaptations in dopaminergic neurons similar 
to those induced by psychostimulants 582. There is convincing evidence that the 
actions of glucocorticoids on dopaminergic transmission and psychostimulant 
responsiveness are dependent on activation of the glucocorticoid receptor (GR) in 
the brain 153,168,308,579,582.
Despite the wealth of data showing that glucocorticoids mediate the effects of stress 
on psychostimulant sensitivity, the context- and time-dependency of their actions is 
poorly understood. Glucocorticoids can either facilitate or attenuate physiological 
or behavioural outcomes depending on timing, context and endpoint. For instance, 
the beneficial effects of glucocorticoids on memory consolidation and retrieval may 
only occur when stress is experienced closely linked in time to, and within the 
context of, the information to be learned (reviewed in: 318). Furthermore, glucocorti-
coids can exert their actions not only via nuclear receptor-mediated transcriptional 
regulation, but also via a non-genomic mechanism involving membrane-bound 
receptors and requiring a considerably shorter time span 55,103,176,338. Indeed, evi-
dence is now accumulating that adrenal glucocorticoids regulate a wide range of 
behaviours via a rapid non-genomic mechanism (e.g. 339,450,451,584,589).
In the present study, we have investigated the critical time-window for the actions 
of corticosterone in sensitisation to the locomotor stimulant effects of cocaine. The 
DBA/2 inbred mouse strain was used, as it displays parallel sensitisation of cocaine-
induced locomotion and corticosterone secretion, whereas surgical removal of the 
adrenals (adrenalectomy: ‘ADX’) prevents behavioural sensitisation 145. We have 
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investigated the time-window for the actions of corticosterone i) in relation to the 
stage of behavioural sensitisation (initiation vs. expression) and ii) in relation to the 
time of drug exposure. First, the glucocorticoid receptor (GR) antagonist mifepris-
tone (RU38486) was administered to previously sensitised animals to investigate 
the contribution of corticosterone to expression of sensitisation. Second, ADX mice 
were given corticosterone replacement (5 minutes or 2 hours prior to each drug 
exposure or chronically), to study the role of the hormone during initiation of sen-




Male DBA/2 Rj mice were obtained from Janvier (Le Genest Saint Isle, France) at the 
age of 8 weeks. Mice were housed in groups of four in perspex cages (35x19x14cm) 
with food and water available ad libitum at a 12 hour light-dark cycle (lights on: 7 
am) in a temperature (21±1ºC) and humidity (55±5%) controlled room. Surgery was 
performed 2 weeks after arrival in the animal facility. Animals were briefly handled 
in the week before surgery and otherwise left undisturbed. Animal experiments 
were approved by the local Committee for Animal Health, Ethics and Research of 
Leiden University. Animal care was conducted in accordance with the EC Council 
Directive of November 1986 (86/609/EEC).
Surgery
Animals were individually housed 1 day prior to surgery. The cages were transported 
to the operating room on the morning of the surgery where mice were allowed 
to recover from transportation for 2 hours. Inhalation anaesthesia consisted of a 
mixture of isoflurane (3 l/min), N2O (0.8 l/min) and O2 (0.4 l/min). Adrenalectomy 
was performed via the dorsal route as described previously 145. SHAM animals were 
treated similarly with the exception of the actual removal of the adrenals. Mice 
were kept individually housed for 24 hours following surgery after which they were 
housed two animals per cage of similar surgery. After surgery, all animals were 
given free access to 0.9% NaCl in addition to normal drinking water. The sensitisa-




Cocaine hydrochloride (BUFA Pharmaceuticals B.V., Uitgeest, The Netherlands) 
was dissolved in sterile saline and administered intraperitoneally (i.p.) in a dos-
age of 7.5 or 15.0 mg/kg. Mifepristone (RU38486, Sigma-Aldrich Chemie B.V., 
Zwijndrecht, The Netherlands) was dissolved to a concentration of 100 mg/ml in 
sterile saline containing 2.5 mg carboxymethylcellulose and 2 µl Tween-20 per ml. 
Animals received 50 µl of this solution applied on oats resulting in a dose of 200 
mg/kg bodyweight. Corticosterone (corticosterone:HBC complex, Sigma-Aldrich) 
was dissolved in sterile saline and administered i.p. in a dosage of 1 mg/kg of 
the free base. Corticosterone pellets (100 mg, w x h: 9 x 2 mm) consisted of 20% 
corticosterone (ICN Biomedicals Inc, Aurora, Ohio, USA) in cholesterol vehicle 
(cholesterol 95% stabilised, Acros Organics, Geel, Belgium) and were implanted 
subcutaneously in the flank of the animal. Control groups received equal volumes 
of saline, 100% cholesterol pellets in the chronic corticosterone substitution study, 
and oats containing vehicle in the mifepristone study. From the start of the sensi-
tisation paradigm, animals were weighed once every two days and the injection 
volumes were adjusted accordingly.
Sensitisation paradigm
One day prior to the first drug administration and thus the first behavioural test, 
animals were individually housed and kept single housed for the remainder of 
the experiment. The sensitisation paradigm consisted of a treatment phase (days 
1-9), a withdrawal interval (days 10-14), a saline challenge (day 14), and a cocaine 
challenge (day 15). The treatment phase consisted of i.p. injections of 15.0 mg/kg 
cocaine (COC) or saline (SAL) on 9 consecutive days and locomotion was measured 
on days 1 (first administration) and 9 (last administration). On these days, animals 
received the treatment in the test setting as described in the following paragraph. 
On days 2-8 animals received the injections in the home cage. The treatment period 
was followed by a withdrawal interval of 5 days (no treatment). On the last day of 
the withdrawal interval (day 14), all animals received a saline challenge and on 
day 15, all animals received a 7.5 mg/kg cocaine challenge. In experiments 2-4, 
cocaine-treated mice were re-challenged with 7.5 mg/kg cocaine on day 21. For this 
day, only data of cocaine-treated mice are presented, as the saline-treated groups 
received cocaine for the second time and can therefore no longer be considered 
proper controls. All injections were given 2 to 5 hours after lights on.
Measurement of locomotor activity
All behavioural tests (days 1, 9, 14, 15 and 21) were performed in the room 
where animals were housed. Mice were placed in a test cage (same type and size 
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(35x19x14cm) as the home cage) containing a standardised amount of sawdust, 
covered with a perspex lid. Following a 2 hour habituation period, animals were 
injected and activity was monitored on video for 30 minutes. At the end of this 
period, a blood sample was taken from the tail vein for endocrine measurements 
and the animals were returned to their home cage.
Analysis of locomotor activity
Video images were digitised and analysed using Ethovision Videotracking, Motion 
Analysis & Behavior Recognition System version 1.96 (‘VTMAS’, Noldus Informa-
tion Technology B.V., Wageningen, The Netherlands). The position of the animal 
was sampled 5 times per second. Of each recording (30 minutes) 27 minutes were 
analysed since the animals were subjected to blood sampling at 30 minutes after 
injection. Data are represented in total distance moved (cm) over the entire 27 
minute treatment period. Locomotion was defined as movement with a minimal 
distance of 2 cm.
Corticosterone assay
Blood samples were taken from the tail vein by a small incision with a razorblade 
30 minutes after treatment on the test days 1, 9, 14, 15 and 21. Blood was col-
lected in small EDTA coated tubes (Microvette DB 200 K3E, Sarstedt, Nümbrecht, 
Germany). Plasma was obtained by centrifugation at 13000 rpm for 20 minutes at 
4ºC and subsequently stored at -20ºC. Corticosterone concentrations were deter-
mined by in-duplo measurement using a radio-immuno-assay kit according to the 
protocol provided by the manufacturer (Corticosterone double antibody 125I RIA kit, 
MP Biomedicals, Asse-Relegem, Belgium). All samples were analysed in one assay 
to exclude inter-assay variability. ADX effectively clamped plasma corticosterone to 
basal concentrations and only animals with successful ADX were included in the 
study.
Experimental design
Experiment 1: Effect of mifepristone (RU38486) on expression of behavioural 
sensitisation to cocaine in intact mice
This experiment was designed to investigate whether corticosterone plays a critical 
role in expression of previously established behavioural sensitisation to cocaine. 
For this purpose, animals were administered the glucocorticoid receptor antagonist 
mifepristone (200 mg/kg, orally via oats) 2.5 hours prior to the cocaine challenge 
on day 15. Unoperated DBA/2 mice were used for this part of the study. In the week 
before start of the sensitisation paradigm, animals were familiarised with the smell 
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and taste of plain oats. A feeding cup was placed permanently in the home cage 
for oat administration. Initially, animals were divided over 2 experimental groups: 
SAL and COC (n=20, 34). Based on behavioural responses on the last day of the 
treatment period (day 9), animals were divided over vehicle and mifepristone (‘RU’) 
treatment groups such that a homogenous distribution of relatively low- and high- 
responders was created (SAL/VEH, SAL/RU, COC/VEH, COC/RU n=10-18). On day 
15, the oats containing mifepristone or vehicle were given 2.5 hours prior to the 
cocaine challenge, thus 30 minutes prior to the onset of the habituation phase. 
When animals were transferred to the test cages, the home cages were checked to 
verify whether all oats had been eaten.
Experiments 2-4 were designed to investigate the role of corticosterone during ini-
tiation of behavioural sensitisation to cocaine and the time-window for the actions 
of the hormone in relation to drug exposure.
Experiments 2 and 3: Effect of corticosterone substituted 5 minutes or 2 hours 
prior to cocaine on behavioural sensitisation in ADX mice
This part of the study consisted of 6 experimental groups (n=8-12). Animals were 
either adrenalectomised (ADX) or SHAM operated. ADX animals were assigned 
to the corticosterone substitution or control groups (ADXcort, ADX). All groups 
were subdivided in saline (SAL) and cocaine (COC) groups, indicating the treat-
ment given during the treatment phase of the sensitisation paradigm. Corticosterone 
(1 mg/kg, free base) or saline was injected i.p. 5 minutes (experiment 2) or 2 hours 
(experiment 3) prior to each treatment (days 1-9, 14 and 15). To investigate drug re-
sponsiveness in absence of corticosterone substitution, animals were re-challenged 
with 7.5 mg/kg cocaine one week after the initial cocaine challenge (day 21). On 
this day, all animals received saline 2 hours prior to drug treatment.
Experiment 4: Effect of chronic corticosterone substitution on behavioural 
sensitisation in ADX mice
Again, 6 treatment groups were used: SHAM (SAL/COC), ADX (SAL/COC) and 
ADXcort (SAL/COC) (n=8-12). Corticosterone (20%) and cholesterol pellets were 
implanted one day prior to the onset of the sensitisation paradigm. To this aim, 
animals were briefly anaesthetised with an isoflurane mixture (see surgical proce-
dures) and the pellet was placed subcutaneously in the flank of the animal. Follow-
ing surgery, animals were housed individually and the sensitisation paradigm was 
started the following day. Also in this study, animals were re-challenged on day 21 




Statistical analysis was performed using SPSS for Windows software (release 7.5, 
SPSS Benelux B.V., Gorinchem, The Netherlands). For the mifepristone study, 
analyses were performed per test day: one factor ANOVA for treatment (days 1, 
9 and 14) and two factor ANOVA for treatment and mifepristone (day 15). For the 
corticosterone substitution studies, overall locomotor activity and corticosterone 
data were subjected to repeated measures ANOVA with three between subject fac-
tors (surgery, substitution and treatment) and one within subject factor (test day). 
Subsequent analyses were performed per test day: three factor ANOVA for surgery, 
substitution and treatment. When statistical significance was revealed, post hoc 
tests were performed (LSD, or for within subject comparison paired t-test). Differ-
ences were considered statistically significant when p<0.05.
rEsults
Experiment 1: Effect of mifepristone (ru38486) on expression of behavioural 
sensitisation to cocaine in intact mice
The GR antagonist mifepristone (RU38486, ‘RU’) was administered orally to intact 
animals 2.5 hours prior to the 7.5 mg/kg cocaine challenge on day 15. Figure 1A 
depicts total distance moved for the treatment groups SAL and COC (days 1, 9 and 
14) and SAL/VEH, SAL/RU, COC/VEH and COC/RU (day 15).
Cocaine stimulated locomotion in the treatment period (day 1: 
F[treatment]1,53=18.412, p<0.001, day 9: F[treatment]1,52=49.246, p<0.001, post 
hoc: p<0.001) and drug responses were enhanced on day 9 compared to day 1 
(p<0.01, paired t-test). Furthermore, cocaine-treated mice displayed elevated 
locomotor responses to the saline challenge on day 14 (F[treatment]1,52=16.192, 
p<0.001, post hoc: p<0.001). Based on responsiveness on day 9, cocaine-
treated mice were distributed over the RU and VEH groups such that relatively 
low- and high-responders were divided equally. The cocaine challenge on day 15 
resulted in augmented locomotion in cocaine- compared to saline-treated mice 
(F[treatment]1,48=9.623, p<0.01, post hoc: p<0.05), while there was no effect of 
mifepristone on drug responses of either cocaine-treated or drug-naïve animals 
(F[RU]1,48=0.000, p=1.000).
Figure 1B depicts plasma corticosterone concentrations 30 minutes after drug 
treatment, thus 3 hours after RU or VEH administration. Plasma corticosterone con-
centrations were elevated in RU compared to VEH-treated groups (F[RU]1,51=126.566, 
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p<0.001, post hoc: p<0.001), with the most pronounced elevation in the COC/RU 
group (F[treatment]1,51=126.566, p=0.210, F[treatment x RU]1,51=9.672, p<0.01, 
post hoc: p<0.01 vs. SAL/RU).
The results of experiment 1 did not support a critical role for glucocorticoid signal-
ling via GR in expression of locomotor sensitisation in DBA/2 mice. We there-
fore hypothesised that corticosterone may contribute to induction of behavioural 
sensitisation. Experiments 2-4 were designed to investigate whether the deficit of 
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Figure 1: The effect of mifepristone on expression of locomotor sensitisation in intact 
DBA/2 mice.
A) Locomotion in response to treatment on days 1, 9, 14 and 15 of the sensitisation 
paradigm. Animals were treated during 9 consecutive days with cocaine (COC, n=33) 15.0 
mg/kg or saline (SAL, n=20), followed by a 5 day withdrawal interval and a saline challenge 
(day 14). Mice received 200 mg/kg mifepristone (‘RU’, n=14-17) or vehicle (VEH, n=9) on 
oats 2.5 hours prior to the 7.5 mg/kg cocaine challenge on day 15. Data are represented in 
average total distance moved (TDM, cm) ± SEM.
B) Plasma corticosterone concentrations 30 minutes after the 7.5 mg/kg cocaine challenge 
and 3 hours after mifepristone or vehicle administration on day 15. Data are represented 
in average corticosterone (CORT, ng/ml) ± SEM. n=9-17 animals/group. *1 p<0.001, 
*2 p<0.01, *3 p<0.05 vs. SAL (LSD), # p<0.001 vs. VEH (LSD), † p<0.001 vs. the previous 
test day (paired t-test).
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ADX mice in locomotor sensitisation to cocaine can be reversed by replacement of 
corticosterone from the start of the sensitisation paradigm, at different time intervals 
in relation to drug exposure.
Plasma corticosterone concentrations
Table 1 shows the effects of ADX and the different hormone replacement regimens 
on plasma corticosterone concentrations 30 minutes after treatment on days 1, 9, 
14, and 15.
For SHAM and ADX mice, data were replicated across experiments and therefore 
pooled. Main effects were found for treatment, surgery, day and the interaction 
between these factors (F[treatment]1,89=19.897, p<0.001, F[surgery]1,89=314.423, 
table 1: Effect of ADX and hormone replacement on plasma corticosterone concentrations.
day 1 day 9 day 14 day 15
saline challenge cocaine challenge 1
sHaM sal 108.9 ± 12.3 140.4 ± 17.3 † 138.8 ± 13.6 216.2 ± 15.7
coc 220.5 ± 13.4 * 364.0 ± 16.4 *† 167.7 ± 18.0 261.1 ± 17.6 *
adX sal  18.6 ± 2.9 #  30.0 ± 4.6 #  35.7 ± 5.3 #  40.4 ± 6.6 #
coc  20.8 ± 3.0 #  30.9 ± 4.2 #  35.6 ± 4.0 #  38.7 ± 4.8 #
cort 5 min. sal 422.9 ± 50.3 # Ω 530.1 ± 31.6 # Ω 577.2 ± 17.1 # Ω 418.5 ± 64.0 # Ω
coc 557.7 ± 31.3 # Ω 633.0 ± 43.3 # Ω 521.6 ± 67.5 # Ω 469.5 ± 63.8 # Ω
cort 2 hrs. sal  71.7 ± 13.4 Ω  72.2 ± 6.8 #  95.3 ± 10.8 Ω 102.0 ± 15.0 # Ω
coc  86.7 ± 13.9 # Ω  84.3 ± 10.3 # Ω  56.8 ± 11.0 #  65.0 ± 9.9 #
cort pellet sal 474.1 ± 22.8 # Ω 129.5 ± 6.2 Ω 118.6 ± 6.5 Ω 135.6 ± 5.9 # Ω
coc 527.5 ± 19.5 # Ω 130.8 ± 4.9 # Ω 110.2 ± 4.6 # Ω 120.5 ± 5.5 # Ω
Plasma corticosterone concentrations 30 minutes after treatment on days 1, 9, 14 and 15. 
Animals were SHAM operated, adrenalectomised (ADX), or ADX and given corticosterone 
(CORT) replacement: 5 minutes or 2 hours prior to drug administration (1 mg/kg, i.p.) 
or chronically (20% pellet). Mice were treated during 9 consecutive days with cocaine 
(COC) 15.0 mg/kg or saline (SAL), followed by a 5 day withdrawal interval. All animals 
received a saline challenge on day 14 and a 7.5 mg/kg cocaine challenge on day 15. Data 
are represented in average plasma corticosterone concentration (ng/ml) ± SEM, n=7-29 
animals/group. * p<0.05 vs. SAL (LSD), # p<0.05 vs. SHAM (LSD), Ω p<0.05 vs. ADX 
(LSD), † p<0.05 vs. day 1 (paired t-test).
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p<0.001, F[day]4,356=22.342, p<0.001, F[day x surgery x treatment]4,356=16.922, 
p<0.001). Corticosterone concentrations were attenuated in ADX compared to 
SHAM mice on all test days (p<0.001). In agreement with previous observations 
(chapter 2, 145), cocaine-induced corticosterone secretion in SHAM mice was 
enhanced on day 9 compared to day 1 (p<0.001, paired t-test) and a similar ef-
fect was observed for the response to saline treatment, though less pronounced 
(p<0.05, paired t-test). In addition, cocaine-treated SHAM mice showed greater 
corti costerone secretion in response to the drug challenge on day 15, when com-
pared to saline-treated mice (p<0.05).
Corticosterone substitution 5 minutes prior to drug treatment resulted in a 
pronounced elevation of the hormone to concentrations even higher than in the 
SHAM groups (F[substitution]1,103=805.511, p<0.001, post hoc: p<0.001 vs. SHAM 
and ADX on all days). By contrast, when corticosterone was administered 2 hours 
prior to drug administration, hormone concentrations were lower than of SHAM 
mice, though not fully normalised to ADX levels 30 minutes after drug treatment 
(F[substitution]1,102=9.839, p<0.01). On day 21, corticosterone substitutions were 
omitted and hormone concentrations were similar to those of ADX mice (data not 
shown).
In animals with corticosterone pellets (F[substitution]1,105=171.434, p<0.001), 
hormone concentrations were elevated above SHAM levels on day 1 (p<0.001) and 
thereafter declined to on average 125 ng/ml on days 9, 14 and 15, being higher than 
in the ADX groups (at least p<0.01), but in the case of cocaine treatment, lower than 
in the SHAM groups (at least p<0.05). A further decline was observed from day 15 
to 21, when corticosterone concentrations in the substituted groups dropped below 
100 ng/ml (ADXcort/SAL: 92 ± 8, ADXcort/COC: 81 ± 6). These data indicate that 
the subcutaneous corticosterone pellet generated plasma corticosterone concentra-
tions that were very high on the first day of the treatment phase and thereafter 
declined to concentrations in the range of stress-induced levels that persisted until 
the first cocaine challenge on day 15.
Experiment 2: Effects of corticosterone substituted 5 minutes prior to cocaine on 
behavioural sensitisation in adX mice
Corticosterone (1 mg/kg, free base) or saline was administered 5 minutes prior 
to drug treatment on days 1-9, 14 and 15, but not 21. Main effects were found 
for treatment, day and the interaction between day, surgery and treatment 
(F[treatment]1,43=37.622, p<0.001, F[day]4,172=12.413, p<0.001, F[day x surgery x 
treatment]4,172=3.444, p<0.05). Responses to saline treatment were not affected by 
either surgery or substitution in any of the tests.
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Figure 2 depicts total distance moved for the treatment groups SHAM (SAL/
COC), ADX (SAL/COC) and ADXcort (SAL/COC) on days 1, 9 and 15. On the 
first day of the treatment period, there was no effect of surgery or substitution on 
cocaine-induced locomotion (F[treatment]1,54=4.532, p<0.05, F[surgery]1,54=0.292, 
p=0.591, F[substitution]1,54=0.235, p=0.630). Consistent with previous observations, 
drug responses of SHAM (p<0.05, paired t-test), but not of ADX mice (p=0.735, 
paired t-test), were enhanced on day 9 compared to day 1. The ADXcort group 
also displayed increased cocaine responsiveness (p<0.01, paired t-test), although 
this effect appeared to be mainly attributable to the slightly lower drug response 
†
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Figure 2: The effect of corticosterone substituted 5 minutes prior to drug administration on 
behavioural sensitisation in ADX mice.
Locomotion in response to treatment on days 1, 9 and 15. Animals were SHAM operated, 
adrenalectomised (ADX), or ADX and given corticosterone replacement 5 minutes prior to 
drug administration (ADXcort). Mice were treated during 9 consecutive days with cocaine 
(COC) 15.0 mg/kg or saline (SAL), followed by a 5 day withdrawal interval. All animals 
received a saline challenge on day 14 and a 7.5 mg/kg cocaine challenge on day 15. Data 
are represented in average total distance moved (TDM, cm) ± SEM, n=7-12 animals/group. 
* p<0.001 vs. SAL (LSD), #1 p<0.001, #2 p<0.01 vs. SHAM (LSD), †1 p <0.01, †2 p <0.05 
vs. day 1 (paired t-test).
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on day 1, rather than to true sensitisation. In support of this, cocaine responses 
of ADX mice were lower than of SHAM mice on day 9 (p<0.01), irrespective of 
substitution (F[treatment]1,54=39.504, p<0.001, F[surgery]1,54=4.339, p<0.05, 
F[substitution]1,54=0.040, p=0.843, F[surgery x treatment]1,54=4.886, p<0.05). 
Furthermore, in contrast to SHAM/COC mice (p<0.001), neither ADX/COC nor 
ADXcort/COC mice displayed augmented responsiveness to the 7.5 mg/kg cocaine 
challenge on day 15 (F[treatment]1,53=29.765, p<0.001, F[surgery]1,53=1.786, 
p=0.188, F[substitution]1,53=1.571, p=0.216, F[surgery x treatment]1,53=12.160, 
p<0.01). Moreover, locomotor responses of cocaine-treated ADX and ADXcort 
mice were lower than of SHAM mice on day 15 (p<0.01) and on day 21 (ADXcort: 
p<0.05, ADX: p=0.068), when animals were re-challenged with 7.5 mg/kg cocaine 
without prior corticosterone substitution (day 21: SHAM: 5603 ± 1038, ADX: 3771 
± 619, ADXcort: 3017 ± 650, F[treatment]1,51=10.536, p<0.01, F[surgery]1,51=0.195, 
p=0.661, F[substitution]1,51=1.965, p=0.168, F[surgery x treatment]1,51=8.059, 
p<0.01).
Experiment 3: Effects of corticosterone substituted 2 hours prior to cocaine on 
behavioural sensitisation in adX mice
Corticosterone (1 mg/kg, free base) or saline was administered 2 hours prior to drug 
treatment on days 1-9, 14 and 15, but not 21. Locomotion was influenced by sur-
gery, treatment and day and interactions between these factors (F[surgery]1,415.566, 
p<0.05, F[treatment]1,41=16.192, p<0.001, F[day]4,164=29.030, p<0.001, F[day x 
surgery]4,164=4.500, p<0.01, F[day x treatment]4,164=2.504, p<0.05). Responses to 
saline treatment were not affected by either surgery or substitution in any of the 
tests.
Locomotor responses of the SHAM (SAL/COC), ADX (SAL/COC) and ADXcort 
(SAL/COC) groups on days 1, 9 and 15 are depicted in figure 3. On the first 
day of the treatment period, there was no effect of surgery or substitution on 
cocaine-induced locomotion (F[treatment]1,57=9.719, p<0.01, F[surgery]1,57=1.529, 
p=0.222, F[substitution]1,57=0.232, p=0.632). Similar to experiment 2, only the 
SHAM group displayed enhanced drug responsiveness on day 9 compared to 
day 1 (p<0.05, paired t-test). Furthermore, cocaine responses of ADX mice were 
lower than of SHAM mice on day 9, irrespective of substitution, although this just 
failed to reach significance for the ADX group (F[treatment]1,50=26.694, p<0.001, 
F[surgery]1,50=2.157, p=0.149, F[substitution]1,50=0.566, p=0.456, post hoc: ADX: 
p=0.055, ADXcort: p<0.01 vs. SHAM). Also in this study, only SHAM/COC mice 
(p<0.05) displayed enhanced responsiveness to the 7.5 mg/kg cocaine chal-
lenge on day 15 (F[treatment]1,49=7.188, p<0.05, F[surgery]1,49=1.572, p=0.216, 
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F[substitution]1,49=0.086, p=0.770). Furthermore, locomotor responses of cocaine-
treated ADX (p=0.066) and ADXcort (p<0.05) mice were lower than of SHAM 
mice on day 15 and this was even more pronounced on day 21 (p<0.05 for both 
groups), when animals were re-challenged with 7.5 mg/kg cocaine without prior 
corticosterone substitution (SHAM: 9859 ± 1481, ADX: 4290 ± 1182, ADXcort: 
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Figure 3: The effect of corticosterone substituted 2 hours prior to drug administration on 
behavioural sensitisation in ADX mice.
Locomotion in response to treatment on days 1, 9 and 15. Animals were SHAM operated, 
adrenalectomised (ADX), or ADX and given corticosterone replacement 2 hours prior to 
drug administration (ADXcort). Mice were treated during 9 consecutive days with cocaine 
(COC) 15.0 mg/kg or saline (SAL), followed by a 5 day withdrawal interval. All animals 
received a saline challenge on day 14 and a 7.5 mg/kg cocaine challenge on day 15. Data 
are represented in average total distance moved (TDM, cm) ± SEM, n=7-12 animals/group. 




Experiment 4: Effect of chronic corticosterone substitution on behavioural 
sensitisation in adX mice
Corticosterone (20% corticosterone in cholesterol) or vehicle (100% cholesterol) 
pellets were implanted subcutaneously (s.c.) one day prior to the first drug ad-
ministration. Main effects were found for surgery, treatment, day and the interaction 
between these factors (F[surgery]1,41=10.640, p<0.01, F[treatment]1,41=37.136, 
p<0.001, F[day]4,164=35.683, p<0.001, F[day x surgery x treatment]4,164=2.800, 
p<0.05). Responses to saline treatment were not affected by either surgery or sub-
stitution in any of the tests.
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Figure 4: The effect of chronic corticosterone substitution on behavioural sensitisation in 
ADX mice.
Locomotion in response to treatment on days 1, 9 and 15. Animals were SHAM operated, 
adrenalectomised (ADX), or ADX and implanted with a 20% corticosterone pellet 
(ADXcort). Mice were treated during 9 consecutive days with cocaine (COC) 15.0 mg/
kg or saline (SAL), followed by a 5 day withdrawal interval. All animals received a saline 
challenge on day 14 and a 7.5 mg/kg cocaine challenge on day 15. Data are represented in 
average total distance moved (TDM, cm) ± SEM, n=6-10 animals/group. * p<0.01 vs. SAL, 
#1 p<0.001, #2 p<0.01, #3 p<0.05 vs. SHAM (LSD), Ω p<0.05 vs. ADX (LSD), †1 p<0.01, 
†2 p<0.05 vs. day 1 (paired t-test).
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Figure 4 depicts locomotor responses of SHAM (SAL/COC), ADX (SAL/COC) and 
ADXcort (SAL/COC) groups on days 1, 9 and 15. On the first day of the treatment 
period, corticosterone substitution reduced cocaine responses (F[treatment]1,53=9.398, 
p<0.01, F[substitution]1,53=4.659, p<0.05, F[surgery]1,53=1.099, p=0.300, post hoc: 
p<0.05 vs. SHAM/COC and ADX/COC). In this experiment, not only SHAM, but 
also ADXcort mice, displayed enhanced cocaine-induced locomotion on day 9 
compared to day 1 (p<0.05, paired t-test). The apparent sensitisation in the ADX-
cort group was not solely due to the reduced drug response on day 1, as cocaine 
responses of these mice were higher than of ADX mice on day 9 (p<0.05), al-
though not fully normalised to SHAM levels (p<0.001) (F[treatment]1,49=46.014, 
p<0.001, F[surgery]1,49=18.168, p<0.001, F[substitution]1,49=2.481, p=0.122, 
F[surgery x treatment]1,49=16.909, p<0.001). However, only SHAM/COC animals 
(p<0.01) displayed enhanced drug responsiveness to the 7.5 mg/kg cocaine chal-
lenge on day 15 (F[surgery]1,50=5.106, p<0.05, F[treatment]1,50=8.135, p<0.01, 
F[substitution]1,50=0.979, p=0.328, F[surgery x treatment]1,50=4.645, p<0.05). Fur-
thermore, locomotor responses of cocaine-treated ADX and ADXcort mice were 
lower than of SHAM mice on day 15 (p<0.05). On day 21 however, when animals 
were re-challenged with 7.5 mg/kg cocaine, only cocaine responses of ADX mice 
were significantly lower than of SHAM mice (SHAM: 7101 ± 1102, ADX: 4651 ± 
761, ADXcort: 5311 ± 572, F[treatment]1,49=3.558, p=0.066, F[surgery]1,49=1.506, 
p=0.226, F[substitution]1,49=1.333, p=0.255, post hoc: ADX: p<0.05, ADXcort: 
p=0.112).
dIscussIon
The present study shows that adrenal glucocorticoids play a role during initiation 
rather than expression of cocaine-induced behavioural sensitisation in DBA/2 mice. 
The time window for the actions of corticosterone during initiation of sensitisa-
tion was investigated in ADX mice. It was demonstrated that whereas intermittent 
corticosterone replacement, either 5 minutes or 2 hours prior to each drug ad-
ministration, was ineffective in reversing the sensitisation deficit of ADX mice, ini-
tiation of behavioural sensitisation was partially restored by chronic corticosterone 
substitution.
The observation that ADX prevents both initiation and expression of locomotor 
sensitisation to cocaine in DBA/2 mice, suggests that adrenal stress hormones con-




This hypothesis was strengthened by the present finding that the GR antagonist 
mifepristone (RU38486) administered 2.5 hours prior to the cocaine challenge 
(day 15) was ineffective in reversing expression of previously established behav-
ioural sensitisation of intact mice (figure 1A). In agreement with this, it has been 
demonstrated that ADX performed in already sensitised animals does not prevent 
expression of the behavioural hyperresponsiveness 527,529. The present finding does 
however contradict two reports in which the motivation to self-administer cocaine, 
and amphetamine-induced behavioural sensitisation, were blocked by pretreatment 
with mifepristone in animals that had previously acquired these behaviours 153,168. 
This discrepancy could result from the use of different species and genetic back-
grounds. In support of this, Deroche-Gamonet et al. show that mifepristone only 
reduces the motivation to obtain cocaine in a subset of outbred rats that display an 
exceptionally high drug response, and we have demonstrated previously that the 
effects of ADX on behavioural sensitisation to cocaine are highly strain-dependent 
145,168.
The dramatic increase in plasma corticosterone observed in mifepristone-
pretreated mice (as measured 30 minutes after drug treatment, figure 1B), indicates 
that the antagonist was effective in preventing negative feedback on the HPA-axis 
and thus in blocking GR. From these data it can however not be concluded whether 
sufficient concentrations of mifepristone reached the brain, but this is likely to have 
occurred since other studies using lower oral doses have shown effects of the an-
tagonist on brain function and behaviour 160,431.
The observation that the 20% corticosterone pellet facilitated initiation of sensitisa-
tion in ADX mice, is in agreement with reports showing that chronic administration 
of the adrenal glucocorticoid in concentrations similar to those induced by stress, 
enhances behavioural responsiveness to single and repeated psychostimulant 
exposure 77,485,498. However, mice implanted with the 20% pellets did not show 
behavioural hyperresponsiveness to the cocaine challenge on day 15. It is conceiv-
able that a certain degree of behavioural sensitisation did develop in mice receiv-
ing chronic corticosterone, and we hypothesise that a longer withdrawal duration 
may be required for this behaviour to become expressed. Indeed, psychostimulant 
sensitisation is characterised by a time-dependent cascade of cellular changes that 
differs between short- and long-term withdrawal periods 520,693. The observation that 
locomotor responses of ADXcort and SHAM mice were no longer different by the 
time of the second cocaine challenge (day 21), supports this hypothesis. This finding 
was replicated in a subsequent experiment in which drug responses of ADXcort 
mice were even equal to those of SHAM mice on day 21 (see chapter 5). Further 
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research is required to investigate the time course of behavioural sensitisation in 
mice receiving chronic corticosterone.
Several explanations can be proposed for the inefficacy of corticosterone in fully 
reversing the effects of ADX on behavioural sensitisation to cocaine.
First, it is conceivable that the hormone was not replaced in sufficient amounts. 
This is however not likely, since the dose of 1 mg/kg used in the intermittent re-
placement studies resulted in extraphysiological peak plasma concentrations of 
1200 ng/ml (5 minutes after i.p. administration, data not shown). Furthermore, 
corticosterone in the same dose range has been shown to sensitise the locomo-
tor response to amphetamine in rats 165. However, it has also been demonstrated 
that administration of 10 mg/kg, but not 5 mg/kg, corticosterone prior to cocaine 
enhances behavioural sensitisation to the drug in intact rats, indicating that even 
in the extra-physiological dose range, there may be dose-dependency for the ef-
fects of corticosterone 529. In the case of the 20% corticosterone pellet, mice were 
exposed to high glucocorticoid levels especially during the initiation of behavioural 
sensitisation, to which the hormone was hypothesised to contribute. Furthermore, 
concentrations in the range of stress-induced levels were still present at the time 
of the first cocaine challenge. Previously, a 20% corticosterone pellet has been 
demonstrated to fully restore amphetamine-induced locomotion in ADX mice 681.
Second, sensitisation of HPA-axis responsiveness to cocaine may be a require-
ment for behavioural sensitisation in this strain. Indeed, DBA/2 mice display paral-
lel sensitisation of locomotion and corticosterone secretion during the treatment 
phase and in response to the cocaine challenge on day 15 (the present study, 145). 
However, it has been shown previously that sensitisation of corticosterone secretion 
may not be a prerequisite for long-term expression of behavioural sensitisation 609. 
Further studies are therefore required to investigate the potential contribution of 
endocrine sensitisation to behavioural responsiveness in this mouse strain.
Third, it may be necessary to restore the circadian and/or ultradian rhyth-
micity in corticosterone secretion. In contrast to rats, mice maintain basal levels of 
corticosterone that are considered sufficient for occupation of the high-affinity min-
eralocorticoid receptor after ADX (the present study, 300). However, ADX mice do 
lack the rise in plasma corticosterone that precedes the nocturnal period. Although 
diurnal concentrations of corticosterone are sufficient for the locomotor response to 
a single cocaine exposure in rats 422,423, a full circadian cycle might be required for 
behavioural sensitisation to repeated drug exposure.
Assuming that sufficient amounts of corticosterone were replaced, the observation 
that only chronic high concentrations of the hormone partially restored initiation of 
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sensitisation, suggests that glucocorticoids may not be the only adrenal factors that 
contribute to behavioural sensitisation in the DBA/2 strain. This conclusion is sup-
ported by several observations. It is well accepted that stress-induced behavioural 
sensitisation to psychostimulants depends on corticosterone secretion 164,166. How-
ever, studies using ADX, genetic- or pharmacological inactivation of the GR have 
generated conflicting results regarding the necessity of adrenal glucocorticoids in 
psychostimulant sensitisation 21,168,527,529,552,609. Furthermore, two recent reports have 
indicated that corticosterone may be necessary, but not sufficient for the effects of 
stress on escalation of cocaine self-administration 417 and on the neurochemical and 
rewarding effects of morphine 161. Mantsch et al. elegantly showed that restoration 
of corticosterone levels in the range of those induced by footshock stress is neces-
sary to reinstate stress-induced escalation of cocaine self-administration in ADX 
animals. However, corticosterone alone was not sufficient to reproduce the effects 
of the stressor in animals that were not exposed to footshock 417. The requirement 
of the stressor suggests that stress-induced factors other than corticosterone play an 
additional role. In view of the present data with ADX, it is tempting to speculate 
a role for the adrenal catecholamine epinephrine. Indeed, the HPA-axis and the 
sympathetic nervous system have been demonstrated to interact in regulation of 
behaviour, most notably in memory processing 53,571. Further research is required 
to investigate the potential role of other adrenal factors such as epinephrine, in 
addition to that of corticosterone, in behavioural sensitisation to cocaine.
The present study showed that, in a mouse strain in which behavioural sensitisa-
tion to cocaine is critically dependent on adrenal hormones, the glucocorticoid 
corticosterone facilitated the initiation and retention of the behavioural sensitisation 
to repeated drug exposure, provided it was continuously circulating. To full blown 
recovery of the impaired behavioural sensitisation to psychostimulants in ADX mice 
other adrenal factors, such as epinephrine, may contribute.
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behavioural sensitisation to cocaine: 
cooperation between glucocorticoids and 
epinephrine




Stressful life experiences facilitate behavioural responsiveness to psychostimulant 
drugs. While there is ample evidence that adrenal glucocorticoids mediate the 
effects of stress, the role of the sympathoadrenal system is poorly understood.
The present study was designed to investigate the role of the two adrenal stress 
hormones, corticosterone and epinephrine, in sensitisation to the locomotor 
stimulant effects of cocaine. The DBA/2 mouse strain was used, as behavioural 
sensitisation in this strain is critically dependent on adrenal hormones. Animals 
were subjected to adrenalectomy (‘ADX’, surgical removal of the adrenals) or SHAM 
surgery and ADX mice were given replacement therapies of epinephrine (5x10-3 mg/
kg, s.c. just prior to each drug administration), corticosterone (20% s.c. pellet) or 
both. We have measured sensitisation to the locomotor stimulant effects of repeated 
cocaine exposure and, in addition, cocaine-induced c-fos mRNA expression in a 
number of brain regions to identify a neural substrate for the actions of the adrenal 
hormones.
In agreement with our previous observations, ADX prevented initiation 
and expression of cocaine-induced locomotor sensitisation. Whereas neither 
corticosterone nor epinephrine alone were sufficient to reverse the ADX effect, both 
adrenal stress hormones were necessary to fully restore the initiation and retention 
of locomotor sensitisation to levels observed in SHAM animals. In addition, we 
show that epinephrine potentiated cocaine-induced c-fos mRNA expression in 
the hypothalamic PVN, indicating that the catecholamine may also contribute to 
sensitisation of the hypothalamic-pituitary-adrenal (HPA) axis to cocaine.
The present findings indicate that corticosterone and epinephrine cooperate 
to facilitate behavioural responsiveness to cocaine. These data emphasise that, in 
addition to the HPA-axis, the autonomic sympathetic nervous system (ANS) plays a 




It is well known that stress, resulting in activation of the hypothalamic-pituitary-
adrenal axis (HPA-axis) and the autonomic sympathetic nervous system (ANS) 
146, can increase sensitivity to the behavioural and reinforcing effects of psycho-
stimulant drugs, a phenomenon known as behavioural sensitisation 249,514. Studies in 
laboratory rodents have demonstrated that stress facilitates acquisition and relapse 
of psychostimulant self-administration 244,277,510,660 and enhances vulnerability to the 
locomotor stimulant properties of these drugs 164,272,284,383,635.
A wealth of data indicates that adrenal glucocorticoids, the output hormones of 
the HPA-axis, mediate the effects of stress on psychostimulant responsiveness 
144,168,240,421, primarily via their actions on the mesencephalic dopamine system 515. 
By contrast, the role of the ANS in psychostimulant sensitivity has received little 
attention. This is surprising since catecholamines (epinephrine, norepinephrine) 
are rapidly released into the general circulation during stress and in response to 
psychostimulant administration 109. Although the catecholamines are not likely to 
cross the blood-brain-barrier due to their polar structure 725, substantial evidence 
indicates that peripheral epinephrine can alter brain function and behaviour indi-
rectly by activating vagal afferents to the central nervous system 54,252,456,641. Indeed, 
it has been shown that, in addition to their independent actions, the HPA- and ANS 
components of the stress response can interact to regulate behaviour 53,571.
We have previously identified a mouse strain, the DBA/2 strain, in which sensitisa-
tion to the locomotor stimulant effects of cocaine is critically dependent on adrenal 
hormones 145. Interestingly, whereas surgical removal of the adrenals (adrenalectomy, 
‘ADX’) prevented initiation and expression of psychomotor sensitisation, replace-
ment of corticosterone to concentrations similar or even higher than those induced 
by stress was not sufficient to fully reverse the effects of ADX (chapter 4). Similarly, 
it has recently been reported that glucocorticoids are necessary, but not sufficient, 
to restore the effects of stress on escalation of cocaine self-administration 417 and 
on morphine-induced conditioned place preference 161 in ADX rats. In addition, 
there is considerable controversy in literature regarding the necessity of adrenal 
glucocorticoids in psychostimulant-induced behavioural sensitisation 21,527,529,552. 
Collectively, these findings suggest that adrenal glucocorticoids may not be ‘the 
sole players on the scene’. In view of our findings with ADX, we propose an ad-
ditional role for the adrenal catecholamine epinephrine 145.
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In the present study, we have therefore investigated the role of adrenal gluco-
corticoids and epinephrine in sensitisation to the locomotor stimulant effects of 
cocaine in the DBA/2 strain. Animals were adrenalectomised or SHAM operated 
and ADX mice were given replacement of corticosterone (20% pellet, see chapter 
4), epinephrine (5x10-3 mg/kg, s.c. prior to each drug administration) or both. We 
have measured sensitisation to the locomotor stimulant effects of cocaine and, in 
addition, cocaine-induced c-fos mRNA expression in a number of brain regions to 
identify a neural substrate for the actions of the adrenal hormones.
MEtHods
animals
Male DBA/2 Rj mice were obtained from Janvier (Le Genest Saint Isle, France) at the 
age of 8 weeks. Mice were housed in groups of four in perspex cages (35x19x14cm) 
with food and water available ad libitum at a 12 hour light-dark cycle (lights on: 7 
am) in a temperature (21±1ºC) and humidity (55±5%) controlled room. Surgery was 
performed 2 weeks after arrival in the animal facility. Animals were briefly handled 
in the week before surgery and otherwise left undisturbed. Animal experiments 
were approved by the local Committee for Animal Health, Ethics and Research of 
Leiden University. Animal care was conducted in accordance with the EC Council 
Directive of November 1986 (86/609/EEC).
Experimental design
Animals were either adrenalectomised (ADX) or SHAM operated. Replacement 
therapies consisted of corticosterone (ADXcort), epinephrine (ADXepi), or both 
(ADXcort+epi). Mice were administered saline (SAL) or cocaine (COC) during the 
treatment phase of the sensitisation paradigm, resulting in 10 treatment groups: 
SHAM (SAL/COC), ADX (SAL/COC), ADXcort (SAL/COC), ADXepi (SAL/COC) and 
ADXcort+epi (SAL/COC).
surgery
Animals were individually housed 1 day prior to surgery. The cages were transported 
to the operating room on the morning of the surgery where mice were allowed 
to recover from transportation for 2 hours. Inhalation anaesthesia consisted of a 
mixture of isoflurane (3 l/min), N2O (0.8 l/min) and O2 (0.4 l/min). Adrenalectomy 
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was performed via the dorsal route as described previously 145. SHAM animals were 
treated similarly with the exception of the actual removal of the adrenals. Mice 
were kept individually housed for 24 hours following surgery after which they were 
housed two animals per cage of similar surgery. After surgery, all animals were 
given free access to 0.9% NaCl in addition to normal drinking water. The sensitisa-
tion paradigm was started following a recovery period of 1 week.
drugs
Cocaine hydrochloride (BUFA Pharmaceuticals B.V., Uitgeest, The Netherlands) was 
dissolved in sterile saline and administered intraperitoneally (i.p.) in a dosage of 7.5 
or 15.0 mg/kg. Corticosterone pellets (100 mg, w x h: 9 x 2 mm) consisted of 20% 
corticosterone (ICN Biomedicals Inc, Aurora, Ohio, USA) in cholesterol vehicle 
(cholesterol 95% stabilised, Acros Organics, Geel, Belgium) and were implanted 
subcutaneously in the flank of the animal. Epinephrine ((-)-epinephrine(+)-bitartrate 
salt, Sigma-Aldrich Chemie B.V., Zwijndrecht, The Netherlands) was dissolved in 
sterile saline and administered subcutaneously (s.c.) in a dosage of 5x10-3 mg/kg. 
The epinephrine solution was made freshly on the day of use, adjusted to pH 5 and 
protected from light. Control groups were implanted with 100% cholesterol pellets 
and received equal volumes of saline instead of cocaine or epinephrine. From the 
start of the sensitisation paradigm, animals were weighed once every two days and 
the injection volumes were adjusted accordingly.
sensitisation paradigm
One day prior to the first drug administration and thus the first behavioural test, 
animals were individually housed and kept single housed for the remainder of the 
experiment. The sensitisation paradigm consisted of a treatment phase (days 1-9), 
a withdrawal interval (days 10-14), a saline challenge (day 14), and two cocaine 
challenges (days 15 and 21). The treatment phase consisted of i.p. injections of 15.0 
mg/kg cocaine (COC) or saline (SAL) on 9 consecutive days and locomotion was 
measured on days 1, 5 and 9. On these days, animals received the treatment in the 
test setting as described in the following paragraph. On the remaining days, animals 
received the injections in the home cage. The treatment period was followed by 
a withdrawal interval of 5 days (no treatment). On the last day of the withdrawal 
interval (day 14), all animals received a saline challenge and on day 15, all ani-
mals received a 7.5 mg/kg cocaine challenge. To investigate drug responsiveness 
in absence of epinephrine, animals were re-challenged with 7.5 mg/kg cocaine 
one week after the initial cocaine challenge (day 21) without prior epinephrine 
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substitution. For this day, only data of cocaine-treated mice are presented, as the 
saline-treated groups received cocaine for the second time and can therefore no 
longer be considered proper controls. All injections were given 2 to 5 hours after 
lights on.
Measurement of locomotor activity
All behavioural tests (days 1, 5, 9, 14, 15 and 21) were performed in the room 
where animals were housed. Mice were placed in a test cage (same type and size 
(35x19x14cm) as the home cage) containing a standardised amount of sawdust, 
covered with a perspex lid. Following a 2 hour habituation period, animals were 
injected and activity was monitored on video for 30 minutes. At the end of this 
period, a blood sample was taken from the tail vein for endocrine measurements 
and the animals were returned to their home cage.
analysis of locomotor activity
Video images were digitised and analysed using Ethovision Videotracking, Motion 
Analysis & Behavior Recognition System version 1.96 (‘VTMAS’, Noldus Informa-
tion Technology B.V., Wageningen, The Netherlands). The position of the animal 
was sampled 5 times per second. Of each recording (30 minutes) 27 minutes were 
analysed since the animals were subjected to blood sampling at 30 minutes after 
injection. Data are represented in total distance moved (cm) over the entire 27 
minute treatment period. Locomotion was defined as movement with a minimal 
distance of 2 cm.
corticosterone assay
Blood samples were taken from the tail vein by a small incision with a razorblade 
30 minutes after drug treatment on the test days 1, 5, 9, 14 and 15 and collected in 
small EDTA coated tubes (Microvette DB 200 K3E, Sarstedt, Nümbrecht, Germany). 
On day 21, animals were sacrificed 30 minutes after treatment and trunk blood 
was collected in large EDTA coated tubes (Tube 10 ml, 95x16.8 mm, K3E, Sarstedt, 
Nümbrecht, Germany). Plasma was obtained by centrifugation at 13000 rpm for 
20 minutes at 4ºC and subsequently stored at -20ºC. Corticosterone concentra-
tions were determined by in-duplo measurement using a radio-immuno-assay (RIA) 
kit from MP Biomedicals according to the protocol provided by the manufacturer 
(Corticosterone double antibody 125I RIA kit, MP Biomedicals, Asse-Relegem, Bel-
gium). All samples were analysed in one assay to exclude inter-assay variability. 
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ADX effectively clamped plasma corticosterone to basal concentrations and only 
animals with successful ADX were included in the study.
c-fos mrna in situ hybridisation
Brains were dissected, snap frozen in isopentane (cooled in ethanol placed in pul-
verised dry ice) and stored at -80 ºC until further use. Sections of 16 μm were cut 
on a cryostat (Leica CM3050). Based on the brain atlas of Franklin and Paxinos 220, 
sections were taken at the level of the prefrontal cortex (PFC: medial orbital (MO, 
bregma: +2.34), infralimbic (IL, bregma: +1.54) and prelimbic (PrL, bregma: +1.54) 
regions), nucleus accumbens (Nac: core and shell regions, bregma: +1.44), rostral 
caudate putamen (rCP, bregma: +1.44), caudal CP (cCP: lateral (Lat), dorsomedial 
(DM) and ventromedial (VM) regions, bregma: +0.32, see chapter 3), paraventricu-
lar nucleus of the hypothalamus (PVN, bregma: -0.82), hippocampus (Hipp: CA1 
and dentate gyrus (DG) subdivisions, bregma: -1.58), amygdala (Amy: basolateral 
(BLA) and central (CE) nuclei, bregma: -0.94), ventral tegmental area (VTA, bregma: 
-3.52), substantia nigra pars compacta (SNc, bregma: -3.52), locus coeruleus (LC, 
bregma: -5.52) and nucleus of the solitary tract (NTS, bregma: -7.20). Sections were 
thaw-mounted on 0.001% poly-L-lysine (Sigma-Aldrich) coated slides and stored at 
-80 ºC until further use.
For prehybridisation purposes, sections were fixed for 30 min. in 4% para-
formaldehyde in PBS (pH 7.4), washed twice in PBS, treated with 1% HCL for 10 
min., treated with 0.25% acetic anhydride in 0.1 M triethanolamine for 10 min., 
rinsed for 10 min. in 2 x SSC (150 mM sodium chloride, 15 mM sodium citrate), 
dehydrated in an ethanol series, delipidated in chloroform for 1 min., air dried and 
stored at room temperature until the hybridisation.
A 45-mer oligonucleotide probe encoding mouse c-fos mRNA was used: 
5’-TGCTGGAGAAGGAGTCGGCTGGGGAATGGTAGTAGGAAAGGCTG-3’. 
To control for specificity we used an oligonucleotide that was identical except for 
6 mismatches (transversions) evenly spaced by 6 nucleotides: 5’-TGCGGGAGAAT-
GAGTCGTCTGGGGCATGGTATTAGGAACGGCTG-3’. The oligonucleotides were 
3’ end-labelled with α [35S]deoxyadenosine triphosphate (GE Healthcare Europe 
Gmbh, Diegem, Belgium) using terminal deoxynucleotidyl transferase (Promega 
Benelux, Leiden, The Netherlands).
To each slide, 160 µl of hybridisation mix containing 2 x 106 dpm of labelled 
oligonucleotide were applied. The hybridisation mix consisted of 50% formamide, 
10% dextran sulfate, 2 x SSC, 20 mM sodium phosphate, 200 mM DTT, 1 x Den-
hardt’s, 0.5 mg/ml sheared herring sperm DNA, 0.25 mg/ml tRNA and 5% sarcosyl. 
Sections were coverslipped and hybridised overnight in a moist chamber at 42 °C. 
Chapter 5
120
The next morning, after removal of the coverslips, sections were rinsed in 1 x SSC 
at room temperature, washed twice for 30 min. in 1 x SSC at 50 °C, washed for 
5 min. in 1 x SSC at room temperature, dehydrated in an ethanol series, air dried 
and apposed to Kodak Biomax MR film for 5-15 days (Kodak, Rochester, NY). After 
development of the films, sections were counter-stained with 0.5% cresyl violet.
Analysis of expression was performed by measuring grey levels from film. A 14C-
standard curve was included to ensure that grey values were within the linear range 
between 0 and 255. There was no signal in tissue hybridised with the mismatch 
oligonucleotide. Average optical density per region (in arbitrary units) was corrected 
for film background.
statistics
Statistical analysis was performed using SPSS for Windows software (release 7.5, 
SPSS Benelux B.V., Gorinchem, The Netherlands). Overall locomotor activity and 
corticosterone data were subjected to repeated measures ANOVA with three between 
subject factors (surgery, substitution and treatment) and one within subject factor 
(test day). Subsequent analyses were performed per test day: three factor ANOVA 
for surgery, substitution and treatment. c-Fos data (grey values) were subjected to 
two factor ANOVA for surgery and substitution. When statistical significance was 
revealed, post hoc tests were performed (LSD, or for within subject comparison 
paired t-test). Differences were considered statistically significant when p<0.05.
rEsults
Effect of corticosterone and epinephrine on behavioural sensitisation in adX mice
Main effects were found for treatment, surgery, substitution, day and interactions 
between these factors (F[treatment]1,126=39.878, p<0.001, F[surgery]1,126=6.667, 
p<0.05, F[substitution]3,126=3.006, p<0.05, F[day]5,630=28.002, p<0.001, F[day x 
substitution]15,630=1.726, p<0.05 and F[day x treatment]5,630=14.038, p<0.001).
Figure 1 depicts locomotor responses of the SHAM (SAL/COC), ADX (SAL/
COC), ADXcort (SAL/COC), ADXepi (SAL/COC) and ADXcort+epi (SAL/COC) 
groups on days 1 and 5 of the treatment period. In agreement with our previous 
observations (chapter 4), corticosterone replacement via the 20% pellet reduced 
the initial cocaine response (p<0.001 vs. SHAM, p<0.05 vs. ADX and ADXepi), 
while there was a strong tendency for epinephrine to reverse this effect (ADXcort vs. 
ADXcort+epi: p=0.060). In addition, cocaine responses on day 1 were highest in the 
Chapter 5
121
SHAM group (F[treatment]1,150=13.131, p<0.001, F[surgery]1,150=2.342, p=0.128, 
F[substitution]3,150=0.317, p=0.813, post hoc: at least p<0.05 vs. all other treatment 
groups).
As described previously (chapters 2 and 4, 145), SHAM mice displayed an increase 
in drug responsiveness during the treatment period (day 5 vs. day 1: p<0.05, paired 
t-test), whereas this was prevented by ADX (p=0.191, paired t-test). Furthermore, 
cocaine responses on day 5 were reduced in ADX when compared to SHAM mice 
(p<0.01). Co-replacement of corticosterone and epinephrine fully restored initia-
tion of sensitisation (day 5 vs. day 1: p<0.001, paired t-test), and drug responses 
on day 5, to the level observed in SHAM mice. The ADXcort and ADXepi groups 
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Hoofdstuk 5, figuur 1.pzf:Locomotion 1-5 - Sun Aug 19 10:26:14 2007
Figure 1: Initiation of behavioural sensitisation.
Locomotion in response to treatment on days 1 and 5 of the treatment period, in which 
mice received daily administration of cocaine (15.0 mg/kg) or saline. Animals were SHAM 
operated or adrenalectomised (ADX) and ADX mice received either no substitution or 
replacement with corticosterone (ADXcort), epinephrine (ADXepi), or both (ADXcort+epi). 
Data are represented in average total distance moved (TDM, cm) ± SEM, n=7-9 (saline) or 
17-24 (cocaine) animals/group. # at least p<0.05 vs. SHAM, Ω p<0.05 vs. ADX, ∅ p<0.05 




also displayed an increase in cocaine responsiveness from day 1 to day 5 (p<0.01, 
paired t-test) but drug responses on day 5 were not different from those of ADX mice 
and lower than in the SHAM and ADXcort+epi groups (F[treatment]1,142=41.974, 
p<0.001, F[surgery]1,142=2.870, p=0.093, F[substitution]3,142=2.373, p=0.073, post 
hoc: at least p<0.05 vs. SHAM and ADXcort+epi).
Drug responses on day 9 of the treatment period showed a similar group distri-
bution and were not further enhanced when compared to day 5, indicating that 
behavioural sensitisation develops during the first half of the treatment period 
(SHAM: 7508 ± 1009, ADX: 4193 ± 725, ADXcort: 5641 ± 747, ADXepi: 5718 
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Figure 2: Expression of behavioural sensitisation (day 15).
Locomotion in response to the 7.5 mg/kg cocaine challenge on day 15. Animals 
were SHAM operated or adrenalectomised (ADX) and ADX mice received either no 
substitution or replacement with corticosterone (ADXcort), epinephrine (ADXepi), or both 
(ADXcort+epi). Previously, mice received daily administrations of 15.0 mg/kg cocaine or 
saline (days 1-9), followed by a 5 day withdrawal interval and a saline challenge (day 14). 
Data are represented in average total distance moved (TDM, cm) ± SEM, n=7-11 (saline) 
or 17-22 (cocaine) animals/group. * at least p<0.05 vs. SAL, # p<0.05 vs. SHAM, $ at least 
p<0.05 vs. ADXcort+epi (LSD).
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drug responses of ADXcort mice exceeded those of ADX mice on day 9, but this 
did not reach statistical significance (p=0.208). A similar trend was observed in the 
ADXepi group (p=0.195) (F[treatment]1,139=43.477, p<0.001, F[surgery]1,139=2.390, 
p=0.125, F[substitution]3,139=0.425, p=0.735).
Figure 2 depicts locomotor responses to the first cocaine challenge on day 15. 
Cocaine-treated SHAM mice displayed hyperresponsiveness to the 7.5 mg/kg co-
caine challenge (p<0.01 vs. SHAM/SAL), whereas this was not observed in ADX mice 
receiving no substitution or either corticosterone or epinephrine alone. By contrast, 
























Hoofdstuk 5, figuur 3.pzf:Locomotion 21 - Sun Aug 12 18:09:23 2007
Figure 3: Expression of behavioural sensitisation (day 21).
Locomotion of cocaine-treated mice in response to the second 7.5 mg/kg cocaine 
challenge on day 21. On this day, epinephrine replacement was omitted. Previously, 
SHAM operated and adrenalectomised (ADX) mice receiving either no substitution or 
replacement with corticosterone (ADXcort), epinephrine (ADXepi) or both (ADXcort+epi), 
were given daily administrations of 15.0 mg/kg cocaine or saline (days 1-9), followed by a 
5 day withdrawal interval, a saline challenge (day 14) and a 7.5 mg/kg cocaine challenge 
(day 15). Data are represented in average total distance moved (TDM, cm) ± SEM, n=7-12 
(saline) or 17-22 (cocaine) animals/group. # p<0.01 vs. SHAM, φ p<0.01 vs. ADXcort, 
$ p<0.001 vs. ADXcort+epi (LSD).
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and epinephrine (ADXcort+epi COC vs. SAL: p<0.05). Furthermore, drug responses 
of cocaine-treated SHAM and ADXcort+epi mice were higher than of ADX and ADX-
epi mice (at least p<0.05, except SHAM/COC vs. ADXepi/COC: p=0.078), but not 
different from ADXcort mice (F[treatment]1,138=8.182, p<0.01, F[surgery]1,138=0.644, 
p=0.424, F[substitution]3,138=1.401, p=0.245). Similar group differences were ob-
served on day 21, when cocaine-treated mice were re-challenged with 7.5 mg/kg 
cocaine without prior epinephrine substitution (figure 3). SHAM and ADXcort+epi 
mice displayed cocaine responses higher than of ADX and ADXepi mice (at least 
p<0.05) but not different from those of ADXcort mice (F[treatment]1,139=6.156, 
p<0.05, F[surgery]1,139=10.867, p<0.01, F[substitution]3,139=6.186, p<0.01).
Remarkably, responses to the saline challenge on day 14 showed a similar distri-
bution as to the cocaine challenges on days 15 and 21, being higher for cocaine-
treated SHAM, ADXcort and ADXcort+epi mice than for ADX and ADXepi mice 
(SHAM: 2496 ± 259, ADX: 1429 ± 114, ADXcort: 2597 ± 208, ADXepi: 1477 ± 
154, ADXcort+epi: 2582 ± 239). A significant effect of treatment was only found in 
the SHAM group (F[treatment]1,139=3.130, p=0.079, F[surgery]1,139=2.969, p=0.087, 
F[substitution]3,139=4.062, p<0.01, post hoc: SHAM COC vs. SAL: p<0.05).
Effect of adX and hormone replacement on plasma corticosterone
Table 1 shows the effects of ADX and hormone replacement on plasma corti-
costerone concentrations 30 minutes after treatment on days 1, 5, 9, 14 and 15. Main 
effects were found for treatment, surgery, substitution, day and interactions between 
these factors (F[treatment]1,108=30.233, p<0.001, F[surgery]1,108=94.276, p<0.001, 
F[substitution]3,108=129.940, p<0.001, F[day]5,540=141.546, p<0.001, F[day x 
substitution]15,540=105.773, p<0.001 and F[day x surgery x treatment]5,540=4.936, 
p<0.001).
Corticosterone concentrations were attenuated in the ADX and ADXepi groups 
compared to the SHAM group on all test days (at least p<0.01, except ADX/SAL 
day 1: p=0.058, day 14: p=0.073, ADXepi/SAL day 1: p=0.055, day 14: p=0.070 
vs. SHAM/SAL). Cocaine-treated SHAM mice exhibited enhanced corticosterone 
secretion on day 5 compared to day 1 of the treatment period (p<0.001, paired 
t-test), with no further increase on day 9, indicating that also endocrine sensitisation 
develops during the first half of the treatment period. In addition, corticosterone 
secretion in response to the saline challenge on day 14 was augmented in SHAM/
COC mice (p<0.001 vs. SHAM/SAL). A similar effect was observed in response 




In animals with corticosterone pellets (ADXcort and ADXcort+epi), hormone 
concentrations were elevated above SHAM levels on day 1 (p<0.001) and thereafter 
gradually declined to on average 90 ng/ml on day 15, being higher than in ADX and 
ADXepi mice (p<0.05), but in the case of cocaine treatment, lower than in SHAM 
mice (p<0.01). On day 21, there was no longer a difference between ADX animals 
substituted with or without corticosterone (data not shown). These data indicate that 
the subcutaneous corticosterone pellet generated plasma corticosterone concentra-
tions that were very high on the first day of the treatment phase and thereafter 
declined to concentrations in the range of those induced by stress, that remained 
until the first cocaine challenge on day 15.
table 1: Effect of ADX and hormone replacement on plasma corticosterone concentrations.





sHaM sal  87.5 ± 13.7  91.7 ± 19.9 125.2 ± 29.9  66.2 ± 11.1 182.2 ± 12.8
coc 161.6 ± 12.0 * 313.1 ± 14.7 *† 307.3 ± 20.1 * 140.3 ± 15.8 * 208.9 ± 21.6
adX sal  14.2 ± 3.5  17.4 ± 6.8 #  28.2 ± 6.6 #  31.2 ± 7.5  32.7 ± 8.8 #
coc  15.0 ± 2.6 #  25.9 ± 4.5 #  35.9 ± 7.1 #  31.7 ± 5.4 #  33.4 ± 6.0 #
cort sal 538.0 ± 32.0 # Ω 169.9 ± 6.2 # Ω 111.7 ± 8.7 Ω  75.5 ± 2.9 Ω  83.9 ± 8.8 # Ω
coc 500.1 ± 23.8 # Ω 179.1 ± 5.8 # Ω 129.6 ± 8.2 # Ω  85.6 ± 4.8 # Ω  92.0 ± 8.7 # Ω
EPI sal  10.9 ± 2.3  19.5 ± 5.6 #  21.7 ± 6.3 #  29.6 ± 8.6  30.4 ± 9.5 #
coc  15.3 ± 2.3 #  28.8 ± 4.2 #  39.0 ± 5.9 #  36.2 ± 5.5 #  38.2 ± 6.1 #
cort+EPI sal 514.4 ± 27.3 # Ω 150.4 ± 9.6 # Ω  91.4 ± 6.6 Ω  69.9 ± 4.7 Ω  78.8 ± 6.1 # Ω
coc 459.8 ± 26.0 # Ω 173.8 ± 7.8 # Ω 131.1 ± 9.0 # Ω  82.6 ± 6.4 # Ω  88.2 ± 7.8 # Ω
Plasma corticosterone concentrations 30 minutes after treatment on days 1, 5, 9, 14, and 
15. Animals were SHAM operated or adrenalectomised (ADX) and ADX mice received 
either no substitution or replacement with corticosterone (cort), epinephrine (epi), or both 
(cort+epi). Mice received daily administrations of 15.0 mg/kg cocaine (COC) or saline (SAL) 
(days 1-9), followed by a 5 day withdrawal interval, a saline challenge (day 14) and a 7.5 
mg/kg cocaine challenge (day 15). Data are represented in average plasma corticosterone 
concentration (ng/ml) ± SEM, n=6-11 (saline) or 17-21 (cocaine) animals/group. * p<0.001 
vs. SAL, # at least p<0.01 vs. SHAM, Ω at least p<0.05 vs. ADX and ADXepi (LSD), 




On day 21, animals were sacrificed 30 minutes after the second cocaine challenge 
and c-fos mRNA expression was measured in a number of brain regions of cocaine-
table 2: c-Fos mRNA expression.
cocaine-treated
sHaM adX adXcort adXepi adXcort+epi
PFc Mo 24.4 ± 5.3 32.6 ± 7.0 28.7 ± 4.1 28.8 ± 4.4 32.6 ± 4.8
PFc Il 41.0 ± 5.6 40.9 ± 6.5 44.4 ± 5.0 41.6 ± 3.8 43.8 ± 5.0
PFc Prl 47.7 ± 5.4 50.8 ± 6.3 54.4 ± 5.3 45.1 ± 2.2 50.8 ± 4.0
nac shell 18.6 ± 4.7 24.2 ± 4.9 20.9 ± 4.5 19.9 ± 3.5 22.7 ± 4.1
nac core 23.6 ± 5.3 27.2 ± 5.6 24.9 ± 4.9 23.6 ± 3.9 29.5 ± 5.7
rcP 22.3 ± 4.8 25.2 ± 5.1 26.7 ± 5.0 23.7 ± 3.6 28.4 ± 5.1
ccP lat 17.9 ± 4.9 19.9 ± 5.5 15.4 ± 3.3 16.1 ± 3.9 18.6 ± 4.2
ccP dM 30.1 ± 5.7 27.4 ± 5.8 33.3 ± 5.2 30.5 ± 2.8 36.2 ± 4.8
ccP VM 15.9 ± 5.0 18.1 ± 4.7 14.6 ± 3.1 14.9 ± 3.5 20.4 ± 4.1
Hipp ca1 59.7 ± 8.6 65.2 ± 10.3 61.5 ± 8.0 56.3 ± 7.7 73.7 ± 9.3
Hipp dG 58.5 ± 11.6 72.5 ± 12.9 66.0 ± 10.3 59.3 ± 12.5 77.6 ± 12.5
amy bla 17.0 ± 3.4 17.7 ± 3.7 19.5 ± 3.7 21.1 ± 3.6 19.8 ± 4.1
amy cE 12.3 ± 2.9 14.9 ± 3.7 12.5 ± 3.5 14.3 ± 3.1 14.2 ± 3.6
Vta 20.1± 6.0 29.2 ± 7.5 31.2 ± 5.9 25.2 ± 5.6 29.2 ± 4.9
snc 24.2 ± 7.6 31.7 ± 8.0 29.7 ± 5.5 25.4 ± 4.8 28.2 ± 4.0
lc 31.7 ± 6.3 28.6 ± 7.5 31.3 ± 6.3 22.4 ± 3.9 27.5 ± 2.7
nts 26.9 ± 5.8 24.8 ± 5.6 23.8 ± 5.5 26.8 ± 5.1 18.2 ± 4.1
c-Fos mRNA expression in cocaine-treated mice, 30 minutes after the 7.5 mg/kg cocaine 
challenge on day 21. Previously, SHAM operated and adrenalectomised (ADX) mice 
receiving either no substitution or replacement with corticosterone (ADXcort), epinephrine 
(ADXepi) or both (ADXcort+epi), were given daily administrations of 15.0 mg/kg cocaine or 
saline (days 1-9), followed by a 5 day withdrawal interval, a saline challenge (day 14) and 
a 7.5 mg/kg cocaine challenge (day 15). Data are represented in optical density in arbitrary 
units (au) ± SEM. n=10-12 animals/group. PFC: prefrontal cortex, MO: medial orbital, IL: 
infralimbic, PrL: prelimbic, NAc: nucleus accumbens, rCP: rostral caudate putamen, cCP: 
caudal CP, Lat: lateral, DM: dorsomedial, VM: ventromedial, Hipp: hippocampus, DG: 
dentate gyrus, Amy: amygdala, BLA: basolateral, CE: central, VTA: ventral tegmental area, 
SNc: substantia nigra pars compacta, LC: locus coeruleus, NTS: nucleus of the solitary tract.
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treated mice (table 2). This time interval was chosen as cocaine-induced c-fos mRNA 
expression can be readily observed 30 minutes after drug administration 40. c-Fos 
mRNA was expressed in all brain regions examined and, with the exception of the 
hypothalamic PVN, no group differences in expression were observed. Figure 4 
depicts c-fos mRNA expression in the hypothalamic PVN. A main effect was found 
for substitution (F[substitution]3,52=9.350, p<0.001, F[surgery]1,52=0.273, p=0.604). 
In animals previously receiving epinephrine replacement, cocaine-induced c-fos 
mRNA expression was higher than in all other groups (at least p<0.05), which just 
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Figure 4: c-Fos mRNA expression in the PVN.
c-Fos mRNA expression in the hypothalamic PVN of cocaine-treated mice, 30 minutes 
after the 7.5 mg/kg cocaine challenge on day 21. Previously, SHAM operated and 
adrenalectomised (ADX) mice receiving either no substitution or replacement with 
corticosterone (ADXcort), epinephrine (ADXepi) or both (ADXcort+epi), were given daily 
administrations of 15.0 mg/kg cocaine or saline (days 1-9), followed by a 5 day withdrawal 
interval, a saline challenge (day 14) and a 7.5 mg/kg cocaine challenge (day 15). Data 
are represented in optical density in arbitrary units (au) ± SEM. n=10-12 animals/group. 
# p<0.01 vs. SHAM, Ω at least p<0.05 vs. ADX, ∅ p<0.001 vs. ADXepi, φ p<0.001 vs. 
ADXcort, $ at least p<0.05 vs. ADXcort+epi (LSD).
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expression was reduced in ADXcort mice when compared to all other groups (at 
least p<0.05). In animals previously receiving epinephrine co-substitution, this 
reduction was reversed (p<0.05 vs. ADXcort), to the level of SHAM and ADX, but 
not of ADXepi mice (p<0.01).
dIscussIon
The major finding emerging from the present experiments is that, in addition to 
corticosterone, epinephrine is necessary for sensitisation to the locomotor stimu-
lant effects of cocaine in DBA/2 mice. By contrast, neither corticosterone nor epi-
nephrine alone were sufficient to reverse the deficit of ADX mice in psychomotor 
sensitisation. In addition, we find that cocaine-induced c-fos mRNA expression in 
the hypothalamic PVN is potentiated in epinephrine-pretreated mice, indicating 
that the adrenal catecholamine may also play a role in endocrine sensitisation to 
the psychostimulant.
The present findings indicate that there is a cross-talk between the HPA-axis and the 
ANS in regulation of the neuronal mechanism underlying behavioural sensitisation 
to cocaine. The notion that adrenal glucocorticoids and catecholamines can interact 
to regulate behaviour is supported by previous studies that describe both synergistic 
and antagonistic interactions, most notably in memory processing 53,571. We show 
that, in the case of behavioural sensitisation to cocaine, corticosterone and epi-
nephrine cooperate. Furthermore, the results suggest that the cooperation between 
the two adrenal stress hormones occurs during initiation rather than expression of 
cocaine-induced behavioural sensitisation in DBA/2 mice. In a previous study, we 
have shown that expression of sensitisation is independent of glucocorticoids as the 
glucocorticoid receptor (GR) antagonist mifepristone failed to block hyperrespon-
siveness to a drug challenge in animals that had previously acquired this behaviour 
(chapter 4). The same holds true for epinephrine, as drug responses of mice receiv-
ing combined corticosterone and epinephrine replacement were maintained when 
epinephrine was omitted prior to the second cocaine challenge (day 21).
The observation that by the time of the second cocaine challenge (day 21), drug 
responses of mice receiving chronic corticosterone mimicked those of SHAM mice 
is in agreement with our previous observations (chapter 4), and suggests that while 
a certain degree of sensitisation develops in mice receiving corticosterone, a longer 
withdrawal duration may be required for this behaviour to become expressed. By 
contrast, mice substituted with only epinephrine did not show drug responses higher 
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than of ADX mice on day 21. Collectively, these findings suggest that, of the two 
adrenal stress hormones, corticosterone plays the most critical role in behavioural 
sensitisation to cocaine, whereas the primary effect of epinephrine is to facilitate 
the actions of the glucocorticoid.
Behavioural sensitisation to psychostimulant drugs is mediated by the mesocorti-
colimbic dopamine system and the neuronal circuitry it is embedded in (reviewed 
in: 520,693). Corticosterone readily passes the blood-brain-barrier and the GR is highly 
expressed throughout the motive circuit and the limbic system 225,279,541. Studies 
using brain-specific GR knockouts have shown that the impact of glucocorticoids 
on psychostimulant sensitivity and behavioural sensitisation is mediated via the GR 
in the brain 168,308. Epinephrine, by contrast, is a polar substance that cannot cross 
the blood-brain-barrier 725. Exogenous epinephrine does however modulate a wide 
variety of brain functions (e.g. memory storage, cortical information processing, 
arousal and attention), suggesting that the catecholamine influences the central ner-
vous system indirectly. The most probable route is via activation of vagal afferents 
to the nucleus of the solitary tract resulting in activation of central noradrenergic 
signalling 251,456,570,730. In addition, it has been proposed that epinephrine may influ-
ence brain function by increasing glucose concentrations in the blood 253, although 
this view has been challenged 228.
To investigate the possible involvement of glucose, we have established a dose-
response curve for the effects of a wide dose-range of epinephrine (5x 10-1, 10-2,10-3 
and 10-5 mg/kg) on plasma glucose (data not shown). Whereas the two highest 
doses increased plasma glucose in a dose-dependent manner, this was not the case 
for the two lowest doses, including the one used in the present study (5 x 10-3 mg/
kg). In addition, we have measured plasma glucose 30 minutes after drug treatment 
on the test days 1, 9, 14 and 15 of the sensitisation paradigm and found no differ-
ence between epinephrine- and saline-substituted mice on any test day (data not 
shown). These observations indicate that the dose of epinephrine that influences 
behavioural sensitisation is devoid of a metabolic effect and therefore excludes the 
possibility that a change in glucose metabolism has contributed to the effects of 
epinephrine on behavioural sensitisation.
We therefore hypothesise that norepinephrine mediates the effects of epinephrine 
on behavioural sensitisation to cocaine. Noradrenergic signalling would then be 
expected to play a critical role in behavioural sensitisation to psychostimulants 
as epinephrine is rapidly secreted in response to these drugs 109,388. In support 
of this hypothesis, it has been shown that α-adrenergic receptors play a role in 
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cocaine- and amphetamine-induced locomotion, -behavioural sensitisation and 
-reward 182,183, although one study reported no effects of α- and β-adrenergic recep-
tor antagonists on behavioural sensitisation to amphetamine or cocaine 691. The 
discrepancy between these studies is likely to have originated from differences in 
experimental procedures, such as e.g. the doses of the psychostimulants (being 
considerably lower in the studies of Drouin et al.), the design of the sensitisation 
paradigm and the species and strain of animals used. Additional evidence for the 
role of norepinephrine in psychostimulant sensitisation has come from a recent 
study by Salomon et al., suggesting that behavioural sensitisation to amphetamine 
results from an uncoupling between noradrenergic and serotonergic signalling 587. 
Taken together, these studies point to a role for norepinephrine in psychostimulant 
sensitisation, although it can of course not be concluded whether this represents an 
indirect effect of epinephrine, direct actions of cocaine on the norepinephrine trans-
porter, or both. In further support of the present findings, it has been demonstrated 
that the adrenergic system plays a role in the interaction between stress and drug 
responsiveness as α2-adrenoreceptor agonists block stress-induced reinstatement of 
cocaine, heroin and alcohol seeking 193,376,620.
Several brain regions are likely to be involved in the interaction between norepi-
nephrine and the mesocorticolimbic dopamine system, and the presence of GRs 
throughout the motive circuit suggests that glucocorticoids can modulate this in-
teraction at multiple levels. Evidence exists that direct noradrenergic innervation 
of the ventral tegmental area regulates dopamine release in the terminal regions 
of these neurons (nucleus accumbens, prefrontal cortex) 302,491. The amygdala is 
an area of interest as norepinephrine in this region is of critical importance for the 
beneficial effects of both epinephrine and corticosterone on memory consolidation 
395,396,535,574 and the amygdala provides excitatory input to the mesocorticolimbic 
dopamine system 566. Furthermore, norepinephrine in the prefrontal cortex (PFC) 
regulates amphetamine-induced reward, -locomotion, and -mesoaccumbens dopa-
mine release 49,141,639,702 and the excitatory corticofugal projections from the PFC to 
the dopamine system are under the control of adrenergic innervation 368,419. Finally, 
the hippocampus, receiving prominent noradrenergic innervation 401, plays a role 
in the acute reinforcing effects of drugs and in relapse to drug taking, and also 
provides excitatory input to the midbrain dopaminergic neurons 216.
In the present study, we have measured c-fos mRNA expression 30 minutes after 
the second cocaine challenge (day 21) to identify a neuronal substrate for the dif-
ferences in behavioural sensitisation resulting from adrenalectomy and hormone 
replacement. The immediate-early-gene c-fos is considered a marker for neuronal 
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activation by cocaine and may contribute to downstream changes in gene expres-
sion that ultimately play a role in drug addiction 469. The observation that c-fos 
mRNA was expressed in the midbrain dopamine system, amygdala, prefrontal 
cortex, hippocampus and the noradrenergic cell bodies, indicates that all these 
brain regions were activated in the context of the complex stimulus (cocaine ad-
ministration in the test context). The specificity of the c-fos signal for the effects of 
cocaine merits further investigation, as there was no group receiving saline ad minis-
tra tion. Interestingly, the pronounced differences in behavioural responsiveness 
to the cocaine challenge did not correlate with group differences in c-fos mRNA 
expression in the abovementioned brain regions. This indicates that expression 
of the immediate-early-gene c-fos might not be a suitable marker to distinguish 
neuronal responsiveness to cocaine at this stage of sensitisation. Rather, there might 
be downstream alterations in gene- or protein expression and modification 46,100,648. 
It is also conceivable that a different withdrawal duration 168,663, or time lapse after 
the cocaine challenge 168, would allow for group differences in c-fos mRNA expres-
sion to be detected. Further studies are required to investigate which brain regions 
mediate the effects of corticosterone and epinephrine on initiation and expression 
of behavioural sensitisation to cocaine.
In the hypothalamic PVN by contrast, c-fos mRNA expression was potentiated in 
epinephrine pretreated mice. This neuronal sensitisation, like behavioural sensitisa-
tion, has become independent of the catecholamine by the time of the drug chal-
lenge, as epinephrine was not administered on day 21. The observation that mice 
pretreated with only epinephrine displayed higher c-fos mRNA expression than ADX 
animals, indicates that this effect of the catecholamine, in contrast to its influence 
on behavioural sensitisation, does not require corticosterone. In fact, epinephrine 
and corticosterone appear to counteract, as the reduction in c-fos mRNA expression 
observed in corticosterone-substituted mice, which is in agreement with the nega-
tive feedback action of corticosterone, was reversed by epinephrine pretreatment to 
the level observed in SHAM and ADX, but not in ADXcort+epi mice.
The finding that epinephrine sensitises PVN neurons to the excitatory effects of 
cocaine is very interesting in several respects. First, it indicates that a history of epi-
nephrine exposure can indeed (indirectly) modulate neurotransmission in the brain. 
Second, by rendering PVN neurons hypersensitive to cocaine, epinephrine may 
contribute to the sensitisation of the HPA-axis that occurs with repeated exposure to 
the psychostimulant in the DBA/2 strain (the present study, 145). This effect of the cat-
echolamine may also involve the noradrenergic system, as the PVN receives promi-
nent direct and indirect noradrenergic input from the brain stem catecholaminergic 
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nuclei 26,134,135,206,218,724. Furthermore, norepinephrine in the PVN regulates HPA-axis 
activation 113,226,382 and may also be involved in sensitisation of the HPA-axis to 
psychostimulants or stressors 315,608. Finally, it is interesting to note that electrical 
stimulation of the afferent vagal nerve has also been shown to increase CRH mRNA 
in the PVN and plasma adrenocorticotrophic hormone and corticosterone concen-
trations 297. Collectively, these findings suggest that epinephrine may, via activation 
of the afferent vagal nerve and direct or indirect noradrenergic projections to the 
PVN, facilitate HPA-axis sensitisation to cocaine, provided that the c-fos activation 
indeed signals activation of CRH neurons. In support of this, it has recently been 
demonstrated that repeated cocaine administration leads to accumulation of fosB 
and the stable isoform delta fosB in the PVN, indicating that long term changes in 
expression of fos family transcription factors may constitute a molecular mechanism 
via which cocaine induces adaptive changes in the HPA-axis 111.
In summary, the present data show that both the HPA-axis and the ANS play a 
crucial role in long-term behavioural sensitisation to cocaine, and that epinephrine 
may in addition facilitate HPA-axis sensitisation to the psychostimulant. This is an 
important finding since numerous investigations have been dedicated to the role 
of the HPA-axis in psychostimulant sensitisation and reward, whereas the ANS has 
hardly gained any attention. Further characterisation of the relationship between 
glucocorticoids, epinephrine and psychostimulant responsiveness will lead to a 
better understanding of the mechanisms that underlie the effects of stress on drug 
addiction.
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Individuals may vary widely in susceptibility to acquire cocaine abuse after rec-
reational use of the drug. This individual difference has led to the distinction of 
phenotypes that are either ‘vulnerable’ or ‘resistant’ to the behavioural and rein-
forcing effects of psychostimulant drugs. Recent studies have identified genes and 
adverse life events as factors that contribute to psychostimulant sensitivity but how 
the genetic and environmental inputs (inter)act is still poorly understood.
The objective of this thesis was to investigate the contribution of adrenal stress 
hormones to individual differences in vulnerability to the psychostimulant effects 
of cocaine. It was hypothesised that adrenal glucocorticoids contribute to cocaine 
sensitivity, while their actions are dependent on the genetic background of the 
individual and on the context in which these hormones operate. For this purpose, 
studies were designed to investigate the impact of adrenal hormones on cocaine 
sensitivity in mice of two genetic backgrounds (C57BL/6 and DBA/2). Only the 
DBA/2 strain was found to be susceptible to the influence of adrenal hormones on 
cocaine sensitivity.
The main focus was on the context in which glucocorticoid hormones oper-
ate, with emphasis on the timing of the corticosteroid action and the role of the 
sympathetic nervous system. To that aim, adrenal hormones were surgically and 
pharmacologically manipulated in the DBA/2 strain by adrenalectomy (surgical re-
moval of the adrenals, ‘ADX’) and hormone replacement respectively. Behavioural 
sensitisation, the progressive enhancement of the motor stimulant effects of cocaine 
with repeated exposure, was used as a read-out parameter as this model reflects 
long-lasting adaptations in neural circuits involved in motivation and reward. The 
results show that corticosterone facilitates initiation and retention of the behavioural 
sensitisation to repeated drug exposure, provided it is continuously circulating. 
However, in addition to corticosterone, epinephrine is required for full behavioural 
sensitisation to cocaine in the DBA/2 strain.
In the following paragraphs, the major findings of this thesis are discussed, starting 
with the importance of genetic background, followed by the critical time-window 
for the glucocorticoid effects and finally the coordinate actions of corticosterone 
and epinephrine. Methodological considerations regarding the sensitisation para-
digm are discussed in box 1.
1. straIn dIFFErEncEs In tHE rEsPonsE to cocaInE
The C57BL/6 and DBA/2 inbred strains represent a model for genetic differences in 
behavioural responsiveness to cocaine (chapter 2, summarised in table 1). Whereas 
C57BL/6 mice showed greater locomotor responses to the first cocaine exposure, 
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only DBA/2 mice exhibited an increase in drug responsiveness during repeated 
drug administration. However, both strains expressed sensitisation if challenged 
with cocaine after a withdrawal interval. The observed strain differences are in line 
with previous studies showing that C57BL/6 and DBA/2 mice differ in sensitivity 
to the behavioural, rewarding and reinforcing properties of virtually all classes of 
abused drugs 43,65,257,447,455. The present findings are however in disagreement with 
reports that C57BL/6 mice are less sensitive to the locomotor activating effects of 
cocaine 483,568,665, whereas one report claimed that neither strain develops behav-
ioural sensitisation during the course of repeated cocaine treatment 483. Differences 
in the design of the sensitisation paradigm (box 1) and, in view of the present data, 
experimental conditions that influence the secretion of adrenal stress hormones, 
may contribute to variable outcomes across laboratories.
Under the given experimental conditions, three factors are discussed that may un-
derlie the strain differences in behavioural responsiveness to cocaine. These are the 
pharmacokinetics of cocaine, the properties of the midbrain dopamine system and 
the stress hormones as modulators of cocaine responsiveness.
First, the psychostimulant may have a different pharmacokinetic profile in the 
C57BL/6 and DBA/2 strains. However, it has been demonstrated that comparable 
concentrations of cocaine reach the brain in both strains following i.p. 664,737 or i.v. 
administration (R. van der Veen, personal communication). This has been contra-
dicted by one report, showing earlier peak concentrations and a longer half-life of 
cocaine in the brains of C57BL/6 mice after i.p. administration 17. Given the positive 
correlation between the rate of psychostimulant bio-availability and the ability to 
produce behavioural sensitisation 588, the latter finding would imply that cocaine 
has greater potency to induce sensitisation in the C57BL/6 strain. This is not sup-
ported by the present data. However, it could explain the high initial drug response 
table 1 : Overview of the locomotor responses of cocaine-treated mice during the 
sensitisation paradigm.
strain day 1 day 9 Increase days 1-9 day 15*
c57bl/6 ↑ ↑ no ↑
dba/2 ↑ yes ↑
Arrows indicate a significant difference compared to saline-treated mice of the same strain. 
No arrow indicates no significant difference. On days 1-9, mice received 15.0 mg/kg 
cocaine. * On day 15, all animals, including the saline-treated control group, received a 
7.5 mg/kg cocaine challenge (data from chapter 2).
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box 1: Behavioural sensitisation: methodological considerations.
Behavioural sensitisation, the progressive enhancement of the motor stimulant effects of cocaine 
with repeated exposure, is thought to reflect long-lasting adaptations in neural circuits involved in 
motivation and reward. Robinson and Berridge first proposed the possible link between behavioural 
sensitisation and drug addiction. The ‘incentive sensitisation’ theory implies that drugs of abuse 
render the neural systems that regulate their motivational aspects hypersensitive, making the drugs 
increasingly more attractive or ‘wanted’ 561. The view that sensitisation is associated with certain 
aspects of addiction is supported by the observations that: i) sensitisation facilitates subsequent 
drug taking as measured in self-administration paradigms 295,296,510,607, ii) it reflects adaptations in 
a common neural substrate, most notably the midbrain dopamine system 708, iii) the neural and 
behavioural adaptations are very stable and persist until months after the discontinuation of repeated 
drug treatment 497, iv) the degree of sensitisation may be positively correlated with vulnerability 
to relapse 152 and, comparable to drug addiction, v) there are considerable individual differences 
in the propensity to develop behavioural sensitisation 291,559, and vi) sensitisation is influenced by 
contextual and environmental influences 22,65,510. However, it is still a matter of debate whether 
behavioural sensitisation represents initial changes in the addiction process, rather than more 
advanced stages 36,154,694. Furthermore, it should be noted that in the present studies, behavioural 
sensitisation was induced by experimenter-delivered drug administrations. Consequently, this model 
does not measure voluntary drug seeking or the motivational aspects thereof. It will be essential to 
extrapolate the present findings to animal models that do, such as the self-administration paradigm. 
Finally, two aspects of behavioural sensitisation, the time- and context- dependency, require further 
consideration and are discussed in the following paragraphs.
 Behavioural sensitisation is not a unitary phenomenon. First, it represents a time-dependent 
cascade of cellular and behavioural adaptations 497,520. The kinetics and direction thereof could be 
influenced by genetics. Indeed, despite considerable differences in locomotor responsiveness during 
repeated drug administration, both strains expressed sensitisation in response to a cocaine challenge 
after a withdrawal interval (chapter 2). Furthermore, there were distinct but also partially overlap-
ping neural adaptations in the midbrain dopamine system of C57BL/6 and DBA/2 mice with a history 
of cocaine exposure (chapter 3). Thus, genotype controls both the nature and/or the time course of 
the neural and behavioural adaptations associated with repeated cocaine exposure. Therefore, the 
observed strain differences in behaviour and neural correlates are representative for the time point 
at which they were measured, whereas further research is required to investigate their significance 
after e.g. longer episodes of withdrawal.
 Second, at least two types of behavioural sensitisation can be distinguished: context-independent 
and -dependent sensitisation. Whereas the former relies primarily on the pharmacological actions 
of the drug, the latter involves learned associations between the psychostimulant effect of the drug 
and otherwise neutral stimuli. Both phenomena may co-exist, however the extent to which they con-
tribute to the behavioural hyperresponsiveness can be influenced by genetics. Indeed, the C57BL/6 
strain is more sensitive to context-dependent sensitisation 20,65,559 and exhibits greater spatial and 
contextual memory 10,499,581,677, when compared to the DBA/2 strain. In the present studies, animals 
received cocaine both in the test cage and in the home cage on several occasions, a setting which 
may promote the development of either type of sensitisation. An important challenge is to unravel 
which neuronal substrates contribute to context dependent vs. -independent sensitisation.
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of C57BL/6 mice 729, which may have masked subsequent behavioural sensitisation 
(chapter 2).
Second, the strain difference in the midbrain dopamine system that mediates the 
behavioural and reinforcing effects of psychostimulant drugs, may play a role in 
the differential cocaine responsiveness (chapter 3, 69,199,470,737). The few studies that 
have investigated neurotransmitter systems other than dopamine, point to strain 
differences in GABA-ergic-, glutamatergic- and endogenous opioid-signalling 
114,156,157,313,453,471,718. However, their contribution to the strain difference in cocaine 
responsiveness remains to be established and would be an interesting line of further 
research. In section 1.1 further aspects of the role of dopamine are discussed.
Third, the adrenal glucocorticoids may modulate behavioural responsiveness 
to cocaine. This argument is based on the wealth of data showing that the glu-
cocorticoids contribute to psychostimulant sensitivity 168,240,418,421,424,516, the notion 
that psychostimulant drugs activate the HPA-axis 31,281,355,448,461,590, and the observed 
strain differences in HPA-axis function 66,321,622. Therefore, an essential aspect of 
the strain comparison in this thesis was to characterise HPA-axis responsiveness to 
cocaine and to investigate the role of adrenal hormones in behavioural sensitisation 
(see sections 1.2 and 1.3, respectively).
1.1 dopamine
The two strains are characterised by pronounced differences in the mesocorticolim-
bic and nigrostriatal dopamine systems (chapter 3, see table 2). The most direct 
measure of dopaminergic transmission is dopamine release. Compared to DBA/2 
mice, C57BL/6 mice display greater amphetamine-induced dopamine release in the 
NAc 700,760, which is a critical determinant of the behavioural response to the drug 
700. The observed differences in initial cocaine responsiveness (chapter 2), suggest 
that a comparable phenomenon applies to cocaine. This appears to be contradicted 
by the higher TH and DAT mRNA expression in cell body regions of the DBA/2 
strain (chapter 3), which is suggestive of a higher tone in the DBA/2 dopamine sys-
tem. However, the increased expression of all presynaptic markers appeared to be 
fully attributable to the higher number of dopaminergic (TH+) neurons in this strain. 
In fact, the latter observation, together with the notion that basal dopamine output 
is comparable in the two strains 760, suggests that there must be greater inhibition 
of dopaminergic transmission in the DBA/2 strain. The PFC may play an important 
role therein, as dopamine in the mPFC controls subcortical dopamine release in a 
strain-dependent manner 700,701. Further studies applying microdialysis to measure 
dopamine release and turnover in response to cocaine in the NAc and PFC are 
required to investigate this issue.
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Whereas several studies have demonstrated strain differences in dopamine receptor 
densities or binding, their role in behavioural responsiveness to psychostimulants 
remains to be established. A consistent finding across laboratories is the strain dif-
ference in D2 receptor density in distinct terminal fields (higher in C57BL/6) and 
the cell body regions (higher in DBA/2) of the mesocorticolimbic and nigrostriatal 
dopamine system (chapter 3, 69,199,470). The latter finding has led to the hypothesis 









tH+ cells snc ↑
Vta ↑












Arrows indicate a significant difference compared to C57BL/6 mice. No arrow indicates 
that there is no significant difference. TH: tyrosine hydroxylase, DAT: dopamine transporter, 
SNc: substantia nigra pars compacta, VTA: ventral tegmental area, NAc: nucleus 
accumbens, (r/c) CP (Lat,DM,VM): (rostral/caudal) caudate putamen (lateral, dorsomedial, 
ventromedial regions) (data from chapter 3).
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that DBA/2 mice have greater auto-inhibition of dopaminergic transmission 69,531. 
However, in view of the abovementioned strain difference in neuron number, it 
remains to be investigated how much of the lower D2 binding is attributable to the 
fewer number of dopaminergic neurons in this strain. The higher D2 binding in the 
CP of C57BL/6 mice could be a marker of greater cocaine responsiveness, given 
that apomorphine-susceptible rats (APO/SUS, see section 2), that are more respon-
sive to psychostimulant-induced locomotion than APO/UNSUS rats 127, also display 
greater D2 binding in the CP when compared to their counterparts 576. However, in 
the C57BL/6 and DBA/2 mouse strains this difference is subregion-dependent, as 
DBA/2 mice displayed greater D2 binding in the lateral subdivision of the caudal 
CP. With respect to D1 receptor binding in the terminal fields, conflicting results 
have been obtained and this is an issue that requires further investigation (chapter 3, 
69,199,470). One approach to investigate the functionality of the strain differences in D1 
and D2 receptor density in the different subfields could involve local administration 
of receptor agonists and antagonists. Furthermore, there are now ligands with rela-
tive selectivity for the 5 individual dopamine receptor subtypes, the contribution of 
which could be another interesting line for further research.
In the present studies, strain differences in behavioural responsiveness to cocaine 
were related to ‘candidate genes’ in the midbrain dopamine system. It should be 
noted that these markers do not prove a causal relationship and further research is 
required to evaluate their role in cocaine responsiveness. In addition, it would be 
interesting to search for novel genes, e.g. by microarray screening. This technique 
may allow the identification of novel pathways that underlie the strain differences 
in cocaine responsiveness. Furthermore, recombinant inbred (RI) strains (cross-
ings between C57BL/6 and DBA/2 strains) can be used to determine quantitative 
trait loci (QTL), sites on a chromosome that contain genes that influence a given 
behaviour. This approach has already been applied for cocaine-induced seizures 
273, acute and sensitised locomotion 507,664. Interestingly, one study found a QTL in 
the region of chromosome 9 that contains the drd2 gene which encodes the D2 
receptor 273. Finally, there are two different splice variants of the D2 receptor (‘short’ 
and ‘long’) 107,139,238,463 and evidence is emerging that there are polymorphisms and 
single-nucleotide-polymorphisms (SNPs) in the dopamine receptors. Especially the 
D4 receptor is unique in having an exceptionally high number of polymorphic sites 
96,477,651,690, some of which have been associated with psychosis 96, novelty seeking 
personality traits 37,188 and heroin abuse 652 in humans. It would be interesting to 
investigate whether there are such polymorphisms in the D2 and D4 receptors in 
the C57BL/6 and DBA/2 strains.
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In conclusion, there are profound differences in the midbrain dopamine system of 
C57BL/6 and DBA/2 mice that may underlie the strain differences in behavioural 
responsiveness to psychostimulants. However, the nature of the crucial event(s) in 
dopamine signalling requires further investigation.
1.2 HPa-axis
The C57BL/6 and DBA/2 strains displayed very different endocrine responses 
to cocaine. In contrast to the HPA-axis activation and endocrine sensitisation in 
DBA/2 mice, cocaine attenuated HPA-axis reactivity in C57BL/6 mice throughout 
the sensitisation paradigm (chapter 2, summarised in table 3).
The endocrine sensitisation observed with repeated cocaine exposure in the 
DBA/2 strain is in agreement with most earlier observations in rats 29,51,387,610,694. The 
data from chapters 2 and 5 suggest that sensitisation takes place at the level of the 
PVN and may in addition involve adrenal hyperresponsiveness to ACTH. In sup-
port of this, HPA-axis sensitisation to amphetamine is associated with neuroplastic 
changes in the PVN 315. Also, chronic cocaine treatment increases the sensitivity 
of adrenocortical cells to the stimulatory effects of ACTH on steroidogenesis 369. 
Furthermore, the data in chapter 5 point to a role for the adrenal epinephrine in 
HPA-axis sensitisation at the level of the PVN. Since epinephrine itself cannot cross 
the blood-brain-barrier, the catecholamine most likely influences brain function via 
β-adrenoreceptors on vagal afferents to the CNS. The contribution of epinephrine to 
HPA-axis sensitisation could be tested by administration of a peripheral β-blocker 
prior to cocaine administration.
The attenuation of HPA-axis activation by cocaine in the C57BL/6 strain was 
unexpected and this phenomenon has, to our knowledge, not been reported previ-
ously. In line with the present findings, C57BL/6 mice display lower, though not 
table 3 : Overview of corticosterone secretion of cocaine-treated mice during the 
sensitisation paradigm.
strain day 1 day 9 Increase days 1-9 day 15*
c57bl/6 ↓ (trend ↓) no
dba/2 ↑ ↑↑ yes ↑
Arrows indicate a significant difference compared to saline-treated mice of the same strain. 
No arrow indicates no significant difference. On days 1-9, mice received 15.0 mg/kg 
cocaine. * On day 15, all animals, including the saline-treated control group, received a 
7.5 mg/kg cocaine challenge (data from chapter 2).
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reduced, corticosterone secretion in response to ethanol when compared to DBA/2 
mice 553. Opposite strain differences exist for endocrine responsiveness to mild 
stressors, such as novelty (S. Dalm, personal communication, 66) or saline ad minis-
tration in the test setting (chapter 2), in response to which C57BL/6 mice show a 
greater increase in corticosterone secretion than DBA/2 mice. By contrast, more 
severe stressors (electrical shock, restraint) induce greater HPA-axis activation in the 
DBA/2 strain 68,321,622. Therefore, the degree of endocrine responsiveness to cocaine 
and various stressors is not necessarily correlated. Depending on their nature and 
severity, these ‘stimuli’ appear to recruit different neuronal pathways that regulate 
activity of the HPA-axis.
Several mechanisms could contribute to the differential HPA-axis responsiveness of 
C57BL/6 and DBA/2 mice to cocaine.
First, pre-existing differences or drug-induced alterations in functioning or wiring 
of the HPA-axis may play a role. Cabib et al. demonstrated higher GR and MR 
binding capacity in vitro in hippocampal cytosol of DBA/2 mice 68. Whether this 
plays a role in the strain differences in HPA-axis activity remains to be established, 
and additional investigation of HPA-axis parameters at the level of the PVN and 
pituitary is required. Furthermore, given the strain-difference in endocrine adapta-
tion to repeated cocaine exposure, it would be interesting to investigate neural 
and functional aspects of the HPA-axis in sensitised mice. In humans, there is 
limited evidence that drugs of abuse influence negative feedback regulation of the 
HPA-axis 14,174. Could it be that cocaine alters glucocorticoid negative feedback 
in a strain-dependent manner? This question could be addressed by performing 
a dexamethasone suppression test in addition to measuring GR densities in the 
pituitary and PVN.
We found that DBA/2 mice have considerably higher AVP mRNA expression 
(on average 25%) in the magnocellular and parvocellular neurons of the PVN 
(data not shown). AVP expression and release are under monoaminergic control 
381,745, suggesting that they can be regulated by cocaine. Interestingly, AVP may not 
only play a role in endocrine-, but also in behavioural responsiveness to cocaine. 
There is considerable evidence that AVP reduces sensitivity to the behavioural 
(locomotion, sensitisation) and reinforcing effects of drugs of abuse 108,155,362,600,687. 
Recently, it was demonstrated that environmental manipulations that increase 
cocaine self- administration in the DBA/2, but not the C57BL/6 strain, are associ-
ated with a decrease in AVP mRNA expression in the extended amygdala of the 
DBA/2 strain only (R. van der Veen et al., personal communication). This suggests 
that extrahypothalamic AVP engages in gene x environment interactions that cor-
relate with sensitivity to the reinforcing effects of cocaine. The role of hypothalamic 
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and extrahypothalamic AVP in the observed strain differences in endocrine and 
behavioural responsiveness to cocaine could be further investigated by e.g. targeted 
knock-down or overexpression of AVP.
Second, there could be strain differences in the neurotransmitter systems that 
regulate HPA-axis activity. Given i) the monoaminergic actions of cocaine, ii) the 
strain differences in the dopamine system (chapter 3), and iii) the role of dopamine 
and norepinephrine in HPA-axis activation 52,113,226,382,398, it is tempting to hypothesise 
a role for the catecholaminergic innervation to the PVN. Indeed, as proposed in 
chapter 5, norepinephrine may play a role in HPA-axis sensitisation in DBA/2 mice. 
Further characterisation of the monoaminergic innervation of the PVN in the two 
strains is required to address this issue.
Third, the differences in HPA-axis responsiveness to cocaine may reflect strain 
differences in coping with drug-induced arousal 454 or in the perception of stressful 
events (e.g. test- and treatment procedures). In these cases, higher brain centers 
involved in perception, appraisal, cognitive processes and emotional arousal exert 
indirect control over HPA-axis activity.
In view of the working hypothesis that adrenal glucocorticoids contribute to the 
strain differences in behavioural responsiveness to cocaine, it is of interest to 
compare locomotor- and corticosterone responses to the psychostimulant. In the 
C57BL/6 strain, there was a clear dissociation between the effect of cocaine on 
locomotion (increased) and corticosterone secretion (attenuated) on all test days. 
Furthermore, C57BL/6 mice displayed behavioural, but not endocrine, sensitisation 
in response to the cocaine challenge. In the DBA/2 strain, by contrast, cocaine 
stimulated locomotion and corticosterone secretion, and both responses sensitised 
with repeated drug exposure.
In summary, the C57BL/6 and DBA/2 inbred strains differ not only in behavioural, 
but also in HPA-axis responsiveness to cocaine. Furthermore, there was a striking 
parallel between behavioural and endocrine sensitisation in the DBA/2 strain. This 
raises the question whether the HPA-axis is involved in behavioural sensitisation, 
and whether it contributes to the differences in cocaine responsiveness between 
the strains.
1.3 role of adrenal hormones
The DBA/2, but not the C57BL/6 strain, is susceptible to the impact of adrenal hor-
mones on behavioural sensitisation to cocaine (chapter 2). ADX prevented initiation 
and retention of behavioural sensitisation in the DBA/2 strain only. However, the 
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strain differences in behavioural responsiveness to cocaine were not diminished, 
but rather enhanced by ADX. By contrast, a period of food shortage abolished the 
strain differences in amphetamine-induced place preference and locomotion by 
increasing responsiveness selectively in the DBA/2 strain 71. This is likely to de-
pend on stress-induced corticosterone secretion, since it could be blocked by a 
glucocorticoid antagonist 420. These data point to an important facilitatory role for 
corticosteroid hormones in behavioural responsiveness to psychostimulants in the 
DBA/2, but not the C57BL/6 strain.
Is it a general phenomenon that the C57BL/6 strain is relatively resistant to gluco-
corticoids, or does this depend on the experimental design or the read-out param-
eter? Among experimental parameters that could influence susceptibility to adrenal 
hormones are the dosage of the psychostimulant and the design of the sensitisation 
paradigm, such as e.g. the context in which the drug was administered. The dose of 
15.0 mg/kg cocaine resulted in pronounced locomotor activation in the C57BL/6, 
but not the DBA/2 strain (chapter 2). It is conceivable that for C57BL/6 mice, this 
dosage was high enough to override the influence of other factors, including adrenal 
hormones. In this respect, it would be interesting to establish a dose-response curve 
for cocaine-induced behavioural sensitisation in SHAM and ADX mice.
Alternatively, different types of behavioural tasks might reveal sensitivity to adrenal 
hormones in the C57BL/6 strain. If compared to DBA/2 mice, C57BL/6 mice exhibit 
greater spatial and contextual memory 10,499,581,677, which has been related to strain 
differences in hippocampal function 575. In support of this, cocaine-treated C57BL/6 
mice displayed greater locomotor responses when exposed to the test context in 
the absence of cocaine (chapter 2). The C57BL/6 strain could be susceptible to the 
influence of adrenal hormones in a sensitisation paradigm designed to exclusively 
reveal context-dependent sensitisation (see also box 1), or in behavioural tasks that 
strongly depend on hippocampal function (e.g. radial arm maze, fear conditioning, 
Morris water maze). Indeed, in C57BL/6 mice, exogenous corticosterone and stress 
modulate spatial learning in water maze and circular hole board tasks 265,266 and 
memory consolidation in tests for passive avoidance 68,95. Therefore, the relative 
resistance of C57BL/6 mice to adrenal hormones or environmental manipulations is 
not a general phenomenon for this strain, although it has been consistently reported 
for behavioural responsiveness to psychostimulant drugs. This could indicate that 
neural mechanisms that mediate psychostimulant responsiveness are relatively 
resistant to glucocorticoid hormones in the C57BL/6 strain. Indeed, the DBA/2, 
but not the C57BL/6 strain, was susceptible to the impact of adrenal hormones 
on neuroadaptations associated with repeated cocaine exposure (chapter 3, sum-
marised in table 4).
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The data point to a role for the nigrostriatal dopamine system and the NAc core 
in mediating the effects of adrenal hormones in a strain dependent manner. In the 
DBA/2 strain, sensitised SHAM mice displayed increased expression of presynaptic 
markers, whereas sensitisation-resistant ADX mice were characterised by reduced 
D2 binding in the terminal fields of the NAc core and rostral CP. These changes 
were not observed in C57BL/6 mice that developed sensitisation independent of 
the adrenals. Although speculative, these data point to i) greater reactivity of the 
nigrostriatal neurons in SHAM mice, and ii) reduced potency for postsynaptic sig-
nalling via the D2-like receptors in ADX mice, of the DBA/2 strain. Further research 
is required to test these hypotheses, and to determine which of the changes are 
critical for the behavioural response to cocaine and the influence of adrenal hor-
mones. One approach could involve overexpression of TH and DAT in ADX mice, 
or conversely, knock down of D2 receptors in SHAM mice. Furthermore, it would 
be of interest to investigate these markers after longer episodes of withdrawal, given 
that neural adaptations associated with behavioural sensitisation are characterised 
by marked time-dependency 497,520. In addition, it will be necessary to investigate 
the contribution of the D2 and D3 receptors individually, in view of their presumed 
opposite effects on psychostimulant-induced locomotion.
With respect to the D2 receptor, there is considerable evidence that D2-like 
dopamine receptors engage in gene x environment interactions. In humans, varia-
tions in D2 receptor alleles have been associated with drug addiction 121,473,475,476 
table 4: Overview of the adaptations in the dopamine system of mice subjected to the 
sensitisation regimen.
dba/2 c57bl/6
sHaM adX sHaM adX
tH snc ↑
dat snc ↑
d2 nac core ↓*
rcP ↓*
ccP dM ↓ ↓
SHAM operated and adrenalectomised (ADX) mice were subjected to the sensitisation 
regimen and sacrificed 24 hours after the cocaine challenge under basal conditions. Arrows 
indicate a significant difference in cocaine- compared to saline-treated mice of similar 
surgery and strain. No arrow indicates that there is no significant difference. * Significantly 
different from cocaine-treated SHAM mice. TH: tyrosine hydroxylase, DAT: dopamine 
transporter, SNc: substantia nigra pars compacta, NAc: nucleus accumbens, (r/c) CP (DM): 
(rostral/caudal) caudate putamen (dorsomedial region) (data from chapter 3).
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and stress differentially affects cigarette craving or performance in a cognitive task 
between carriers and non-carriers of the A1 allele 41,198. Furthermore, stress induces 
opposite alterations in D2 receptor binding in the C57BL/6 and DBA/2 strains 69. In 
view of the affinity of the D2-like receptor ligand iodosulpride for both D2 and D3 
receptors, it is interesting to note that the D3 receptor has been suggested to play a 
role in gene x environment interactions in schizophrenia and other psychotic dis-
orders 490. In addition, studies in laboratory rodents have demonstrated that the D3 
receptor contributes to stress-induced reinstatement of cocaine seeking 740. Thus, 
signalling via D2-like receptors may be subject to regulation by adrenal hormones 
in a genotype-dependent manner.
Finally, the lack of major changes in the dopamine system of sensitised C57BL/6 
mice suggests that other neurotransmitter systems play a more prominent role in 
sensitisation of this strain. A likely candidate is glutamate, given that the C57BL/6 
strain is relatively more susceptible to contextual information, and glutamatergic 
transmission has been proposed to play a prominent role in context-dependent 
sensitisation 10,35,499,581,677. In addition, glutamate may contribute to the effects of 
glucocorticoids on behavioural sensitisation in the DBA/2 strain. There is consider-
able evidence that adrenal glucocorticoids modulate glutamatergic transmission 
in the limbic system, e.g. in the midbrain dopamine system, hippocampus and 
prefrontal cortex 2,275,400,414,460,638,720. These effects of corticosterone have been most 
extensively characterised for the hippocampus and involve regulation of glutamate 
receptor expression 275,414, glutamate release 400,460,638 and transmission via NMDA 
and AMPA receptors 337,655. It has been demonstrated both in vitro and in vivo that 
corticosterone potentiates responses of VTA dopaminergic neurons to excitatory 
amino acids, although there is controversy regarding the roles of GR and MR 110,488. 
The time course of the effects of corticosterone in the study of Cho et al. suggests 
that this may involve non-genomic actions of the hormone 110, which is in good 
agreement with a growing body of evidence that glucocorticoids can modulate 
excitatory transmission via a rapid, non-genomic mode of action involving mem-
brane-bound receptors 175,338,466,655,699,759. By contrast, other effects of glucocorticoids 
on glutamatergic transmission require genomic mechanisms 337. Taken together, 
the direct facilitatory effect of glucocorticoids on responsiveness of midbrain do-
pamine neurons to excitatory amino acids, in combination with the actions on 
glutamatergic transmission in other limbic regions such as the hippocampus, may 
facilitate responsiveness to psychostimulant drugs. It would be of great interest to 
further investigate the interplay between glucocorticoids and glutamate in behav-
ioural sensitisation to cocaine with special emphasis on genomic- vs. non-genomic 
mechanisms. Especially given the present observation that a modest degree of 
sensitisation was observed in DBA/2 mice receiving corticosterone 5 min. prior to 
Chapter 6
147
cocaine administration (chapter 4, see section 3.2 for discussion). In addition, two 
recent studies have demonstrated that the rapid effects of glucocorticoids on gluta-
mate release in the hypothalamus are mediated via endocannabinoid release and 
subsequent CB1 receptor activation 175,176. Given the role of endocannabinoids in 
drug addiction, it would be interesting to investigate whether a similar mechanism 
applies to the contribution of corticosterone to behavioural sensitisation. Finally, 
in view of the present data, an important line of further research involves compar-
ing the C57BL/6 and DBA/2 mouse strains with respect to the interaction between 
corticosteroids and glutamate in behavioural sensitisation to psychostimulants.
In summary, the evidence presented in chapters 2 and 3 shows that the two inbred 
strains provide a model for genetic differences in neural, behavioural and endocrine 
responsiveness to cocaine. Furthermore the DBA/2, but not the resistant C57BL/6 
strain, is susceptible to the impact of adrenal stress hormones on cocaine sensitivity at 
the level of both dopaminergic neurotransmission and behavioural responsiveness.
2.  otHEr ModEls For IndIVIdual dIFFErEncEs In PsycHostIMulant 
sEnsItIVIty
Individual differences in psychostimulant sensitivity have gained increasing atten-
tion during the past decades. A number of models have been developed in which 
animals were selected based on genetics (inbred rat or mouse strains) 214,485,626, or 
pre-existing traits 44,203,237,287,290,354,378,509,684. These models may reflect different mo-
tivational aspects of drug-taking that have also been distinguished in humans 268: 
to ‘seek novelty (sensation)’ 509 or to ‘alleviate negative affect’ 287. In the following 
paragraphs, the C57BL/6 and DBA/2 strains are compared to other selected animals 
such as e.g. the so-called high- (HR) and low responder (LR) rats of Piazza et al., 
to which they bear striking resemblance. It should be noted that inbred strains 
represent one particular set of genes and it is fraught with difficulty to draw a direct 
parallel to outbred strains.
The HR and LR rats are distinguished from an outbred population, based on 
behavioural reactivity in a novel environment (above or below the mean, respec-
tively) 509. These sub-populations of animals have certain phenotypic characteristics 
that have been observed in various animal models. A positive correlation may exist 
between behavioural reactivity in a novel environment 200,232,511 and i) the locomotor 
response to acute administration of psychostimulants 82,203,290,378,509, ii) psychostim-
ulant-induced dopamine release in the NAc 82,236,290,378,578 and iii) the propensity 
to self-administer psychostimulants 232,354,509. In addition, these parameters have 
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been positively correlated with the endocrine response to stress, although this is 
an issue of debate 255,511,716. These characteristics are however not consistent across 
all models 287,684. The APO/SUS and -UNSUS rat lines, bred from rats that were 
selected for apomorphine-induced gnawing (gnawing score: APO/SUS: >500/45 
min, -UNSUS: <10/45 min in response to 1.5 mg/kg apomorphine) are an example. 
Whereas APO/SUS rats are more responsive to novelty and psychostimulant-induced 
locomotion, they self-administer less cocaine under habituated conditions 126,127,684. 
However, these animals were selected and bred for a dopaminergic phenotype, 
which makes them essentially different from the HR/LR rats.
The notion that a cluster of phenotypic parameters is observed across laboratories 
in animals with different genetic backgrounds, indicates that these are representative 
for at least a sub-population of individuals. The C57BL/6 and DBA/2 strains display 
differences in behavioural and endocrine responsiveness to novelty comparable 
to those of the HR and LR rats, respectively (personal observations, 66). The HR 
rats show greater amphetamine-induced locomotion when compared to LR rats, 
and these differences are abolished with repeated drug exposure by a progressive 
increase in the LR, but not the HR group 509, although this may depend on experi-
mental parameters 179,291. Similarly, whereas C57BL/6 mice were more responsive to 
the first cocaine exposure, only DBA/2 showed an increase in drug responsiveness 
during the treatment period (chapter 2). Furthermore, C57BL/6 mice and HR rats 
show greater psychostimulant-induced dopamine release in the NAc and propen-
sity for amphetamine self-administration, when compared to DBA/2 mice and LR 
rats respectively 290,354,447,509,701,760.
The parallel between the HR/LR rats and the two mouse strains also extends to 
susceptibility to the effects of corticosterone and stressors. Administration of corti-
costerone (prior to a self-administration session or in the amphetamine solution) and 
social defeat stress facilitate psychostimulant self-administration in LR rats, while 
decreasing it in HR rats 323,516. Similarly, adrenal hormones (chapter 2) and envi-
ronmental manipulations 20,71 facilitate behavioural responsiveness to cocaine and 
amphetamine in the DBA/2, but not the C57BL/6 strain. A comparable phenomenon 
has been observed for the Fischer 344 and Lewis inbred rat strains. Fischer 344 
rats (comparable to LR rats in terms of behavioural responsiveness to novelty and 
psychostimulants), were susceptible to the influence of corticosterone on cocaine 
sensitisation, whereas Lewis rats (HR-like) were not 485. However, with respect to 
novelty-induced corticosterone secretion, these rat strains are distinct from the HR/LR 
rats, with Fischer 344 rats having higher corticosterone secretion than Lewis rats 255. 
There are also differences between the HR/LR rats and the two inbred mouse strains. 
Whereas exposure to similar concentrations of corticosterone abolishes the differ-
ence in amphetamine-induced locomotion between HR and LR rats 516, the C57BL/6 
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and DBA/2 strains by nature show opposite strain differences in cocaine-induced 
locomotion and corticosterone secretion (chapter 2). Therefore, it is not possible 
to draw a general conclusion regarding the relationship between the HPA-axis and 
psychostimulant responsiveness across models. Further analysis of corticosterone 
concentrations prior to drug administration and, given the present data, in response 
to the psychostimulant, would be an interesting line of further research.
At the level of dopaminergic transmission, there appears to be little consistency 
between the models (see table 5). For example, the dopaminergic markers in drug 
naïve animals of the different ‘high-low’ responder pairs (HR-LR, C57BL/6-DBA/2, 
Lewis-Fischer 344) do not show a consistent pattern. Furthermore, stress- or 
corticosterone-induced dopamine release in the NAc is higher in HR rats, but lower 
in C57BL/6 mice 73,518,580,683,703, when compared to their counterparts. In addition, 
table 5: Overview of parameters of the dopamine system in various animal models for 
individual differences in sensitivity to psychostimulants.
Hr/lr c57/dba sus/unsus lEw/FIs reference
d2 nac ↓ (p) ↑ (p) ↔ (p) ↓ (p) 69,214,292,576*
cP ↓ (p) ↔ ↓ ↑ (p) ↑ (p) ↓ (p) 69,199,214,292,470,576*
Vta ↓ (p) 69*
snc ↓ (p) ↔ (p) 69,576*
d1 nac ↑ (p) ↔ ↓ (p) ↔ (p) ↔ (p) 69,214,292,576*
cP ↔ (p) ↔ ↑ (p) ↔ (p) ↔ (p) 69,199,214,292,470,576*
tH nac ↔ (p) ↑ (p) ↓ (p) 32,408,682
cP ↔ (p) ↔ (p) 32,408
Vta ↔ (m) ↓ (p) ↓ (m) ↔ (m) ↑ (p) 32,293,408,576 *
snc ↔ (m) ↔ (p) ↓ (m) ↑ (m) ↔ (p) 32,293,408,576*
dat nac ↔ (p) ↓ (p) 214,292
cP ↔ (p) ↓ (p) 214,292
Vta ↓ (m) *
snc ↓ (m) *
Arrows indicate significant difference compared to LR, DBA/2, APO/UNSUS or Fischer 
344. p: protein, results obtained with radioligand binding or immunostaining, m: mRNA, 
measured by in situ hybridisation, TH: tyrosine hydroxylase, DAT: dopamine transporter, 
NAc: nucleus accumbens, CP: caudate putamen, VTA: ventral tegmental area, SNc: 
substantia nigra pars compacta, * data from the present studies. It should be noted that the 
binding studies are not fully comparable due to the use of different ligands with different 
affinities for the dopamine receptor subtypes.
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whereas the DBA/2 strain is most susceptible to the impact of ADX on drug-induced 
adaptations in the dopamine system (chapter 3), ADX selectively reduces stress-
induced dopamine release in the HR rat 580. This indicates that, except for dopamine 
release in response to psychostimulants, other markers of the dopamine system do 
not seem to be predictive for psychostimulant-induced behaviour across models. 
This does, however, not exclude that in any particular setting or strain dopamine is 
the key determinant for psychostimulant sensitivity.
In summary, the C57BL/6 and DBA/2 mice show resemblance to animals that 
are selected on the basis of high and low ‘novelty seeking’. Interestingly, it appears 
that stressors or exogenous corticosterone facilitate behavioural responsiveness to 
psychostimulants in less sensitive individuals, such as the LR rats, Fischer 344 rats 
and DBA/2 mice. By contrast, ‘high-responders’ appear less susceptible to the influ-
ence of corticosterone. This interpretation should be regarded with caution, given 
that the ‘HR/LR’ phenotype in psychostimulant responsiveness might depend on the 
dose of the psychostimulant (see section 1.3), as well as on the experimental design, 
a good example being the susceptibility to context dependent (higher in C57BL/6) 
versus -independent (higher in DBA/2) sensitisation of the two inbred strains (see 
box 1) 65,559. Furthermore, it would be interesting to characterise the C57BL/6 and 
DBA/2 strains for behavioural parameters that reflect coping with negative affect, 
e.g. stress-induced self-grooming, which has been demonstrated to predict cocaine 
self-administration 287.
In summary, the genetic differences in behavioural responsiveness to novelty and 
psychostimulant drugs are not unique to the C57BL/6 and DBA/2 strains. The HPA-
axis plays a prominent role in psychostimulant responsiveness, which is especially 
evident in animals that are less sensitive to the drugs under the given experimental 
conditions. However the exact contribution of adrenal hormones may vary with the 
genetic background, which is consistent with the view that there are considerable 
individual differences in susceptibility to the impact of glucocorticoids on psycho-
stimulant sensitivity.
3. tHE contEXt oF strEss HorMonE actIon
The actions of adrenal glucocorticoid hormones are highly context-dependent 318. 
However, despite convincing evidence that glucocorticoids mediate the effects of 
stress on psychostimulant sensitivity, the context- and time-dependency of their 
actions is poorly understood. The studies presented in chapters 4 and 5 were 
therefore designed to investigate the role of adrenal glucocorticoids in behavioural 
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sensitisation to cocaine in relation to i) the stage of behavioural sensitisation, ii) 
the time of drug exposure, and iii) the activity of the sympathetic nervous system. 
The DBA/2 strain was used because of its susceptibility to the impact of adrenal 
hormones.
3.1 stage of behavioural sensitisation
Glucocorticoids play a role during the initiation, rather than the expression of 
cocaine sensitisation in DBA/2 mice. Administration of the GR antagonist mife-
pristone to previously sensitised animals failed to block expression of locomotor 
sensitisation to cocaine (chapter 4), whereas substitution of ADX mice from the start 
of the sensitisation paradigm with chronic corticosterone alone (chapter 4), or in 
combination with epinephrine (chapter 5), respectively partially and fully restored 
the deficit in behavioural sensitisation.
The role of glucocorticoids in initiation of sensitisation is supported by previous 
studies 498,527 and points to a coordinate mechanism of action of glucocorticoids 
and psychostimulant drugs in facilitating neurochemical and behavioural adapta-
tions. In support of this, glucocorticoids can increase extracellular concentrations 
of dopamine by i) increasing the levels of TH 485,637, ii) decreasing dopamine ca-
tabolism 397, and iii) decreasing catecholamine re-uptake 598, but see also 186,397. 
Furthermore, glucocorticoids may control dopaminergic transmission through other 
neurotransmitter systems that modulate the activity of DA neurons 459,488. Stressors 
and exogenous glucocorticoids increase psychostimulant-induced dopamine 
release in the NAc 77,164,518,577, induce (cross-) sensitisation to the neurochemi-
cal-, behavioural- and reinforcing effects of psychostimulants 165,166,472,493,510, and 
facilitate psychostimulant self-administration already during the acquisition phase 
244,418,516. Furthermore, adrenal glucocorticoids can induce synaptic alterations on 
dopaminergic neurons similar to those induced by drugs of abuse 582 and are readily 
self-administered by laboratory rodents 512. Finally, in humans, high glucocorticoid 
concentrations can induce ‘steroid psychoses’ 274 and adverse life experiences may 
precipitate drug use and abuse.
Whereas there is a considerable body of evidence that glucocorticoids contribute 
to initiation and acquisition of hyperresponsiveness to the behavioural and rein-
forcing effects of psychostimulants (in animals with certain genetic backgrounds), 
controversy exists regarding the contribution of corticosteroids to sustained expres-
sion of these behaviours once they have been established. Indeed, the present data 
(chapter 4) do not support a role for glucocorticoids in expression of behavioural 
sensitisation to cocaine, which is in agreement with observations that ADX per-
formed in already sensitised animals does not prevent expression of the behavioural 
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hyperresponsiveness 527,529. However, other studies have shown that mifepristone can 
reduce the motivation to self-administer cocaine, and block amphetamine-induced 
behavioural sensitisation, in rats that had previously acquired these behaviours 
153,168. Furthermore, stress and glucocorticoids can play a role during maintenance 
92,131,245,246,417 and reinstatement 163,194,517 of psychostimulant self-administration. 
Therefore, it appears that glucocorticoids can contribute to expression of these 
behaviours, whereas the experimental parameters and possibly genetic influences 
determine whether this is revealed. Indeed, Deroche-Gamonet et al. demonstrated 
that mifepristone only reduces motivation for cocaine self-administration in a subset 
of outbred rats that display an exceptionally high drug response 168. Furthermore, 
the length of the withdrawal duration and the extent to which behavioural sensitisa-
tion has developed, may determine whether its expression is susceptible to adrenal 
hormones or environmental manipulations at a given time point.
In conclusion, adrenal glucocorticoids contribute to initiation of cocaine-induced 
behavioural sensitisation in DBA/2 mice. A next step towards understanding the 
context in which glucocorticoids operate, was to investigate the time-window for 
the actions of corticosterone within the initiation phase. To achieve this, ADX mice 
were given corticosterone replacement either 5 min. or 2 hrs. prior to each drug 
exposure, or continuously via release from a s.c. implanted pellet.
3.2 time dependence: mode of corticosterone replacement
Neither of the three corticosterone replacement regimens was effective in fully 
restoring behavioural sensitisation in ADX mice (chapter 4, see table 6). This is 
intriguing, given the vast body of evidence that glucocorticoid hormones contribute 
to the neurochemical and behavioural effects of psychostimulants, as outlined in 
the previous section. In agreement with reports that repeated stress and chronic 
administration of high doses of corticosterone can enhance locomotor responsive-
ness and behavioural sensitisation to psychostimulants 77,284,383,485,498, the continu-
ous hormone replacement via the s.c. pellet was effective in (partially) restoring 
behavioural sensitisation to cocaine in ADX mice. However, the data suggest that 
the time-kinetics of the sensitisation in mice receiving chronic corticosterone is 
different from that observed in SHAM-operated animals and may require a longer 
withdrawal duration (chapters 4 and 5).
The continuous and stable corticosterone level achieved through a slow release 
pellet does not represent a physiological condition, because it does not mimic 
the ultradian and circadian rhythms in circulating corticosterone concentrations 
751. Therefore, the time-window for the action of glucocorticoids requires further 
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investigation. Piazza et al. demonstrated that administration of corticosterone 10 
minutes prior to a session facilitates self-administration in LR rats 516. In the present 
study, a slight degree of sensitisation was observed in mice receiving corticosterone 
5 minutes prior to cocaine administration, although locomotor responses did not 
exceed those of ADX mice on day 9. In view of the findings of Piazza et al., this 
suggests that there might be a non-genomic mode of action of the hormone, since 
the involvement of genomic effects that develop at 2 hours after corticosterone 
administration when the hormone concentrations are declining, is less likely. The 
rapid non-genomic effects of glucocorticoids can be mediated via both MR or GR 
putatively located in the cell membrane, that have considerably lower affinity for 
glucocorticoids than their ‘classical’ intracellular form 319,338,755. Administration of 
MR or GR antagonists shortly prior to drug administration could be an interesting 
approach to investigate the involvement of non-genomic glucocorticoid actions. 
Furthermore, given the critical role for the ANS (chapter 5, see section 3.3 for dis-
cussion), it would be interesting to repeat the 2 hrs. and 5 mins. replacement studies 
in combination with epinephrine substitution.
An obvious line of reasoning to explain the insufficiency of corticosterone in fully 
reversing the ADX effect, would be to focus on experimental parameters such as the 
hormone dosage, the necessity of endocrine sensitisation and the possible require-
ment of ultradian and circadian rhythmicity. These aspects could very well play a 
role and are discussed in detail in chapter 4. However, the discrepancy in literature 
regarding the role of corticosterone in psychostimulant responsiveness, even when 
similar strains of animals are used, suggests that glucocorticoids are not the only fac-
tors of importance (e.g. 21,510). Furthermore, two recent publications have proposed 
table 6: Overview of the locomotor responses of cocaine-treated DBA/2 mice receiving 
various regimens of corticosterone replacement during the sensitisation paradigm.
Method day 1 day 9 Increase days 1-9 Expression day 15* day 21
5 mins. yes (minor) no
2 hrs. no no
chronic ↓ ↑ yes no ↑
Arrows indicate a significant difference compared to adrenalectomised (ADX) mice 
receiving cholesterol replacement. No arrow indicates no significant difference. On days 
1-9 mice received 15.0 mg/kg cocaine and on days 15 and 21 animals were given a 7.5 
mg/kg cocaine challenge. * Enhanced response to the cocaine challenge when compared 
to saline-treated controls receiving similar substitution (data from chapter 4).
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that an elevation of glucocorticoids is necessary, but not sufficient, for the effects 
of stress on escalation of cocaine self-administration 417 and on morphine-induced 
conditioned place preference and dopamine release in the NAc shell 161. For in-
stance, in the study by Mantsch et al., it was shown that stress-induced escalation 
of cocaine self-administration was prevented in ADX animals with diurnal corti-
costerone replacement. Administration of additional corticosterone (in the range 
of that induced by the stressor) by itself did not restore the ADX effect, while it was 
only effective in animals that were in addition exposed to the stressor 417. This sug-
gests that factors other than corticosterone may play an additional role in the effects 
of stress on the behavioural and reinforcing effects of psychostimulants.
In conclusion, corticosterone facilitates initiation and retention of sensitisation to 
the locomotor stimulant effects of cocaine in DBA/2 mice. However, a full restora-
tion of the ADX effect was not achieved with various regimens of corticosterone 
replacement. Because stressors and psychostimulants activate the autonomic sym-
pathetic nervous system (ANS) even more rapidly than the HPA-axis, studies were 
designed to investigate the actions of corticosterone in the context of epinephrine 
administration.
3.3 the role of the sympathetic nervous system
In chapter 5 it was demonstrated that the ANS and the HPA-axis act in a coordinate 
fashion to facilitate behavioural sensitisation of DBA/2 mice to cocaine. Whereas 
neither corticosterone nor epinephrine alone were sufficient, both adrenal stress 
hormones were necessary to fully restore locomotor sensitisation of ADX mice to 
cocaine. Previous studies have demonstrated that the HPA-axis and the ANS are 
intimately linked during processes of learning and memory 53,571, however little at-
tention has been dedicated to the role of the ANS in sensitivity to drugs of abuse.
The polar substance epinephrine does not cross the blood-brain-barrier. 
The catecholamine therefore most likely modulates brain function by activating 
β-adrenoreceptors on vagal afferents to the noradrenergic cell bodies in the solitary 
tract nucleus (NTS) 251,456,570,730. Interestingly, cocaine itself increases availability of 
synaptic norepinephrine by blocking the NET 549. The present data therefore sug-
gest that additional noradrenergic stimulation (by peripheral epinephrine) may be 
required for full behavioural sensitisation in DBA/2 mice. Studies showing that 
adrenoreceptor agonists block stress-induced reinstatement of cocaine, heroin and 
alcohol seeking provide further evidence for the role of the noradrenergic system 
in mediating the effects of stress on drug responsiveness 193,376,620. This would imply 
an important role for norepinephrine in psychostimulant sensitisation, a proposal 
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that is supported by most 182,183,587, but not all 691 studies. In the light of the present 
data (chapter 2), this discrepancy could be explained by the use of different strains 
and species. Furthermore, the considerable number of reports that glucocorticoids 
alone are sufficient to restore the effects of ADX, suggest that differences in sympa-
thetic tone and, consequently, release of norepinephrine from sympathetic nerve 
terminals, may determine whether additional adrenergic stimulation is required.
The mechanism underlying the coordinate actions of corticosterone and epi-
nephrine in cocaine sensitisation forms an interesting topic for further research. 
First, it would be of interest to investigate which of the hormones is rate-limiting. 
The observation that chronic corticosterone, but not repeated epinephrine adminis-
trations, partially reverses the sensitisation deficit in ADX mice (chapters 4 and 5), 
suggests that the glucocorticoid (if continuously present) is the primary regulator, 
whereas the role of epinephrine would be to facilitate the actions of corticosterone. 
However, this is highly speculative as these experiments involved ‘artificial’ condi-
tions such as ADX, which by itself is likely to change the set point of the sympathetic 
nervous system, and hormone replacement in a non-physiological manner. Further-
more, especially during arousing tasks, there may be substantial norepinephrine 
release from sympathetic nerve terminals, which may have facilitated the actions 
of corticosterone. The independent contribution of adrenal glucocorticoids and 
epinephrine could be investigated by administration of MR and GR antagonists, or 
peripheral β-blockers.
Second, it is of great interest to investigate which brain regions are a substrate 
for the (inter)action of corticosterone and epinephrine, e.g. by microinjections of 
agonists and antagonists of glucocorticoid- (MR and GR) and adrenoreceptors. This 
may involve both direct 302,491 and indirect (via e.g. amygdala, hippocampus or PFC) 
368,395,396,419,535,574 noradrenergic projections to the midbrain dopamine system. Of 
particular interest are the basolateral amygdala (BLA) and the NAc, as these brain 
regions are critical for the effects of glucocorticoids and epinephrine on memory 
consolidation 437,572-574,616.
Taken together, behavioural sensitisation of DBA/2 mice to cocaine depends on 
adrenal glucocorticoids. These hormones play a role during initiation, rather than 
expression, of sensitisation. Furthermore, the glucocorticoid action appears to 
require activation of the sympathetic nervous system. Regarding the time frame 
of action, a continuous presence of corticosterone is most effective in facilitating 
behavioural sensitisation, whereas the effects of the intermittent hormone substitu-
tions (2 hrs. and 5 mins. prior to cocaine) need to be revisited in the light of the 




Clinical and experimental studies point to a role for adverse life-events and gluco-
corticoid hormones in vulnerability to the reinforcing effects of drugs of abuse. This 
thesis revealed that susceptibility to the psychostimulant effects of cocaine results 
from complex interactions between genetic factors, the HPA-axis and the sympa-
thetic nervous system. Our studies in mice of two genetic backgrounds show that 
certain individuals may acquire long-term neural and behavioural adaptations to 
cocaine independent of stress hormones, whereas in others adrenal glucocorticoids 
and catecholamines constitute important risk factors.
Figure 1 depicts the interplay between adrenal corticosteroids and catecholamines in 
the process of behavioural sensitisation to cocaine. In agreement with observations 
in other laboratories, it was demonstrated that glucocorticoids facilitate initiation of 
sensitisation 240,418,514,516, but only in certain genotypes (the DBA/2 strain). However, 
the present studies point to an additional role for the sympathetic nervous system. 
Adrenal glucocorticoids and catecholamines act in a coordinate fashion to enhance 
behavioural sensitisation to cocaine, which may involve facilitated dopaminergic 
transmission in the nigrostriatal circuit and regulation of D2 receptor densities in 
the projection areas of the dopamine system. Furthermore, whereas glucocorticoids 
have a permissive role in adrenal epinephrine synthesis 583,738, the current data 
suggest that epinephrine in turn facilitates HPA-axis activation by cocaine at the 
level of the PVN. Therefore, under conditions of repeated cocaine exposure, the 
two adrenal hormones may mutually facilitate each other’s synthesis and release 
in a feed-forward fashion, which could further enhance the contribution of these 
hormones to psychomotor sensitisation.
The present data open up a window of opportunities for further research.
First, the DBA/2 strain provides an interesting animal model to investigate the 
neural, endocrine and genetic mechanisms underlying vulnerability to psychostim-
ulant drugs that may precipitate in response to adverse events. This inbred strain is 
susceptible to the influence of adrenal hormones and environmental manipulations 
and is characterised by considerable inter-individual variability in cocaine respon-
siveness (chapter 2). Identification of population extremes, so-called ‘responders’ 
and ‘non-responders’, and subsequent phenotyping constitutes one approach to 
investigate precipitation of drug responsiveness by stress hormones. Alternatively, 
manipulations in early life (e.g. lack of maternal care) or in adulthood (e.g. expo-
sure to various chronic stressors) can be applied to further discriminate phenotypes 
that are relatively resistant or hypersensitive to psychostimulants. Combining these 
Chapter 6
157
approaches with genome-wide microarray gene expression profiling on reward-
related brain regions may lead to the identification of new pathways and molecular 
targets that underlie susceptibility to psychostimulant drugs and dopaminergic 
psychoses in general.
Second, an important next step involves the extrapolation of the present results to 
other models for drug addiction in laboratory animals, such as the self-administration 
paradigm. It would be of great interest to investigate the coordinate action of cor-
ticosteroids and catecholamines in acquisition, maintenance and relapse of self-
administration. The present data, which show a critical role for adrenal hormones 
in the initiation of behavioural sensitisation, suggest that these hormones play a 
role in acquisition of drug self-administration. This has indeed been demonstrated 
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Figure 1: Proposed model for the interaction between adrenal glucocorticoids and 
epinephrine in behavioural sensitisation to cocaine.
The model represents the DBA/2 strain that is ‘susceptible’ to the impact of adrenal 
hormones on initiation of behavioural sensitisation to cocaine. Corticosterone (cort) 
and epinephrine (epi) act or interact in a coordinate fashion to facilitate initiation of 
sensitisation via adaptations in the nigrostriatal dopamine system and the NAc core that 
may include i) greater reactivity of nigrostriatal neurons, and ii) alterations in D2 receptor 
signalling in the terminal fields, possibly towards supersensitivity as reported elsewhere 
306,675,695. Corticosterone can enter the reward-related brain areas directly, whereas 
epinephrine activates the noradrenergic system in the nucleus of the solitary tract (NTS). 
With repeated drug exposure, there is enhanced secretion of corticosterone, which may 
be further facilitated by epinephrine, and possibly also increased epinephrine release from 
the adrenals. The resulting feed-forward cascade involving epinephrine and corticosterone 
interactions may further facilitate behavioural sensitisation to cocaine. PVN: hypothalamic 
paraventricular nucleus, NAc: nucleus accumbens, CP: caudate putamen.
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for corticosteroids 418,516, however the role of epinephrine is unknown. Furthermore, 
given that glucocorticoid hormones act in a context-dependent fashion, it would 
be interesting to investigate the role of adrenal hormones in cue-controlled cocaine 
seeking and relapse, e.g. under a second-order schedule of reinforcement.
Third, the mechanism and brain circuitry via which the ANS and the HPA-axis 
modulate psychostimulant responsiveness form an important focus for further re-
search. With respect to the ANS, this issue can be addressed by local or systemic 
administration of α- and β-adrenoreceptor agonists and antagonists prior to an 
experimenter- or self-administered drug infusion. This could be combined with te-
lemetry or continuous blood sampling to monitor the activity of the ANS. Agonists/
antagonists that are incapable of crossing the blood-brain-barrier would provide 
a useful tool to distinguish between the central and peripheral actions of cat-
echolamines. Glucocorticoid actions can be manipulated systemically or centrally 
via the ‘classical’ endocrine and pharmacological methods as applied in this thesis, 
as well as by the use of transgenic animals or the application of small-interference 
(si)RNA-mediated knock-down of GR and MR (and their targets) in distinct brain 
regions. The initial focus could be on the dopaminergic and noradrenergic nuclei, 
the primary substrates for cocaine and epinephrine in the brain, thereafter being ex-
tended to brain regions such as the amygdala, prefrontal cortex and hippocampus 
that provide the midbrain dopamine system with excitatory or inhibitory input.
Fourth, whereas there is a wealth of data on the influence of stress and glu-
cocorticoids on psychostimulant sensitivity, an interesting line of further research 
would be to study the role of adrenal hormones in the behavioural and reinforcing 
effects of different classes of drugs of abuse, such as opioids, nicotine, ethanol and 
cannabinoids. Indeed, there is limited evidence that corticosteroids differentially 
facilitate dopamine-mediated behavioural responses to cocaine and morphine 422. 
Furthermore, whereas direct or indirect activation of the midbrain dopamine sys-
tem is a commonality shared by all drugs of abuse, distinct classes of drugs have 
diverging pharmacological actions that may be differentially influenced by adrenal 
hormones.
Finally, the implications of the present findings for human drug addiction remain 
to be investigated. In individuals with cocaine dependence, acute cortisol can trig-
ger craving 192 and plasma cortisol concentrations are positively correlated with the 
subjective effects of the drug and drug-induced dopamine release in the midbrain 
486. Despite the controversy regarding the role of glucocorticoids in established drug 
responsiveness (the present data, 153,168), this suggests that GR antagonists may have 
therapeutic potential in reducing some of the subjective and neurochemical effects 
of cocaine. Interestingly, recent clinical trials have demonstrated that the GR antago-




In the present studies, locomotion was measured as an index of behavioural responsiveness to 
cocaine. However, the effects of psychostimulants in rodents are dose-dependent and can initiate a 
spectrum of behavioural responses. Whereas lower doses induce horizontal locomotor hyperactivity, 
higher doses produce stereotyped behaviours; repetitions of movements that are part of the normal 
behavioural repertoire including head shaking, rearing, sniffing, gnawing, licking and circling. In hu-
mans, stereotyped behaviours are symptoms of a number of psychiatric disorders 262,640,667. Stereotypy 
is an issue that deserves attention in the light of gene x environment interaction in psychostimulant 
responsiveness.
It has been proposed that stereotypy serves a coping function that reduces drug-induced arousal and 
stress 410,454. Indeed, an amphetamine sensitisation regimen that significantly increases stereotyped 
behaviours, has been shown to attenuate the normal amphetamine-induced elevation in corticoster-
one 454. Conversely, a decrease in amphetamine stereotypy induced by mesostriatal dopamine deple-
tion prolonged the amphetamine-induced elevation in corticosterone secretion 322. Furthermore, 
stressful conditions can enhance amphetamine- and cocaine-induced stereotypy, and this has been 
proposed to occur only when the stress is uncontrollable 410. Thus, coping is an important variable 
in the interaction between the HPA-axis and psychostimulant drugs, which may be reflected by 
stereotyped behaviour 410.
 Strain differences may exist in the susceptibility of laboratory rodents to psychostimulant-induced 
stereotypies. This has also been demonstrated for the C57BL/6 and DBA/2 strains, the latter but 
not the former, developing stereotyped behaviours during the course of repeated cocaine (32 mg/
kg) treatment 666 or in response to food restriction 67. In the present studies, the test setting did not 
allow for the detailed behavioural analysis required to distinguish subtle stereotyped movements. 
It is therefore conceivable that a difference in stereotyped responding may have contributed to the 
observed strain differences in behavioural sensitisation to cocaine. However, the doses of cocaine 
used in the present study (15.0 mg/kg during the treatment phase and 7.5 mg/kg for the drug chal-
lenge) were relatively low and, especially the challenge dose is not likely to have induced a high 
degree of stereotypy 45. Furthermore, the observation that corticosterone secretion was attenuated by 
cocaine in the C57BL/6 strain that displayed high horizontal locomotion throughout the sensitisation 
paradigm (chapter 2), contradicts the notion that stereotypy might function to attenuate HPA-axis 
responsiveness in this strain.
 The possibility of stereotypy in ADX animals should also be considered. Activation of the HPA-axis 
and the ANS enable an organism to respond and adapt to stressful situations and are therefore part 
of their coping mechanism. ADX mice are however not capable of releasing adrenal corticosterone 
or catecholamines in response to any stimulus. It is therefore conceivable that ADX animals develop 
stereotyped behaviours to cope with cocaine-induced arousal. In this line of reasoning, stereotypy 
would be part of the coping response not only in animals that are exposed to too high, but also too 
low levels of stress hormones. Further studies are therefore required to investigate whether stereotypy 
plays a significant role in the behavioural response of ADX mice to cocaine, especially given the 
seemingly high susceptibility of DBA/2 mice to develop such behavioural responses.
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34,160. Moreover, mifepristone selectively reduced psychotic rather than depressive 
symptoms, which suggests that the antagonist modulates dopaminergic transmission 
160. Therefore, it would be interesting to test the effects of this compound on drug 
craving in human cocaine addicts. Clearly, more research is required to investigate 
the involvement of the sympathetic nervous system alone, and in interaction with 
various components of the HPA-axis, in human drug addiction. The present data 
suggest that β-blockers may have therapeutic potential. One first approach could be 
to investigate whether, in addition to cortisol secretion, the activity of the ANS (e.g. 
heart frequency) is a parameter that correlates with the extent of drug craving, and 
whether craving can be reduced by administration of β-blockers.
The data presented in this thesis indicate that, depending on genetic background, 
stress hormones can provide important risk factors for vulnerability to the psycho-
stimulant effects of cocaine. Furthermore, these data add a new dimension to the 
concept of stress in addiction research, extending the focus from being solely on 
glucocorticoids to a wider scope involving the HPA-axis and the sympathoadrenal 




i) Genetic background determines sensitivity to the psychostimulant effects of 
cocaine and the contribution of adrenal hormones. One strain was identified, the 
DBA/2 strain, that is susceptible to the influence of adrenal stress hormones on 
behavioural sensitisation to cocaine.
ii) The interaction between genetic background and adrenal stress hormones in 
cocaine sensitivity can be monitored by measuring markers in the midbrain dopa-
mine system. Most notably the D2 receptor in the terminal fields of the nigrostriatal 
dopamine system and the NAc core is an interesting candidate to mediate this 
interaction.
iii) The initiation phase of behavioural sensitisation is a critical time-window for 
the action of adrenal glucocorticoids. During this phase, continuous presence of 
high glucocorticoid concentrations facilitates sensitisation, whereas it remains to be 
established whether this involves non-genomic and/or genomic mechanisms.
iv) The sympathetic nervous system may signal aspects of the physiological context 
in which glucocorticoids operate. Adrenal epinephrine and corticosterone act in a 







Despite the powerful psychostimulant properties of cocaine, not every individual 
will acquire cocaine abuse after occasional use of the drug. A fundamental question 
in the neurobiology of addiction is therefore how these individual differences in 
susceptibility to drugs of abuse emerge. Evidence is accumulating that genes and 
adverse life experience can constitute risk factors. Especially the hypothalamic-
pituitary-adrenal (HPA) axis and the sympathetic nervous system responses to stress 
have gained increasing attention for their role in vulnerability to psychostimulants 
in both humans and laboratory animals. The objective of this thesis was to assess 
the role of the end products of both stress response systems -the adrenal gluco-
corticoid hormones and epinephrine- in the susceptibility to the psychostimulant 
effects of cocaine, taking into account the midbrain dopamine circuits, the genetic 
background of the individual and the context in which the hormones operate.
Studies were designed with two inbred mouse strains (C57BL/6 and DBA/2) that 
can be considered a model for genetic differences in the midbrain dopamine sys-
tem, the HPA-axis and susceptibility to the behavioural and reinforcing properties of 
psychostimulant drugs. The context required for the action of adrenal hormones was 
investigated in the DBA/2 strain that proved most susceptible to adrenal hormones 
in cocaine sensitivity. Adrenal hormones were manipulated by surgical removal of 
the adrenals (adrenalectomy: ‘ADX’) and subsequent hormone replacement. The 
sensitisation measured as an enhanced locomotor response to repeated drug expo-
sure is thought to reflect long term neuronal adaptations underlying certain aspects 
of drug addiction. In addition, endocrine parameters were measured to investigate 
HPA-axis responsiveness to cocaine. Since the dopamine system plays a critical 
role in the rewarding effects of drugs of abuse, several markers of dopaminergic 
transmission were measured.
In chapter 2 the C57BL/6 and DBA/2 inbred mouse strains were characterised for 
behavioural and endocrine responsiveness to cocaine. Whereas C57BL/6 mice 
showed greater locomotor responses to the first cocaine exposure, only DBA/2 
mice exhibited an increase in drug responsiveness during repeated drug treatment. 
However, when exposed to a challenge dose of cocaine after a 5 day withdrawal 
interval, both strains expressed behavioural sensitisation. Therefore, the sensitisa-
tion paradigm was suitable to investigate the contribution of adrenal hormones in 
both strains. ADX completely prevented initiation and expression of behavioural 
sensitisation in the DBA/2, but not the C57BL/6 strain. Furthermore, only the DBA/2 
strain displayed sensitisation of corticosterone secretion with repeated cocaine 
exposure, whereas the psychostimulant attenuated this endocrine measure in the 
C57BL/6 strain. These data indicate that the C57BL/6 and DBA/2 strains represent 
a model for genetic differences in behavioural and endocrine responsiveness to 
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cocaine. Moreover, the adrenals play an essential role in cocaine-induced behav-
ioural sensitisation, but only in the DBA/2 strain.
In chapter 3 it was investigated whether a neural correlate for the strain differ-
ences in behavioural responsiveness to cocaine, and susceptibility to the impact 
of adrenal stress hormones, can be found in the midbrain dopamine system. 
Whereas ADX did not affect strain differences in the basal dopamine system or the 
locomotor response to the first cocaine exposure, strain-dependent adaptations 
were observed in behavioural and neural responsiveness to cocaine. In the DBA/2 
strain, sensitisation resistant ADX mice were characterised by reduced D2 binding 
in the nucleus accumbens core and rostral caudate putamen. Conversely, ADX 
prevented the cocaine-induced increase in TH and DAT mRNA expression in the 
substantia nigra and the decrease in D2 binding in a subdivision of the dorsal 
caudate putamen observed in SHAM mice. In the C57BL/6 strain, by contrast, be-
havioural sensitisation was independent of the adrenals and ADX only marginally 
affected drug-induced neuroadaptations. These results demonstrate that adrenal 
stress hormones affect psychostimulant sensitivity in a strain-dependent fashion, 
possibly through adaptations in the midbrain dopamine system. Furthermore, the 
DBA/2, but not the C57BL/6 strain, is vulnerable to the impact of adrenal stress 
hormones on cocaine sensitivity at the level of dopaminergic neurotransmission 
and behavioural responsiveness. This strain was therefore chosen to investigate the 
context-dependency of the glucocorticoid actions (chapters 4 and 5).
In chapter 4, the critical time-window for the actions of adrenal glucocorticoids was 
investigated in DBA/2 mice in relation to i) the stage of behavioural sensitisation to 
cocaine (induction vs. expression) and ii) the time of drug exposure. Administration 
of the glucocorticoid receptor antagonist mifepristone to sensitised animals failed to 
block expression of previously established behavioural sensitisation. This suggests 
that corticosterone plays a role during initiation of sensitisation, as appeared from 
the observations in the ADX mice. Intermittent corticosterone replacement 2 hours 
or 5 minutes prior to cocaine was ineffective in reversing the effect of ADX on 
behavioural sensitisation. By contrast, initiation of behavioural sensitisation was 
partially restored if the glucocorticoid was continuously substituted through release 
from a s.c. implanted pellet. These data indicate that corticosterone facilitates 
initiation rather than expression of behavioural sensitisation to cocaine, provided 
that the hormone is continuously circulating. However, because only chronic high 
concentrations of the hormone partially restored behavioural sensitisation, it ap-
peared that the adrenal glucocorticoid is necessary, though not sufficient, for full 
sensitisation in the DBA/2 strain.
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Therefore, the possible involvement of other adrenal factors was investigated 
in chapter 5. The focus was on epinephrine, the catecholamine that is rapidly 
released in response to both stress and psychostimulant administration. Whereas 
replacement with neither epinephrine nor continuous corticosterone alone was 
sufficient to reverse the ADX effect, co-substitution of the two adrenal hormones 
was sufficient to fully restore initiation and retention of behavioural sensitisation 
to the level observed in SHAM-operated mice. In addition, the catecholamine may 
play a permissive or facilitatory role in the HPA-axis sensitisation in the DBA/2 
strain, since cocaine-induced c-fos mRNA expression in the hypothalamic PVN was 
potentiated in mice with a history of epinephrine replacement. Given the critical 
role for glucocorticoids in cocaine sensitivity of DBA/2 mice, this might be one of 
the mechanisms via which epinephrine facilitates behavioural sensitisation. These 
findings indicate that corticosterone and epinephrine act in a coordinate fashion to 
facilitate behavioural responsiveness to cocaine in the DBA/2 genotype.
Overall, the data presented in this thesis show that complex interactions between 
genes, the HPA-axis and the sympathetic nervous system contribute to the existence 
of individual differences in susceptibility to the psychostimulant effects of cocaine. 
It was demonstrated that genetic background determines the contribution of adrenal 
hormones to cocaine sensitivity. The C57BL/6 and DBA/2 strains represent a model 
for respectively resistance and susceptibility to the impact of adrenal hormones on 
cocaine-induced behavioural sensitisation and associated neuroadaptations in the 
brain dopamine system. Regarding the context required for the hormone actions, 
the initiation phase of sensitisation constitutes the critical time-window, whereas 
the sympathetic nervous system may signal aspects of the physiological context. 
Therefore, in susceptible individuals, not only adrenocortical but also adrenomedul-









Cocaïne behoort tot de stimulerende middelen; stoffen die energie en alertheid ver-
hogen en een kortstondig goed gevoel of zelfs euforie geven. Herhaaldelijk gebruik 
van cocaïne kan echter leiden tot een oncontroleerbare drang om te gebruiken, 
oftewel verslaving. Verslaving is een groot probleem in de maatschappij, gezien de 
gevolgen hiervan voor gezondheid, sociaal functioneren en criminaliteit. Ondanks 
het feit dat cocaïne een zeer verslavende stof is, wordt het risico op het ontstaan 
van verslaving na recreatief gebruik geschat op 15-20%. Dit geeft aan dat niet elk 
persoon even gevoelig is voor de verslavende werking van de stof. Dergelijke indi-
viduele verschillen bestaan voor alle verslavende drugs, ondanks het feit dat zij tot 
zeer verschillende farmacologische klassen kunnen behoren (bijv. psychostimulan-
tia, alcohol, opiaten, cannabis). Een belangrijke vraag in het onderzoek naar het 
ontstaan van verslaving is hoe deze grote individuele verschillen in gevoeligheid tot 
stand komen. Het is bekend dat enerzijds genetische factoren en anderzijds (nega-
tieve) levenservaringen een belangrijke rol spelen. Echter, de hersenmechanismen 
die hieraan ten grondslag liggen, zijn veelal onbekend.
strEssHorMonEn
Recent onderzoek heeft aangetoond dat stress, en de hormonen die tijdens stress 
worden uitgescheiden door de bijnier, belangrijke risicofactoren vormen voor 
verslaving. Wanneer een individu een situatie of gebeurtenis als stressvol ervaart, 
of wanneer er veranderingen optreden in de omgeving of in het lichaam, wor-
den hormonale en neuronale processen geactiveerd die de balans in het lichaam 
herstellen en die de persoon in staat stellen adequaat op de situatie te reageren. 
Twee verschillende systemen kunnen worden onderscheiden: het sympathische ze-
nuwstelsel en de hypofyse-bijnier-as (in het Engels: Hypothalamic-Pituitary-Adrenal 
(HPA) as). Activering van het sympathische zenuwstelsel, resulterend in afgifte van 
adrenaline door de bijnieren en noradrenaline door bepaalde zenuwen, zorgt o.a. 
voor verhogingen in hartfrequentie, bloeddruk en bloedtoevoer naar de spieren. 
Dit is een zeer snel proces en stelt de persoon in staat vrijwel direct op de situatie 
te reageren. Activering van de HPA-as leidt tot afgifte van glucocorticoïd hormonen 
door de bijnieren (cortisol bij de mens en corticosteron bij knaagdieren). Zoals 
uit de naam valt af te leiden, zorgen deze hormonen o.a. voor het vrijmaken van 
glucose waardoor zij de beschikbare energie verhogen. Daarnaast beïnvloeden 
glucocorticoïden processen in de hersenen die te maken hebben met cognitie, per-
ceptie, stemming en beloning. Kortstondige afgifte van glucocorticoïden is daarom 
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van essentieel belang voor een adequate reactie op veranderingen in de omgeving. 
Echter, langdurige of juist onvoldoende afgifte van deze hormonen kan het ontstaan 
van bepaalde ziekten, waaronder verslaving, in de hand werken. De mechanismen 
die hieraan ten grondslag liggen zijn echter nog veelal onbekend.
Het onderzoek in dit proefschrift was gericht op de rol van beide stresssystemen 
in gevoeligheid voor cocaïne, met speciale aandacht voor de genetische achter-
grond van het individu. De interactie tussen deze factoren werd in een muismodel 
onderzocht.
MuIsModEl
Pyschostimulantia zoals cocaïne en amfetamine verhogen de afgifte van de sig-
naalstof dopamine in hersenkernen die betrokken zijn bij motivatie en beloning. 
Bij knaagdieren uit de stimulerende werking van deze drugs zich in een verhoging 
van de beweeglijkheid (locomotoriek), wat direct gerelateerd is aan de dopamine 
afgifte in de hersenen. Eén van de processen die een rol spelen bij verslaving is 
sensitisatie: de toename van de respons op de drug, of hiermee geassocieerde 
stimuli, bij herhaaldelijke blootstelling. Sensitisatie gaat gepaard met blijvende 
veranderingen in het dopaminesysteem en wordt geacht bij te dragen aan de, voor 
verslaving kenmerkende, buitensporige motivatie om de drug te verkrijgen. Ook de 
locomotorische respons van knaagdieren kan toenemen bij herhaalde toediening 
van psychostimulantia, wat een diermodel vormt voor sensitisatie. In het huidige 
onderzoek werd dit principe toegepast door aan muizen gedurende 9 opeenvol-
gende dagen cocaïne toe te dienen en te bepalen of, en zo ja in welke mate, de 
motorische respons toeneemt (‘initiatie’ van sensitisatie). Tevens werden dieren na 
een ontwenningsperiode van enkele dagen opnieuw aan cocaïne blootgesteld om 
te onderzoeken of de sensitisatie van langdurige aard is (‘expressie’ van sensitisatie). 
Hierbij werd de respons van met cocaïne voorbehandelde dieren vergeleken met 
die van dieren die niet eerder aan de drug waren blootgesteld.
Om de invloed van genetische achtergrond te onderzoeken, werd gebruik ge-
maakt van twee verschillende inteelt muizenstammen, C57BL/6 en DBA/2, die ge-
kenmerkt worden door verschillen in gevoeligheid voor verslavende drugs en stress. 
De bijdrage van beide stresssystemen aan cocaïne sensitisatie werd onderzocht 
door de bijnieren, bron van zowel corticosteroïden als adrenaline, chirurgisch te 
verwijderen (adrenalectomie ‘ADX’). Door aan ADX dieren vervolgens corticosteron 
en/of adrenaline toe te dienen, werd de afzonderlijke en/of gezamenlijke werking 
van deze hormonen onderzocht. Aangezien het dopaminesysteem in de hersenen 
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een cruciale rol speelt bij de verslavende effecten van drugs, werden verschillende 
markers in het dopaminesysteem gemeten.
In hoofdstuk 2 worden de onderzochte cocaïnegevoeligheid van beide muizen-
stammen, en de rol van bijnierhormonen hierin, beschreven. C57BL/6 muizen wa-
ren gevoeliger voor de activerende effecten van de eerste cocaïne injectie, terwijl 
DBA/2 muizen een sterke toename in de locomotorische respons vertoonden bij 
herhaalde blootstelling. Ondanks deze verschillen werd bij beide stammen sensiti-
satie waargenomen bij hernieuwde blootstelling aan cocaïne na een ontwennings-
periode van vijf dagen. Daarentegen vertoonde alleen de DBA/2 stam een toename 
in corticosteron secretie bij herhaalde cocaïne toediening. ADX voorkwam de 
gedragssensitisatie in de DBA/2, maar niet de C57BL/6 stam. Uit deze bevindingen 
kan worden geconcludeerd dat de C57BL/6 en DBA/2 muizenstammen een model 
vormen voor genetische verschillen in gevoeligheid voor cocaïne, zowel wat betreft 
de gedragsmatige als de hormonale respons. De bijnieren lijken alleen in de DBA/2 
stam een essentiële rol te spelen in sensitisatie van de locomotorische respons op 
cocaïne.
In hoofdstuk 3 worden verschillende markers in het dopaminesysteem beschreven 
die gemeten zijn met als doel een neuronaal correlaat te vinden voor de stamver-
schillen in gevoeligheid voor cocaïne en de rol van bijnierhormonen hierin. De 
markers reflecteren verschillende aspecten van dopaminerge transmissie: tyrosine 
hydroxylase (TH, een cruciaal enzym in de synthese van dopamine), dopamine 
transporter (DAT, bewerkstelligt heropname van dopamine in het neuron, wat de 
transmissie ‘beëindigt’) en de twee meest voorkomende klassen van dopamine-
receptoren (D1 en D2). Expressie van deze markers werd onderzocht in twee 
dopaminerge circuits, die beide een rol spelen bij verslaving: i) het mesolimbisch 
systeem, met neuronen die van het ventraal tegmentaal gebied (VTA) naar o.a. 
de nucleus accumbens (NAc) projecteren, en ii) het nigrostriataal systeem dat de 
substantia nigra (SN) met het striatum (caudate putamen, CP) verbindt. ADX had 
geen invloed op de stamverschillen in het dopaminesysteem van onbehandelde 
dieren en op de locomotorische respons bij eerste cocaïne toediening (hoofdstuk 
2). Daarentegen werden stamafhankelijke veranderingen waargenomen in de 
locomotorische en neuronale responsen bij herhaalde blootstelling aan de drug. 
‘Sensitisatie-resistente’ ADX muizen van de DBA/2 stam werden gekarakteriseerd 
door i) verminderde D2 binding in subdivisies van de NAc en het CP (de NAc 
core en het rostrale CP respectievelijk), en ii) een gebrek aan toename in TH en 
DAT mRNA expressie in de SN geassocieerd met sensitisatie in SHAM muizen. 
Echter, in de C57BL/6 stam was sensitisatie van locomotoriek onafhankelijk van de 
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bijnieren en waren er slechts marginale veranderingen in dopaminerge markers ten 
gevolge van ADX. Deze resultaten geven aan dat bijnierhormonen cocaïne gevoe-
ligheid beïnvloeden op een stamafhankelijke wijze, wellicht door adaptaties in het 
dopaminesysteem. De DBA/2, maar niet de C57BL/6 stam was gevoelig voor de 
effecten van ADX op cocaïne gevoeligheid zowel op het niveau van dopaminerge 
neurotransmissie als op dat van locomotorische responsen. Om deze reden werd 
de DBA/2 stam gekozen voor verdere studies naar de rol van bijnierhormonen in 
cocaïne gevoeligheid (hoofdstukken 4 en 5).
In hoofdstuk 4 wordt de ‘timing’ van de effecten van glucocorticoïden onderzocht 
met betrekking tot i) het stadium van de sensitisatie (initiatie vs. expressie), en ii) 
de tijd waarop cocaïne blootstelling plaats vindt. Blokkering van de receptor voor 
glucocorticoïden (GR) in eerder gesensitiseerde dieren had geen effect op de ex-
pressie van de sensitisatie. Dit suggereert dat corticosteron een rol speelt tijdens 
initiatie van sensitisatie, wat overeenkomt met de observaties in ADX muizen. 
Echter, toediening van corticosteron 2 uur of 5 minuten voor elke cocaïne injectie 
was niet voldoende om het effect van ADX op gedragssensitisatie te herstellen. 
Continue blootstelling aan corticosteron door afgifte vanuit een onderhuidse pellet 
resulteerde in gedeeltelijk herstel van sensitisatie. Deze bevindingen geven aan 
dat corticosteron de initiatie, maar niet de expressie, van sensitisatie faciliteert. 
Echter, de observatie dat alleen hoge concentraties van het hormoon de effecten 
van ADX deels herstellen, suggereert dat het glucocorticoïd noodzakelijk, maar niet 
voldoende, is voor volledige sensitisatie in de DBA/2 stam.
Daarom wordt in hoofdstuk 5 de mogelijke betrokkenheid van andere bijnier-
hormonen onderzocht. Hierbij was de focus op adrenaline, gezien het feit dat 
dit ‘catecholamine’ zeer snel wordt uitgescheiden door de bijnieren in respons 
op zowel stress als blootstelling aan psychostimulantia. Terwijl substitutie met 
adrenaline of met corticosteron afzonderlijk onvoldoende was om de effecten van 
ADX terug te draaien, kon met co-substitutie van beide hormonen zowel de initi-
atie als de expressie van cocaïne sensitisatie volledig worden hersteld. Daarnaast 
speelt adrenaline wellicht een rol bij de sensitisatie van de HPA-as die optreedt in 
de DBA/2 stam bij herhaalde cocaïne toediening. In met adrenaline behandelde 
dieren werd in respons op cocaïne een verhoogde expressie waargenomen van 
c-fos, een marker voor neuronale activiteit, in de nucleus paraventricularis, de kern 
van de hypothalamus die een cruciale rol speelt bij de regulatie van de HPA-as 
en dus de corticosteron afgifte. Gezien de belangrijke rol van corticosteron in co-
caïne gevoeligheid van de DBA/2 stam, is dit wellicht één van de mechanismen 
via welke adrenaline gedragssensitisatie faciliteert. Uit deze resultaten kan worden 
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geconcludeerd dat de gezamenlijke werking van corticosteron én adrenaline bij-
draagt aan het tot stand komen van sensitisatie van de locomotorische respons op 
cocaïne in de DBA/2 stam.
Uit het onderzoek beschreven in dit proefschrift kan worden geconcludeerd dat 
complexe interacties tussen genen, de HPA-as en het sympathische zenuwstelsel 
bijdragen aan individuele verschillen in gevoeligheid voor cocaïne. Het werd 
aangetoond dat de bijdrage van bijnierhormonen aan cocaïne gevoeligheid wordt 
bepaald door de genetische achtergrond van het individu. De C57BL/6 en DBA/2 
muizenstammen vormen een model voor respectievelijk resistentie en gevoeligheid 
voor de impact van bijnierhormonen op sensitisatie van de locomotorische respons 
en geassocieerde veranderingen in het dopaminesysteem. Wat betreft de context 
waarin de glucocorticoïden werken, kan worden geconcludeerd dat de initiatie 
van sensitisatie de kritieke periode vormt, waarin activatie van het sympathische 
zenuwstelsel een onderdeel van de fysiologische context vormt. In hiervoor gevoe-
lige individuen, kunnen dan ook zowel glucocorticoïden als catecholamines uit 
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